17. Literaturverzeichnis – Harnblasenkarzinom
1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1, 2017., https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik
2. Robert Koch Institut, u.d. G. d. e. K. i. D. e. V., Krebs in Deutschland, 2012. 8:
3. Sylvester, R. J., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., et.al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 2006. 49: p. 466-5; discussion 475-7.
4. Hautmann, R. E., Volkmer, B. G., Schumacher, M. C., Gschwend, J. E., Studer, U. E., Long-term results of standard procedures in urology: the ileal neobladder, World J Urol, 2006. 24(3): p. 305-14., https://www.ncbi.nlm.nih.gov/pubmed/16830152
5. von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., et.al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J Clin Oncol, 2005. 23: p. 4602-8.
6. Kunath, F., Krause, S. F., Wullich, B., Goebell, P. J., Engehausen, D. G., Burger, M., et.al. Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov, BMC Urol, 2013. 13: p. 56.
7. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:
8. Robert Koch Institut, u.d. G. d. e. K. i. D. e. V., Krebs in Deutschland, 2015. 10:
9. Giedl, J., Wild, P. J., Stoehr, R., Junker, K., Boehm, S., van Oers, J. M., et.al. [Urothelial neoplasms in individuals younger than 20 years show very few genetic alterations and have a favourable clinical outcome], Verh Dtsch Ges Pathol, 2006. 90: p. 253-63.
10. Owen, H. C., Giedl, J., Wild, P. J., Fine, S. W., Humphrey, P. A., Dehner, L. P., et.al. Low frequency of epigenetic events in urothelial tumors in young patients, J Urol, 2010. 184: p. 459-63.
11. Dudek, A. M., Grotenhuis, A. J., Vermeulen, S. H., Kiemeney, L. A., Verhaegh, G. W., Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?, Int J Mol Sci, 2013. 14: p. 12346-66.
12. Barrow, P., Khan, M., Lalloo, F., Evans, D. G., Hill, J., Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome, Br J Surg, 2013. 100: p. 1719-31.
13. Skeldon, S. C., Semotiuk, K., Aronson, M., Holter, S., Gallinger, S., Pollett, A., et.al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer, Eur Urol, 2013. 63: p. 379-85.
14. Kiemeney, L. A., Thorlacius, S., Sulem, P., Geller, F., Aben, K. K., Stacey, S. N., et.al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer, Nat Genet, 2008. 40: p. 1307-12.
15. Rafnar, T., Sulem, P., Stacey, S. N., Geller, F., Gudmundsson, J., Sigurdsson, A., et.al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types, Nat Genet, 2009. 41: p. 221-7.
16. Wu, X., Ye, Y., Kiemeney, L. A., Sulem, P., Rafnar, T., Matullo, G., et.al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer, Nat Genet, 2009. 41: p. 991-5.
17. Fu, Y. P., Kohaar, I., Rothman, N., Earl, J., Figueroa, J. D., Ye, Y., et.al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk, Proc Natl Acad Sci U S A, 2012. 109: p. 4974-9.
18. Kiemeney, L. A., Sulem, P., Besenbacher, S., Vermeulen, S. H., Sigurdsson, A., Thorleifsson, G., et.al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer, Nat Genet, 2010. 42: p. 415-9.
19. Rothman, N., Garcia-Closas, M., Chatterjee, N., Malats, N., Wu, X., Figueroa, J. D., et.al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci, Nat Genet, 2010. 42: p. 978-84.
20. Tang, W., Fu, Y. P., Figueroa, J. D., Malats, N., Garcia-Closas, M., Chatterjee, N., et.al. Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer, Hum Mol Genet, 2012. 21: p. 1918-30.
21. Rafnar, T., Vermeulen, S. H., Sulem, P., Thorleifsson, G., Aben, K. K., Witjes, J. A., et.al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene, Hum Mol Genet, 2011. 20: p. 4268-81.
22. Golka, K., Hermes, M., Selinski, S., Blaszkewicz, M., Bolt, H. M., Roth, G., et.al. Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure, Pharmacogenet Genomics, 2009. 19: p. 903-6.
23. Golka, K., Selinski, S., Lehmann, M. L., Blaszkewicz, M., Marchan, R., Ickstadt, K., et.al. Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs", Arch Toxicol, 2011. 85: p. 539-54.
24. 2013a., DFG Deutsche Forschungsgemeinschaft Senatskommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe, MAK-Werte-Liste (DFG) (Band 49), 2013. 2013:
25. Forschungsgemeinschaft, DFG Deutsche, Ständige Senatskommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe, 2013. 2013:
26. Golka, K., Kopps, S., Myslak, Z. W., Carcinogenicity of azo colorants: influence of solubility and bioavailability, Toxicol Lett, 2004. 151: p. 203-10.
27. Forschungsgemeinschaft, DFG Deutsche, Gesundheitsschädliche Arbeitsstoffe. Toxikologisch-arbeitsmedizinische Begründungen von MAK-Werten. o-ToluidinWiley-VCH, 2007. 43:
28. Weibull, C. E., Eloranta, S., Altman, D., Johansson, A. L., Lambe, M., Childbearing and the risk of bladder cancer: a nationwide population-based cohort study, Eur Urol, 2013. 63: p. 733-8.
29. Bolt HM, Golka K, Berufsbedingte Krebserkrankungen - Altlasten oder aktuelle Bedrohung?, Dtsch Med Wochenschr., 2007. 132(4):133-4:
30. Kim, Y., Park, J., Shin, Y. C., Dye-manufacturing workers and bladder cancer in South Korea, Arch Toxicol, 2007. 81: p. 381-4.
31. Fairchild, W. V., Spence, C. R., Solomon, H. D., Gangai, M. P., The incidence of bladder cancer after cyclophosphamide therapy, J Urol, 1979. 122: p. 163-4.
32. Travis, L. B., Curtis, R. E., Glimelius, B., Holowaty, E. J., Van Leeuwen, F. E., Lynch, C. F., et.al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma, J Natl Cancer Inst, 1995. 87: p. 524-30.
33. Fortuny, J., Kogevinas, M., Garcia-Closas, M., Real, F. X., Tardon, A., Garcia-Closas, R., et.al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain, Cancer Epidemiol Biomarkers Prev, 2006. 15: p. 1696-702.
34. Fortuny, J., Kogevinas, M., Zens, M. S., Schned, A., Andrew, A. S., Heaney, J., et.al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study, BMC Urol, 2007. 7: p. 13.
35. Chen, C. H., Dickman, K. G., Huang, C. Y., Moriya, M., Shun, C. T., Tai, H. C., et.al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes, Int J Cancer, 2013. 133: p. 14-20.
36. Li, H. Z., Xia, M., Han, Y., Xu, X. G., Zhang, Y. S., De novo urothelial carcinoma in kidney transplantation patients with end-stage aristolochic acid nephropathy in China, Urol Int, 2009. 83: p. 200-5.
37. Lemy, A., Wissing, K. M., Rorive, S., Zlotta, A., Roumeguere, T., Muniz Martinez, M. C., et.al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up, Am J Kidney Dis, 2008. 51: p. 471-7.
38. Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to, Tobacco smoke and involuntary smoking, 2004.
39. Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to, Personal habits and indoor combustions, 2012.
40. Brennan, P., Bogillot, O., Cordier, S., Greiser, E., Schill, W., Vineis, P., et.al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies, Int J Cancer, 2000. 86: p. 289-94.
41. Brennan, P., Bogillot, O., Greiser, E., Chang-Claude, J., Wahrendorf, J., Cordier, S., et.al. The contribution of cigarette smoking to bladder cancer in women (pooled European data), Cancer Causes Control, 2001. 12: p. 411-7.
42. Kantor, A. F., Hartge, P., Hoover, R. N., Narayana, A. S., Sullivan, J. W., Fraumeni, J. F., Jr., Urinary tract infection and risk of bladder cancer, Am J Epidemiol, 1984. 119: p. 510-5.
43. Kjaer, S. K., Knudsen, J. B., Sorensen, B. L., Moller Jensen, O., The Copenhagen case-control study of bladder cancer. V. Review of the role of urinary-tract infection, Acta Oncol, 1989. 28: p. 631-6.
44. Kunze, E., Chang-Claude, J., Frentzel-Beyme, R., Life style and occupational risk factors for bladder cancer in Germany. A case-control study, Cancer, 1992. 69: p. 1776-90.
45. Salem, H. K., Mahfouz, S., Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade, Urology, 2012. 79: p. 379-83.
46. Welk, B., McIntyre, A., Teasell, R., Potter, P., Loh, E., Bladder cancer in individuals with spinal cord injuries, Spinal Cord, 2013. 51: p. 516-21.
47. Abol-Enein, H., Infection: is it a cause of bladder cancer?, Scand J Urol Nephrol Suppl, 2008. p. 79-84.
48. Chow, W. H., Lindblad, P., Gridley, G., Nyren, O., McLaughlin, J. K., Linet, M. S., et.al. Risk of urinary tract cancers following kidney or ureter stones, J Natl Cancer Inst, 1997. 89: p. 1453-7.
49. Brinkman, M., Zeegers, M. P., Nutrition, total fluid and bladder cancer, Scand J Urol Nephrol Suppl, 2008. p. 25-36.
50. Zhou, Y., Tian, C., Jia, C., A dose-response meta-analysis of coffee consumption and bladder cancer, Prev Med, 2012. 55: p. 14-22.
51. Steinmaus, C. M., Nunez, S., Smith, A. H., Diet and bladder cancer: a meta-analysis of six dietary variables, Am J Epidemiol, 2000. 151: p. 693-702.
52. Boice, J. D., Jr., Day, N. E., Andersen, A., Brinton, L. A., Brown, R., Choi, N. W., et.al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries, J Natl Cancer Inst, 1985. 74: p. 955-75.
53. Chaturvedi, A. K., Engels, E. A., Gilbert, E. S., Chen, B. E., Storm, H., Lynch, C. F., et.al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk, J Natl Cancer Inst, 2007. 99: p. 1634-43.
54. Reulen, R. C., Kellen, E., Buntinx, F., Brinkman, M., Zeegers, M. P., A meta-analysis on the association between bladder cancer and occupation, Scand J Urol Nephrol Suppl, 2008. p. 64-78.
55. Bosetti, C., Boffetta, P., La Vecchia, C., Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005, Ann Oncol, 2007. 18: p. 431-46.
56. Butz, M., Beruflich verursachte Krebserkrankungen, DGUV, 2012. 10:
57. IARC, Working Group on the Evaluation of Carcinogenic Risks to Humans, Painting, Firefighting, and ShiftworkIARC Monogr Eval Carcinog Risks Hum, 2010.
58. Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to, Painting, Firefighting, and Shiftwork, 2010.
59. Claude, J. C., Frentzel-Beyme, R. R., Kunze, E., Occupation and risk of cancer of the lower urinary tract among men. A case-control study, Int J Cancer, 1988. 41: p. 371-9.
60. Myslak, Z. W., Bolt, H. M., Brockmann, W., Tumors of the urinary bladder in painters: a case-control study, Am J Ind Med, 1991. 19: p. 705-13.
61. Pesch, B., Haerting, J., Ranft, U., Klimpel, A., Oelschlagel, B., Schill, W., Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study, Int J Epidemiol, 2000. 29: p. 1014-24.
62. Golka, K., Heitmann, P., Gieseler, F., Hodzic, J., Masche, N., Bolt, H. M., et.al. Elevated bladder cancer risk due to colorants--a statewide case-control study in North Rhine-Westphalia, Germany, J Toxicol Environ Health A, 2008. 71: p. 851-5.
63. Bolm-Audorff U, Jöckel KH, Kilguss B, Pohlabeln H, Siepenkothen T, Bösartige Tumoren der ableitenden Harnwege und Risiken am ArbeitsplatzWirtschaftsverlag NW, Schriftenreihe der Bundesanstalt für Arbeitsschutz, Dortmund, Forschung, 1993. 1993; 697:
64. Humans, IARC Monographs on the Evaluation of Carcinogenic Risks to, Some Aromatic Amines, Organic Dyes, and Related Exposures, 2010.
65. Case, R. A., Hosker, M. E., Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales, Br J Prev Soc Med, 1954. 8: p. 39-50.
66. Humans, IARC Monographs on the Evaluation of Carcinogenic Risks to, A Review of Human Carcinogens: Chemical Agents and Related Occupations, 2012.
67. Straif, K., Weiland, S. K., Werner, B., Chambless, L., Mundt, K. A., Keil, U., Workplace risk factors for cancer in the German rubber industry: Part 2. Mortality from non-respiratory cancers, Occup Environ Med, 1998. 55: p. 325-32.
68. Vlaanderen, J., Taeger, D., Wellman, J., Keil, U., Schuz, J., Straif, K., Extended cancer mortality follow-up of a German rubber industry cohort, J Occup Environ Med, 2013. 55: p. 966-72.
69. Carreon, T., Hein, M. J., Hanley, K. W., Viet, S. M., Ruder, A. M., Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant, Occup Environ Med, 2014. 71: p. 175-82.
70. Golka, K., Bandel, T., Schlaefke, S., Reich, S. E., Reckwitz, T., Urfer, W., et.al. Urothelial cancer of the bladder in an area of former coal, iron, and steel industries in Germany: a case-control study, Int J Occup Environ Health, 1998. 4: p. 79-84.
71. Manz, A., Atem- und Harnwege als Lokalisationsstellen berufsbedingter (Teer-) Karzinome bei Kokerei- und Rohrnetzarbeitern, VDI-Berichte, 1980. 358: p. 227-235.
72. A., Manz, Atem- und Harnwege als Lokalisationsstellen berufsbedingter (Teer-) Karzinome bei Kokerei- und RohrnetzarbeiternWirtschaftsverlag NW, VDI-Berichte, 1980. 358:227-235:
73. Manz, A., Berger, J., Waltsgott, H., Zur Frage des Berufskrebses bei Beschäftigten der GasindustrieWirtschaftsverlag NW, Schriftenreihe der Bundesanstalt für Arbeitsschutz: Forschung, 1983.
74. Letzel S, Letzel H, Blümner E, Hendrichs A, Sommerburg C, Haut-, Bronchial-, Kehlkopf-, und Harnwegskarzinommorbidität bei Patienten mit berufsbedingter Teerhaut, Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, 1992.
75. Golka, K., Kopps, S., Prager, H. M., Mende, Sv, Thiel, R., Jungmann, O., et.al. Bladder cancer in crack testers applying azo dye-based sprays to metal bodies, J Toxicol Environ Health A, 2012. 75: p. 566-71.
76. Noon, A. P., Pickvance, S. M., Catto, J. W., Occupational exposure to crack detection dye penetrants and the potential for bladder cancer, Occup Environ Med, 2012. 69: p. 300-1.
77. BKV, Berufskrankheiten-Verordnung, 1997.
78. HVBG, Erfahrungen mit der Anwendung von § 9 Abs. 2 SGB VII (5. Erfahrungsbericht), 2006.
79. Cancer of the urinary bladder in highly exposed workers in the production of dinitrotoluenes: a case report, 2005.
80. IARC, Working Group on the Evaluation of Carcinogenic Risks to Humans, Some drinking-water disinfectants and contaminants, including arsenic, IARC Monogr Eval Carcinog Risks Hum, 2004. p. 1-477.
81. Muller, M., Bocher, A., Buchter, A., [Induction of urothelial carcinoma due to chronic arsenic ingestion? A occupational medicine-toxicological excursion], Urologe A, 2007. 46: p. 511-2, 514-5.
82. Catsburg, C. E., Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Cortessis, V. K., Pike, M. C., et.al. Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles bladder cancer study, Int J Cancer, 2014. 134: p. 125-35.
83. Mucci, L. A., Dickman, P. W., Steineck, G., Adami, H. O., Augustsson, K., Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden, Br J Cancer, 2003. 88: p. 84-9.
84. Ward, M. H., Cantor, K. P., Riley, D., Merkle, S., Lynch, C. F., Nitrate in public water supplies and risk of bladder cancer, Epidemiology, 2003. 14: p. 183-90.
85. Feki-Tounsi, M., Olmedo, P., Gil, F., Khlifi, R., Mhiri, M. N., Rebai, A., et.al. Low-level arsenic exposure is associated with bladder cancer risk and cigarette smoking: a case-control study among men in Tunisia, Environ Sci Pollut Res Int, 2013. 20: p. 3923-31.
86. Michaud, D. S., Wright, M. E., Cantor, K. P., Taylor, P. R., Virtamo, J., Albanes, D., Arsenic concentrations in prediagnostic toenails and the risk of bladder cancer in a cohort study of male smokers, Am J Epidemiol, 2004. 160: p. 853-9.
87. Saint-Jacques, N., Parker, L., Brown, P., Dummer, T. J., Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence, Environ Health, 2014. 13: p. 44.
88. Wu, S., Li, F., Huang, X., Hua, Q., Huang, T., Liu, Z., et.al. The association of tea consumption with bladder cancer risk: a meta-analysis, Asia Pac J Clin Nutr, 2013. 22: p. 128-37.
89. Bates, M. N., Hopenhayn, C., Rey, O. A., Moore, L. E., Bladder cancer and mate consumption in Argentina: a case-control study, Cancer Lett, 2007. 246: p. 268-73.
90. Villanueva, C. M., Silverman, D. T., Murta-Nascimento, C., Malats, N., Garcia-Closas, M., Castro, F., et.al. Coffee consumption, genetic susceptibility and bladder cancer risk, Cancer Causes Control, 2009. 20: p. 121-7.
91. De Stefani, E., Boffetta, P., Deneo-Pellegrini, H., Correa, P., Ronco, A. L., Brennan, P., et.al. Non-alcoholic beverages and risk of bladder cancer in Uruguay, BMC Cancer, 2007. 7: p. 57.
92. Wang, C., Jiang, H., Meat intake and risk of bladder cancer: a meta-analysis, Med Oncol, 2012. 29: p. 848-55.
93. Lumbreras, B., Garte, S., Overvad, K., Tjonneland, A., Clavel-Chapelon, F., Linseisen, J. P., et.al. Meat intake and bladder cancer in a prospective study: a role for heterocyclic aromatic amines?, Cancer Causes Control, 2008. 19: p. 649-56.
94. Michaud, D. S., Holick, C. N., Giovannucci, E., Stampfer, M. J., Meat intake and bladder cancer risk in 2 prospective cohort studies, Am J Clin Nutr, 2006. 84: p. 1177-83.
95. Liu, B., Mao, Q., Lin, Y., Zhou, F., Xie, L., The association of cruciferous vegetables intake and risk of bladder cancer: a meta-analysis, World J Urol, 2013. 31: p. 127-33.
96. Ros, M. M., Bueno-de-Mesquita, H. B., Kampman, E., Buchner, F. L., Aben, K. K., Egevad, L., et.al. Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition, Eur J Cancer, 2012. 48: p. 3267-77.
97. Brinkman, M. T., Buntinx, F., Kellen, E., Van Dongen, M. C., Dagnelie, P. C., Muls, E., et.al. Consumption of animal products, olive oil and dietary fat and results from the Belgian case-control study on bladder cancer risk, Eur J Cancer, 2011. 47: p. 436-42.
98. Kellen, E., Zeegers, M., Paulussen, A., Van Dongen, M., Buntinx, F., Fruit consumption reduces the effect of smoking on bladder cancer risk. The Belgian case control study on bladder cancer, Int J Cancer, 2006. 118: p. 2572-8.
99. Talaska, G., Al-Zoughool, M., Malaveille, C., Fiorini, L., Schumann, B., Vietas, J., et.al. Randomized controlled trial: effects of diet on DNA damage in heavy smokers, Mutagenesis, 2006. 21: p. 179-83.
100. Wakai, K., Hirose, K., Takezaki, T., Hamajima, N., Ogura, Y., Nakamura, S., et.al. Foods and beverages in relation to urothelial cancer: case-control study in Japan, Int J Urol, 2004. 11: p. 11-9.
101. Michaud, D. S., Pietinen, P., Taylor, P. R., Virtanen, M., Virtamo, J., Albanes, D., Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study, Br J Cancer, 2002. 87: p. 960-5.
102. Zeegers, M. P., Goldbohm, R. A., van den Brandt, P. A., Are retinol, vitamin C, vitamin E, folate and carotenoids intake associated with bladder cancer risk? Results from the Netherlands Cohort Study, Br J Cancer, 2001. 85: p. 977-83.
103. Ros, M. M., Bueno-de-Mesquita, H. B., Kampman, E., Aben, K. K., Buchner, F. L., Jansen, E. H., et.al. Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition, Am J Clin Nutr, 2012. 96: p. 902-10.
104. Mondul, A. M., Weinstein, S. J., Mannisto, S., Snyder, K., Horst, R. L., Virtamo, J., et.al. Serum vitamin D and risk of bladder cancer, Cancer Res, 2010. 70: p. 9218-23.
105. Lotan, Y., Goodman, P. J., Youssef, R. F., Svatek, R. S., Shariat, S. F., Tangen, C. M., et.al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT, J Urol, 2012. 187: p. 2005-10.
106. Brinkman, M. T., Buntinx, F., Kellen, E., Dagnelie, P. C., Van Dongen, M. C., Muls, E., et.al. Dietary intake of micronutrients and the risk of developing bladder cancer: results from the Belgian case-control study on bladder cancer risk, Cancer Causes Control, 2011. 22: p. 469-78.
107. ., Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study, 2011.
108. Mondul, A. M., Weinstein, S. J., Horst, R. L., Purdue, M., Albanes, D., Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial, Cancer Epidemiol Biomarkers Prev, 2012. 21: p. 1222-5.
109. Brinkman, M. T., Karagas, M. R., Zens, M. S., Schned, A., Reulen, R. C., Zeegers, M. P., Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire Study, Cancer Causes Control, 2010. 21: p. 609-19.
110. Boehm, K., Borrelli, F., Ernst, E., Habacher, G., Hung, S. K., Milazzo, S., et.al. Green tea (Camellia sinensis) for the prevention of cancer, Cochrane Database Syst Rev, 2009. p. CD005004.
111. Myung, S. K., Kim, Y., Ju, W., Choi, H. J., Bae, W. K., Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials, Ann Oncol, 2010. 21: p. 166-79.
112. Amaral, A. F., Cantor, K. P., Silverman, D. T., Malats, N., Selenium and bladder cancer risk: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 2407-15.
113. Wallace, K., Kelsey, K. T., Schned, A., Morris, J. S., Andrew, A. S., Karagas, M. R., Selenium and risk of bladder cancer: a population-based case-control study, Cancer Prev Res (Phila), 2009. 2: p. 70-3.
114. Munday, R., Mhawech-Fauceglia, P., Munday, C. M., Paonessa, J. D., Tang, L., Munday, J. S., et.al. Inhibition of urinary bladder carcinogenesis by broccoli sprouts, Cancer Res, 2008. 68: p. 1593-600.
115. Kellen, E., Zeegers, M., Buntinx, F., Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer, Int J Urol, 2006. 13: p. 1180-4.
116. Jacobs, E. J., Henion, A. K., Briggs, P. J., Connell, C. J., McCullough, M. L., Jonas, C. R., et.al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women, Am J Epidemiol, 2002. 156: p. 1002-10.
117. Virtamo, J., Edwards, B. K., Virtanen, M., Taylor, P. R., Malila, N., Albanes, D., et.al. Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland), Cancer Causes Control, 2000. 11: p. 933-9.
118. Messing, E. M., Madeb, R., Young, T., Gilchrist, K. W., Bram, L., Greenberg, E. B., et.al. Long-term outcome of hematuria home screening for bladder cancer in men, Cancer, 2006. 107: p. 2173-9.
119. Steiner, H., Bergmeister, M., Verdorfer, I., Granig, T., Mikuz, G., Bartsch, G., et.al. Early results of bladder-cancer screening in a high-risk population of heavy smokers, BJU Int, 2008. 102: p. 291-6.
120. Davis, R., Jones, J. S., Barocas, D. A., Castle, E. P., Lang, E. K., Leveillee, R. J., et.al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline, J Urol, 2012. 188: p. 2473-81.
121. Britton, J. P., Dowell, A. C., Whelan, P., Harris, C. M., A community study of bladder cancer screening by the detection of occult urinary bleeding, J Urol, 1992. 148: p. 788-90.
122. Turco, P., Houssami, N., Bulgaresi, P., Troni, G. M., Galanti, L., Cariaggi, M. P., et.al. Is conventional urinary cytology still reliable for diagnosis of primary bladder carcinoma? Accuracy based on data linkage of a consecutive clinical series and cancer registry, Acta Cytol, 2011. 55: p. 193-6.
123. Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W., Comperat, E., et.al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013, Eur Urol, 2013. 64: p. 639-53.
124. Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., et.al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers, Eur Urol, 2013. 63: p. 4-15.
125. Screening Adults for Bladder Cancer: Update of the 2004 Evidence Review for the US Preventive Services Task Force, 2010.
126. Pu, X. Y., Wang, Z. P., Chen, Y. R., Wang, X. H., Wu, Y. L., Wang, H. P., The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine, J Cancer Res Clin Oncol, 2008. 134: p. 659-65.
127. Guo, B., Luo, C., Xun, C., Xie, J., Wu, X., Pu, J., Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR, Exp Oncol, 2009. 31: p. 43-7.
128. Eissa, S., Swellam, M., Amin, A., Balbaa, M. E., Yacout, G. A., El-Zayat, T. M., The clinical relevance of urine-based markers for diagnosis of bladder cancer, Med Oncol, 2011. 28: p. 513-8.
129. Srivastava, R., Arora, V. K., Aggarwal, S., Bhatia, A., Singh, N., Agrawal, V., Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma, Diagn Cytopathol, 2012. 40: p. 755-9.
130. Gkialas, I., Papadopoulos, G., Iordanidou, L., Stathouros, G., Tzavara, C., Gregorakis, A., et.al. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma, Urology, 2008. 72: p. 1159-63.
131. Goodison, S., Rosser, C. J., Urquidi, V., Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests, Mol Diagn Ther, 2013. 17: p. 71-84.
132. Grossman, H. B., Messing, E., Soloway, M., Tomera, K., Katz, G., Berger, Y., et.al. Detection of bladder cancer using a point-of-care proteomic assay, JAMA, 2005. 293: p. 810-6.
133. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study, 2012.
134. Pesch, B., Taeger, D., Johnen, G., Gawrych, K., Bonberg, N., Schwentner, C., et.al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines, Int Arch Occup Environ Health, 2014. 87: p. 715-24.
135. Lotan, Y., Capitanio, U., Shariat, S. F., Hutterer, G. C., Karakiewicz, P. I., Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection, BJU Int, 2009. 103: p. 1368-74.
136. Lotan, Y., Elias, K., Svatek, R. S., Bagrodia, A., Nuss, G., Moran, B., et.al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker, J Urol, 2009. 182: p. 52-7; discussion 58.
137. Bangma, C. H., Loeb, S., Busstra, M., Zhu, X., Bouazzaoui, S. E., Refos, J., et.al. Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers, Eur Urol, 2013.
138. Todenhofer, T., Hennenlotter, J., Esser, M., Mohrhardt, S., Tews, V., Aufderklamm, S., et.al. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma, Cancer Cytopathol, 2013. 121: p. 252-60.
139. Kapila, K., Kehinde, E. O., Anim, J. T., Mojiminiyi, O. A., Vinsu, A., George, S. S., et.al. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University, Cytopathology, 2008. 19: p. 369-74.
140. van Rhijn, B. W. G., H. G. van der Poel, et al, Cytology and Urinary Markers for the Diagnosis of Bladder Cancer, European Urology Supplements, 2009. 8(7):536-541:
141. Van Tilborg, A. A., Bangma, C. H., Zwarthoff, E. C., Bladder cancer biomarkers and their role in surveillance and screening, Int J Urol, 2009. 16: p. 23-30.
142. Bonberg, N., Taeger, D., Gawrych, K., Johnen, G., Banek, S., Schwentner, C., et.al. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study, BJU Int, 2013. 112: p. E372-82.
143. Dimashkieh, H., Wolff, D. J., Smith, T. M., Houser, P. M., Nietert, P. J., Yang, J., Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation, Cancer Cytopathol, 2013. 121: p. 591-7.
144. Schlomer, B. J., Ho, R., Sagalowsky, A., Ashfaq, R., Lotan, Y., Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder, J Urol, 2010. 183: p. 62-7.
145. Gayed, B. A., Seideman, C., Lotan, Y., Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma, J Urol, 2013. 190: p. 1181-6.
146. Wadhwa, N., Jatawa, S. K., Tiwari, A., Non-invasive urine based tests for the detection of bladder cancer, Journal of Clinical Pathology, 2012. 65: p. 970-975.
147. Vrooman, O. P., Witjes, J. A., Urinary Markers in Bladder Cancer, Eur Urol, 2007.
148. Miyake, M., Goodison, S., Rizwani, W., Ross, S., Bart Grossman, H., Rosser, C. J., Urinary BTA: indicator of bladder cancer or of hematuria, World J Urol, 2012. 30: p. 869-73.
149. Giberti, C., Gallo, F., Schenone, M., Genova, A., Early results of urothelial carcinoma screening in a risk population of coke workers: urothelial carcinoma among coke workers, Biomed Environ Sci, 2010. 23: p. 300-4.
150. Odisho, A. Y., Berry, A. B., Ahmad, A. E., Cooperberg, M. R., Carroll, P. R., Konety, B. R., Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology, Eur Urol, 2013. 63: p. 936-40.
151. Moch, H.; Humphrey, PA; Ulbright, TM; Reuter, VE, WHO Classification of Tumours of the Urinary System and Male Genital OrgansInternational Agency for Research on Cancer (IARC), WHO OMS, 2016. 4:
152. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray, 2007.
153. Miettinen, M., McCue, P. A., Sarlomo-Rikala, M., Rys, J., Czapiewski, P., Wazny, K., et.al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors, Am J Surg Pathol, 2014. 38: p. 13-22.
154. Amin, M. B., Trpkov, K., Lopez-Beltran, A., Grignon, D., Members of the, Isup Immunohistochemistry in Diagnostic Urologic Pathology Group, Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference, Am J Surg Pathol, 2014. 38: p. e20-34.
155. Dabbs DJ, Thompson LDR, Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 2013.
156. Kaufmann, O., Fietze, E., Mengs, J., Dietel, M., Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas, Am J Clin Pathol, 2001. 116: p. 823-30.
157. Comperat, E., Camparo, P., Haus, R., Chartier-Kastler, E., Bart, S., Delcourt, A., et.al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases, Virchows Arch, 2006. 448: p. 319-24.
158. Langner, C., Ratschek, M., Tsybrovskyy, O., Schips, L., Zigeuner, R., P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors, J Histochem Cytochem, 2003. 51: p. 1097-9.
159. Nobre, A. R., Albergaria, A., Schmitt, F., p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63, Acta Cytol, 2013. 57: p. 1-8.
160. Lin, X., Zhu, B., Villa, C., Zhong, M., Kundu, S., Rohan, S. M., et.al. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma, Hum Pathol, 2014. 45: p. 1824-9.
161. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma., 2015.
162. Wang, H. L., Lu, D. W., Yerian, L. M., Alsikafi, N., Steinberg, G., Hart, J., et.al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma, Am J Surg Pathol, 2001. 25: p. 1380-7.
163. Jiang, J., Ulbright, T. M., Younger, C., Sanchez, K., Bostwick, D. G., Koch, M. O., et.al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis, Arch Pathol Lab Med, 2001. 125: p. 921-3.
164. Mhawech, P., Uchida, T., Pelte, M. F., Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma, Hum Pathol, 2002. 33: p. 1136-40.
165. Qureshi, H. S., Ormsby, A. H., Lee, M. W., Zarbo, R. J., Ma, C. K., The diagnostic utility of p63, CK5/6, CK 7, and CK 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas, J Cutan Pathol, 2004. 31: p. 145-52.
166. Esheba, G. E., Longacre, T. A., Atkins, K. A., Higgins, J. P., Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations, Am J Surg Pathol, 2009. 33: p. 347-53.
167. Gulmann, C., Paner, G. P., Parakh, R. S., Hansel, D. E., Shen, S. S., Ro, J. Y., et.al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract, Hum Pathol, 2013. 44: p. 164-72.
168. Kaufmann, O., Volmerig, J., Dietel, M., Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas, Am J Clin Pathol, 2000. 113: p. 683-7.
169. Smith, S. C., Mohanty, S. K., Kunju, L. P., Chang, E., Chung, F., Carvalho, J. C., et.al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings, Histopathology, 2014. 65: p. 132-8.
170. Tian, W., Guner, G., Miyamoto, H., Cimino-Mathews, A., Gonzalez-Roibon, N., Argani, P., et.al. Utility of uroplakin II expression as a marker of urothelial carcinoma, Hum Pathol, 2015. 46: p. 58-64.
171. Li, W., Liang, Y., Deavers, M. T., Kamat, A. M., Matin, S. F., Dinney, C. P., et.al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants, Am J Clin Pathol, 2014. 142: p. 864-71.
172. McKenney, J. K., Desai, S., Cohen, C., Amin, M. B., Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens, Am J Surg Pathol, 2001. 25: p. 1074-8.
173. Mallofre, C., Castillo, M., Morente, V., Sole, M., Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia, Mod Pathol, 2003. 16: p. 187-91.
174. Yildiz, I. Z., Recavarren, R., Armah, H. B., Bastacky, S., Dhir, R., Parwani, A. V., Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies, Diagn Pathol, 2009. 4: p. 35.
175. Knuchel-Clarke, R., Gaisa, N. T., [Preneoplastic lesions and precursors of urothelial cancer], Pathologe, 2016. 37: p. 33-9.
176. Mazzucchelli, R., Cheng, L., Lopez-Beltran, A., Scarpelli, M., Montironi, R., Clinicopathological significance of lymphovascular invasion in urothelial carcinoma, Anal Quant Cytopathol Histpathol, 2012. 34: p. 173-9.
177. Paner, G. P., Shen, S. S., Lapetino, S., Venkataraman, G., Barkan, G. A., Quek, M. L., et.al. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma, Am J Surg Pathol, 2009. 33: p. 91-8.
178. Miyamoto, H., Sharma, R. B., Illei, P. B., Epstein, J. I., Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma, Am J Surg Pathol, 2010. 34: p. 418-22.
179. Ch. Wittekind, H.-J. Meyer, UICC TNM-Klassifikation maligner TumorenWiley-VCH Verlag, 2010. 7:
180. Council, L., Hameed, O., Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma, Mod Pathol, 2009. 22: p. 639-50.
181. Bertz, S., Schmitz-Drager, B. J., Protzel, C., Hartmann, A., Intraoperative frozen section diagnosis of the genitourinary tract, Pathologe, 2012. 33: p. 441-9.
182. Gordetsky, J., Bivalacqua, T., Schoenberg, M., Epstein, J. I., Ureteral and urethral frozen sections during radical cystectomy or cystoprostatectomy: an analysis of denudation and atypia, Urology, 2014. 84: p. 619-23.
183. Gakis, G., Schilling, D., Perner, S., Schwentner, C., Sievert, K. D., Stenzl, A., Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis, World J Urol, 2011. 29: p. 451-6.
184. Gakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., et.al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder, Eur Urol, 2013. 63: p. 45-57.
185. Reder, N. P., Maxwell, S. P., Pambuccian, S. E., Barkan, G. A., Diagnostic accuracy of intraoperative frozen sections during radical cystectomy does not affect disease-free or overall survival: a study of 364 patients with urothelial carcinoma of the urinary bladder, Ann Diagn Pathol, 2015. 19: p. 107-12.
186. Palou, J., Wood, D., Bochner, B. H., van der Poel, H., Al-Ahmadie, H. A., Yossepowitch, O., et.al. ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate, Eur Urol, 2013. 63: p. 81-7.
187. Varinot, J., Camparo, P., Roupret, M., Bitker, M. O., Capron, F., Cussenot, O., et.al. Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage, Virchows Arch, 2009. 455: p. 449-53.
188. Gaya, J. M., Matulay, J., Badalato, G. M., Holder, D. D., Hruby, G., McKiernan, J., The role of preoperative prostatic urethral biopsy in clinical decision-making at the time of radical cystectomy, Can J Urol, 2014. 21: p. 7228-33.
189. Anleitung zur pathologisch-anatomischen Diagnostik von Tumoren des Nierenbeckens, des Ureters und der Harnblase, 2012.
190. Gaisa, N. T., Wilms, H., Wild, P. J., Jakse, G., Heidenreich, A., Knuechel, R., In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance, Virchows Arch, 2015. 466: p. 423-32.
191. Ch. Wittekind, J. Brierley, C.C. Compton, L.H. Sobin, UICC TNM-Supplement. Erläuterungen zur einheitllichen AnwendungWiley-VCH Verlag, 2013. 1:
192. Eble JN, Sauter G, Epstein JI, Sesterhenn IA., Pathology and genetics of tumours of the urinary system and male genital organs, IARC Press, 2004.
193. Moch, H.; Humphrey, PA; Ulbright, TM; Reuter, VE, WHO classification of Tumours of the Urinary System and Male Genital Organs.WHO, Blue Book, 2016. 4th edition:
194. Mostofi FK, Sobin LH, Histologic typing of urinary bladder tumorsWorld Health Organization, 1973.
195. Catto, J. W., Hartmann, A., Stoehr, R., Bolderson, E., Rehman, I., Rosario, D. J., et.al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance, J Urol, 2006. 175: p. 2323-30.
196. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies, 2002.
197. Abd El-Latif, A., Watts, K. E., Elson, P., Fergany, A., Hansel, D. E., The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy, J Urol, 2013. 189: p. 1263-7.
198. Mitra, A. P., Bartsch, C. C., Bartsch, G., Jr., Miranda, G., Skinner, E. C., Daneshmand, S., Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis, Urol Oncol, 2014. 32: p. 117-27.
199. Jordan, E. J., Iyer, G., Targeted therapy in advanced bladder cancer: what have we learned?, Urol Clin North Am, 2015. 42: p. 253-62, ix.
200. Otto, W., Denzinger, S., Fritsche, H. M., Burger, M., Wieland, W. F., Hofstadter, F., et.al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer, BJU Int, 2011. 107: p. 404-8.
201. Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., Ulbright, T. M., The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours, Eur Urol, 2016. 70: p. 93-105.
202. Beltran, A. L., Cheng, L., Montironi, R., Blanca, A., Leva, M., Roupret, M., et.al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder, Virchows Arch, 2014. 465: p. 199-205.
203. Linder, B. J., Frank, I., Cheville, J. C., Thompson, R. H., Thapa, P., Tarrell, R. F., et.al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis, J Urol, 2013. 189: p. 1670-5.
204. Zhong, M., Tian, W., Zhuge, J., Zheng, X., Huang, T., Cai, D., et.al. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation, Am J Surg Pathol, 2015. 39: p. 127-31.
205. Lopez, J. I., Angulo, J. C., Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance, Int Urol Nephrol, 2009. 41: p. 847-54.
206. Zarei, S., Frank, I., Boorjian, S. A., Thompson, R. H., Kim, S., Weight, C., et.al. Prognostic significance of measured depth of invasion of urothelial carcinoma of the bladder compared to the 2010 American Joint Committee on Cancer pT2 and pT3 classifications, J Urol, 2012. 188: p. 1706-11.
207. Idrees, M. T., Alexander, R. E., Kum, J. B., Cheng, L., The spectrum of histopathologic findings in vesical diverticulum: implications for pathogenesis and staging, Hum Pathol, 2013. 44: p. 1223-32.
208. Baltaci, S., Adsan, O., Ugurlu, O., Aslan, G., Can, C., Gunaydin, G., et.al. Reliability of frozen section examination of obturator lymph nodes and impact on lymph node dissection borders during radical cystectomy: results of a prospective multicentre study by the Turkish Society of Urooncology, BJU Int, 2011. 107: p. 547-53.
209. Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent, 2015.
210. Reis, S. T., Feitosa, E. B., Pontes-Junior, J., Marin, C. C., Abe, D. K., Crippa, A., et.al. Tumor banks: the cornerstone of basic research in urology, Int Braz J Urol, 2010. 36: p. 348-54.
211. Schumacher, M. C., Studer, U. E., Ureteric frozen sections during radical cystectomy for transitional cell carcinoma of the bladder--to do or not to do?, BJU Int, 2009. 103: p. 1149-50.
212. Truong, L. D., Krishnan, B., Shen, S. S., Intraoperative pathology consultation for kidney and urinary bladder specimens, Arch Pathol Lab Med, 2005. 129: p. 1585-601.
213. Volkmer, B. G., Schnoeller, T., Kuefer, R., Gust, K., Finter, F., Hautmann, R. E., Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?, J Urol, 2009. 182: p. 2632-7.
214. Raj, G. V., Tal, R., Vickers, A., Bochner, B. H., Serio, A., Donat, S. M., et.al. Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer, Cancer, 2006. 107: p. 2167-72.
215. Tollefson, M. K., Blute, M. L., Farmer, S. A., Frank, I., Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma, J Urol, 2010. 183: p. 81-6.
216. Akkad, T., Gozzi, C., Deibl, M., Muller, T., Pelzer, A. E., Pinggera, G. M., et.al. Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center, J Urol, 2006. 175: p. 1268-71; discussion 1271.
217. Donat, S. M., Wei, D. C., McGuire, M. S., Herr, H. W., The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer, J Urol, 2001. 165: p. 1580-4.
218. Kassouf, W., Spiess, P. E., Brown, G. A., Liu, P., Grossman, H. B., Dinney, C. P., et.al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction, J Urol, 2008. 180: p. 164-7; discussion 167.
219. Cho, K. S., Seo, J. W., Park, S. J., Lee, Y. H., Choi, Y. D., Cho, N. H., et.al. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder, Urol Int, 2009. 82: p. 306-11.
220. Osman, Y., El-Tabey, N., Abdel-Latif, M., Mosbah, A., Moustafa, N., Shaaban, A., The value of frozen-section analysis of ureteric margins on surgical decision-making in patients undergoing radical cystectomy for bladder cancer, BJU Int, 2007. 99: p. 81-4.
221. Massey, B. D., Nation, E. F., Gallup, C. A., Hendricks, E. D., Carcinoma of the Bladder: 20-Year Experience in Private Practice, J Urol, 1965. 93: p. 212-6.
222. Wallace, D. M., Harris, D. L., Delay in Treating Bladder Tumours, Lancet, 1965. 2: p. 332-4.
223. The effects of a haematuria service on the early diagnosis of bladder cancer., in Bladder cancer: principles of combination therapy, 1.
224. Lee, L. W., Davis, E., Jr., Gross urinary hemorrhage: a symptom, not a disease, J Am Med Assoc, 1953. 153: p. 782-4.
225. Burkholder, G. V., Dotin, L. N., Thomason, W. B., Beach, P. D., Unexplained hematuria. How extensive should the evaluation be?, JAMA, 1969. 210: p. 1729-33.
226. Turner, A. G., Hendry, W. F., Williams, G. B., Wallace, D. M., A haematuria diagnostic service, Br Med J, 1977. 2: p. 29-31.
227. Shephard, E. A., Stapley, S., Neal, R. D., Rose, P., Walter, F. M., Hamilton, W. T., Clinical features of bladder cancer in primary care, Br J Gen Pract, 2012. 62: p. e598-604.
228. Bruyninckx, R., Buntinx, F., Aertgeerts, B., Van Casteren, V., The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice, Br J Gen Pract, 2003. 53: p. 31-5.
229. Jones, R., Latinovic, R., Charlton, J., Gulliford, M. C., Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database, BMJ, 2007. 334: p. 1040.
230. Carson, C. C., 3rd, Segura, J. W., Greene, L. F., Clinical importance of microhematuria, JAMA, 1979. 241: p. 149-50.
231. Golin, A. L., Howard, R. S., Asymptomatic microscopic hematuria, J Urol, 1980. 124: p. 389-91.
232. Fracchia, J. A., Motta, J., Miller, L. S., Armenakas, N. A., Schumann, G. B., Greenberg, R. A., Evaluation of asymptomatic microhematuria, Urology, 1995. 46: p. 484-9.
233. Barocas, DA, Boorjian, SA, Alvarez, RD, Downs, TM, Gross, CP, Hamilton, BD, et.al. Microhematuria: AUA/SUFU Guideline., J Urol, 2020. 204 (4)(4): p. 778-786., https://pubmed.ncbi.nlm.nih.gov/32698717/
234. Woldu, SL, Ng, CK, Loo, RK, Slezak, JM, Jacobsen, SJ, Tan, WS, et.al. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria., J Urol, 2021. 205 (5)(5): p. 1387-1393., https://pubmed.ncbi.nlm.nih.gov/33356483/
235. Farrow, G. M., Utz, D. C., Rife, C. C., Greene, L. F., Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder, Cancer Res, 1977. 37: p. 2794-8.
236. The Paris System for Reporting Urinary Cytology - chapter 12, in ISBN 9783030886875+9783030886851+9783030886868, 2022.
237. Rossi, R., Jaeger, T., Borgermann, C., Furtkamp, C., Moos Stahl, R., Rubben, H., et.al. [Comparison of perioperative methylene blue-stained and permanent Papanicolaou-stained urine cytology to detect patients with high-grade urothelial cancer or the urinary bladder. Part 1], Urologe A, 2007. 46: p. 1145-7.
238. Wronska, D. B., Krajewska, M., Lygina, N., Morrison, J. C., Juzumiene, D., Culp, W. D., et.al. Peptide-conjugated glass slides for selective capture and purification of diagnostic cells: Applications in urine cytology, Biotechniques, 2014. 57: p. 63-71.
239. Busch, Y., vom Dorp, F., Schenck, M., Rossi, R., Witschier, J., Rubben, H., Effect of disturbing factors on the specificity of exfoliative urinary cytology, Urologe A, 2007. 46: p. 1141-4.
240. Rubben, H., Bubenzer, J., Bokenkamp, K., Lutzeyer, W., Rathert, P., Grading of transitional cell tumours of the urinary tract by urinary cytology, Urol Res, 1979. 7: p. 83-91.
241. Yafi, F. A., Brimo, F., Auger, M., Aprikian, A., Tanguay, S., Kassouf, W., Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer, Urol Oncol, 2014. 32: p. 27 e1-6.
242. Reid, M. D., Osunkoya, A. O., Siddiqui, M. T., Looney, S. W., Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement, Int J Clin Exp Pathol, 2012. 5: p. 882-91.
243. Glatz, K., Willi, N., Glatz, D., Barascud, A., Grilli, B., Herzog, M., et.al. An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system, Am J Clin Pathol, 2006. 126: p. 294-301.
244. Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?, 2011.
245. Barlandas-Rendon, E., Muller, M. M., Garcia-Latorre, E., Heinschink, A., Comparison of urine cell characteristics by flow cytometry and cytology in patients suspected of having bladder cancer, Clin Chem Lab Med, 2002. 40: p. 817-23.
246. Laukhtina, E, Pradere, B, Mori, K, Schuettfort, VM, Quhal, F, Mostafaei, H, et.al. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review., Urol Oncol, 2021. 39 (8)(8): p. 471-479., https://pubmed.ncbi.nlm.nih.gov/33888424/
247. Soorojebally, Y, Neuzillet, Y, Roumiguié, M, Lamy, PJ, Allory, Y, Descotes, F, et.al. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review., World J Urol, 2023. 41 (2)(2): p. 345-359., https://pubmed.ncbi.nlm.nih.gov/36592175/
248. EAU-guidelines Muscle-invasive and Metastatic Bladder Cancer, 2022., https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
249. Humphrey, PA, Moch, H, Cubilla, AL, Ulbright, TM, Reuter, VE, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours., Eur Urol, 2016. 70 (1)(1): p. 106-119., https://pubmed.ncbi.nlm.nih.gov/26996659/
250. Stanzione, N, Ahmed, T, Fung, PC, Cai, D, Lu, DY, Sumida, LC, et.al. The continual impact of the Paris System on urine cytology, a 3-year experience., Cytopathology, 2020. 31 (1)(1): p. 35-40., https://pubmed.ncbi.nlm.nih.gov/31596979/
251. de Paula, R, Oliveira, A, Nunes, W, Bovolim, G, Domingos, T, De Brot, L, et.al. Two-year study on the application of the Paris system for urinary cytology in a cancer centre., Cytopathology, 2020. 31 (1)(1): p. 41-46., https://pubmed.ncbi.nlm.nih.gov/31654587/
252. EAU, EAU guidelines on muscle-invasive and metastatic bladder cancer, 2023.
253. EAU Guideline on Non-muscle-invasive Bladder Cancer, 2023.
254. Suo, L, Vega, I, Thrall, M, Cyto-histo correlations of plasmacytoid and micropapillary variants of high-grade urothelial carcinoma: do they fit well in The Paris System for reporting urinary cytology?, J Am Soc Cytopathol, 2021. 10 (1)(1): p. 20-24., https://pubmed.ncbi.nlm.nih.gov/32620533/
255. Grossfeld, G. D., Wolf, J. S., Jr., Litwan, M. S., Hricak, H., Shuler, C. L., Agerter, D. C., et.al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations, Am Fam Physician, 2001. 63: p. 1145-54.
256. Jones, TD, Cheng, L, Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer., Urol Oncol, 2021. 39 (5)(5): p. 286-290., https://pubmed.ncbi.nlm.nih.gov/35550107/
257. Barkan, GA, Wojcik, EM, Nayar, R, Savic-Prince, S, Quek, ML, Kurtycz, DF, et.al. The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology., Adv Anat Pathol, 2016. 23 (4)(4): p. 193-201., https://pubmed.ncbi.nlm.nih.gov/27233050/
258. Yamasaki, M, Taoka, R, Katakura, K, Matsunaga, T, Kani, N, Honda, T, et.al. The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma., BMC Urol, 2022. 22 (1)(1): p. 51., https://pubmed.ncbi.nlm.nih.gov/35382830/
259. Kurtycz, DFI, Barkan, GA, Pavelec, DM, Rosenthal, DL, Wojcik, EM, VandenBussche, CJ, et.al. Paris Interobserver Reproducibility Study (PIRST)., J Am Soc Cytopathol, 2018. 7 (4)(4): p. 174-184., https://pubmed.ncbi.nlm.nih.gov/31043274/
260. Grossman, HB, Soloway, M, Messing, E, Katz, G, Stein, B, Kassabian, V, et.al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay., JAMA, 2006. 295 (3)(3): p. 299-305., https://pubmed.ncbi.nlm.nih.gov/16418465/
261. Rübben, H, Bubenzer, J, Bökenkamp, K, Lutzeyer, W, Rathert, P, Grading of transitional cell tumours of the urinary tract by urinary cytology., Urol Res, 1979. 7 (2)(2): p. 83-91., https://pubmed.ncbi.nlm.nih.gov/473447/
262. Yafi, FA, Brimo, F, Auger, M, Aprikian, A, Tanguay, S, Kassouf, W, Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer., Urol Oncol, 2014. 32 (1)(1): p. 27.e1-6., https://pubmed.ncbi.nlm.nih.gov/23410943/
263. Cha, E. K., Tirsar, L. A., Schwentner, C., Christos, P. J., Mian, C., Hennenlotter, J., et.al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study, Eur Urol, 2012. 61: p. 185-92.
264. Soyuer, I., Sofikerim, M., Tokat, F., Soyuer, S., Ozturk, F., Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression, Diagn Pathol, 2009. 4: p. 20.
265. Schmitz-Drager, B. J., Droller, M., Lokeshwar, V. B., Lotan, Y., Hudson, M. A., van Rhijn, B. W., et.al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus, Urol Int, 2015. 94: p. 1-24.
266. Vriesema, J. L., Atsma, F., Kiemeney, L. A., Peelen, W. P., Witjes, J. A., Schalken, J. A., Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence, Urology, 2001. 58: p. 367-71.
267. Dong, Y, Zhang, T, Li, X, Yu, F, Yu, H, Shao, S, Urine Biomarkers for the Diagnosis of Bladder Cancer: a Network Meta-Analysis., Urol J, 2021. 18 (6)(6): p. 623-632., https://pubmed.ncbi.nlm.nih.gov/34585369/
268. Sciarra, A, Di Lascio, G, Del Giudice, F, Leoncini, PP, Salciccia, S, Gentilucci, A, et.al. Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review., Curr Urol, 2021. 15 (1)(1): p. 22-32., https://pubmed.ncbi.nlm.nih.gov/34084118/
269. Soputro, NA, Gracias, DN, Dias, BH, Nzenza, T, O'Connell, H, Sethi, K, Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis., BJUI Compass, 2022. 3 (5)(5): p. 334-343., https://pubmed.ncbi.nlm.nih.gov/35950042/
270. Li, H. X., Li, M., Li, C. L., Ma, J. H., Wang, M. R., Rao, J., et.al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study, Anal Quant Cytol Histol, 2010. 32: p. 45-52.
271. Politi, E. N., Lazaris, A. C., Lambropoulou, S., Alexopoulou, D., Kyriakidou, V., Koutselini, H., Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens, Cytopathology, 2005. 16: p. 303-8.
272. Negri, S, Biavati, P, Bondi, A, The diagnostic value of cytohistological urine analysis and cytokeratin 20 in malignant and atypical urothelial cells., Pathologica, 2016. 108 (3)(3): p. 130-135., https://pubmed.ncbi.nlm.nih.gov/28195264/
273. Mowatt, G., Zhu, S., Kilonzo, M., Boachie, C., Fraser, C., Griffiths, T. R., et.al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer, Health Technol Assess, 2010. 14: p. 1-331, iii-iv.
274. Goebell, P. J., Kamat, A. M., Sylvester, R. J., Black, P., Droller, M., Godoy, G., et.al. Assessing the quality of studies on the diagnostic accuracy of tumor markers, Urol Oncol, 2014. 32: p. 1051-60.
275. Poulakis, V., Witzsch, U., De Vries, R., Altmannsberger, H. M., Manyak, M. J., Becht, E., A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results, BJU Int, 2001. 88: p. 692-701.
276. Sanchez-Carbayo, M., Herrero, E., Megias, J., Mira, A., Soria, F., Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, J Urol, 1999. 162: p. 1951-6.
277. Kundal, V. K., Pandith, A. A., Hamid, A., Shah, A., Kundal, R., Wani, S. M., Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence, Asian Pac J Cancer Prev, 2010. 11: p. 1279-82.
278. Lotan, Y., Roehrborn, C. G., Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses, Urology, 2003. 61: p. 109-18; discussion 118.
279. van Rhijn, B. W., van der Poel, H. G., van der Kwast, T. H., Urine markers for bladder cancer surveillance: a systematic review, Eur Urol, 2005. 47: p. 736-48.
280. Glas, A. S., Roos, D., Deutekom, M., Zwinderman, A. H., Bossuyt, P. M., Kurth, K. H., Tumor markers in the diagnosis of primary bladder cancer. A systematic review, J Urol, 2003. 169: p. 1975-82.
281. Sharma, S., Zippe, C. D., Pandrangi, L., Nelson, D., Agarwal, A., Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat, J Urol, 1999. 162: p. 53-7.
282. Shariat, S. F., Marberger, M. J., Lotan, Y., Sanchez-Carbayo, M., Zippe, C., Ludecke, G., et.al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer, J Urol, 2006. 176: p. 919-26; discussion 926.
283. Barbieri, C. E., Cha, E. K., Chromecki, T. F., Dunning, A., Lotan, Y., Svatek, R. S., et.al. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial, BJU Int, 2012. 109: p. 685-90.
284. Shariat, S. F., Savage, C., Chromecki, T. F., Sun, M., Scherr, D. S., Lee, R. K., et.al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis, Cancer, 2011. 117: p. 2892-7.
285. Priolo, G., Gontero, P., Martinasso, G., Mengozzi, G., Formiconi, A., Pelucelli, G., et.al. Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer, Clin Chim Acta, 2001. 305: p. 47-53.
286. Abogunrin, F., O'Kane, H. F., Ruddock, M. W., Stevenson, M., Reid, C. N., O'Sullivan, J. M., et.al. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria, Cancer, 2012. 118: p. 2641-50.
287. Lotan, Y., Svatek, R. S., Krabbe, L. M., Xylinas, E., Klatte, T., Shariat, S. F., Prospective external validation of a bladder cancer detection model, J Urol, 2014. 192: p. 1343-8.
288. Leyh, H., Marberger, M., Conort, P., Sternberg, C., Pansadoro, V., Pagano, F., et.al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer, Eur Urol, 1999. 35: p. 52-6.
289. Nasuti, J. F., Gomella, L. G., Ismial, M., Bibbo, M., Utility of the BTA stat test kit for bladder cancer screening, Diagn Cytopathol, 1999. 21: p. 27-9.
290. Hakenberg, OW, Fuessel, S, Richter, K, Froehner, M, Oehlschlaeger, S, Rathert, P, et.al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma., Urology, 2004. 64 (6)(6): p. 1121-6., https://pubmed.ncbi.nlm.nih.gov/15596183/
291. Babjuk, M., Kostirova, M., Mudra, K., Pecher, S., Smolova, H., Pecen, L., et.al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder, Eur Urol, 2002. 41: p. 34-9.
292. May, M., Hakenberg, O. W., Gunia, S., Pohling, P., Helke, C., Lubbe, L., et.al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice, Urology, 2007. 70: p. 449-53.
293. Sanchez, A., Wszolek, M. F., Bladder cancer: Quality of life in patients with non-muscle-invasive bladder cancer, Nat Rev Urol, 2015. 12: p. 186-8.
294. Schroeder, G. L., Lorenzo-Gomez, M. F., Hautmann, S. H., Friedrich, M. G., Ekici, S., Huland, H., et.al. A side by side comparison of cytology and biomarkers for bladder cancer detection, J Urol, 2004. 172: p. 1123-6.
295. Al-Maghrebi, M., Kehinde, E. O., Kapila, K., Anim, J. T., Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek(R) and urine cytology in the detection of transitional cell carcinoma of the bladder, Med Princ Pract, 2012. 21: p. 295-7.
296. Konety, B. R., Nguyen, T. S., Dhir, R., Day, R. S., Becich, M. J., Stadler, W. M., et.al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4, Clin Cancer Res, 2000. 6: p. 2618-25.
297. Huang, YL, Chen, J, Yan, W, Zang, D, Qin, Q, Deng, AM, Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis., Tumour Biol, 2015. 36 (5)(5): p. 3137-45., https://pubmed.ncbi.nlm.nih.gov/25854170/
298. Svatek, R. S., Herman, M. P., Lotan, Y., Casella, R., Hsieh, J. T., Sagalowsky, A. I., et.al. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer, Cancer, 2006. 106: p. 1701-7.
299. van Oers, J. M., Lurkin, I., van Exsel, A. J., Nijsen, Y., van Rhijn, B. W., van der Aa, M. N., et.al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine, Clin Cancer Res, 2005. 11: p. 7743-8.
300. Karnes, R. J., Fernandez, C. A., Shuber, A. P., A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria, Mayo Clin Proc, 2012. 87: p. 835-42.
301. Laukhtina, E, Shim, SR, Mori, K, D'Andrea, D, Soria, F, Rajwa, P, et.al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis., Eur Urol Oncol, 2021. 4 (6)(6): p. 927-942., https://pubmed.ncbi.nlm.nih.gov/34753702/
302. Sanchini, M. A., Gunelli, R., Nanni, O., Bravaccini, S., Fabbri, C., Sermasi, A., et.al. Relevance of urine telomerase in the diagnosis of bladder cancer, JAMA, 2005. 294: p. 2052-6.
303. Kelly, J. D., Dudderidge, T. J., Wollenschlaeger, A., Okoturo, O., Burling, K., Tulloch, F., et.al. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22, PLoS One, 2012. 7: p. e40305.
304. Saeb-Parsy, K., Wilson, A., Scarpini, C., Corcoran, M., Chilcott, S., McKean, M., et.al. Diagnosis of bladder cancer by immunocytochemical detection of minichromosome maintenance protein-2 in cells retrieved from urine, Br J Cancer, 2012. 107: p. 1384-91.
305. Stoeber, K, Swinn, R, Prevost, AT, de Clive-Lowe, P, Halsall, I, Dilworth, SM, et.al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments., J Natl Cancer Inst, 2002. 94 (14)(14): p. 1071-9., https://pubmed.ncbi.nlm.nih.gov/12122098/
306. Puerta-Gil, P., Garcia-Baquero, R., Jia, A. Y., Ocana, S., Alvarez-Mugica, M., Alvarez-Ossorio, J. L., et.al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer, Am J Pathol, 2012. 180: p. 1808-15.
307. de Martino, M., Shariat, S. F., Hofbauer, S. L., Lucca, I., Taus, C., Wiener, H. G., et.al. Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer, World J Urol, 2015. 33: p. 105-10.
308. O'Sullivan, P., Sharples, K., Dalphin, M., Davidson, P., Gilling, P., Cambridge, L., et.al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria, J Urol, 2012. 188: p. 741-7.
309. Breen, V., Kasabov, N., Kamat, A. M., Jacobson, E., Suttie, J. M., O'Sullivan, P. J., et.al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion(R) FISH, NMP22(R) and cytology based on imputation of multiple datasets, BMC Med Res Methodol, 2015. 15: p. 45.
310. Mengual, L., Ribal, M. J., Lozano, J. J., Ingelmo-Torres, M., Burset, M., Fernandez, P. L., et.al. Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models, J Urol, 2014. 191: p. 261-9.
311. Kramer, MW, Golshani, R, Merseburger, AS, Knapp, J, Garcia, A, Hennenlotter, J, et.al. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer., Eur Urol, 2010. 57 (1)(1): p. 86-93., https://pubmed.ncbi.nlm.nih.gov/19345473/
312. Wang, J, Zhao, X, Jiang, XL, Lu, D, Yuan, Q, Li, J, Diagnostic performance of nuclear matrix protein 22 and urine cytology for bladder cancer: A meta-analysis., Diagn Cytopathol, 2022. 50 (6)(6): p. 300-312., https://pubmed.ncbi.nlm.nih.gov/35322590/
313. Milowich, D, Le Mercier, M, De Neve, N, Sandras, F, Roumeguere, T, Decaestecker, C, et.al. Diagnostic value of the UCA1 test for bladder cancer detection: a clinical study., Springerplus, 2015. 4 (): p. 349., https://pubmed.ncbi.nlm.nih.gov/26191476/
314. Dardeer, KT, Mohammed, KA, Hussein, TD, Elsheemy, MS, Apolipoprotein A1 as a novel urinary biomarker for diagnosis of bladder cancer: A systematic review and meta-analysis., Indian J Urol, 2021. 37 (3)(3): p. 217-225., https://pubmed.ncbi.nlm.nih.gov/34465950/
315. Li, C, Li, H, Zhang, T, Li, J, Liu, L, Chang, J, Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis., Biochem Biophys Res Commun, 2014. 446 (4)(4): p. 1047-52., https://pubmed.ncbi.nlm.nih.gov/24661883/
316. Aalami, AH, Abdeahad, H, Mesgari, M, Sathyapalan, T, Sahebkar, A, Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis., Biomed Res Int, 2021. 2021 (): p. 5557309., https://pubmed.ncbi.nlm.nih.gov/33997007/
317. van Kessel, KE, Van Neste, L, Lurkin, I, Zwarthoff, EC, Van Criekinge, W, Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria., J Urol, 2016. 195 (3)(3): p. 601-7., https://pubmed.ncbi.nlm.nih.gov/26327355/
318. Jazayeri, SB, Dehghanbanadaki, H, Hosseini, M, Taghipour, P, Alam, MU, Balaji, KC, et.al. Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis., Urol Oncol, 2022. 40 (2)(2): p. 45-55., https://pubmed.ncbi.nlm.nih.gov/34895996/
319. Aslan, S, Cakir, IM, Oguz, U, Bekci, T, Demirelli, E, Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion?, Abdom Radiol (NY), 2022. 47 (2)(2): p. 771-780., https://pubmed.ncbi.nlm.nih.gov/34919161/
320. Jocham, D., Stepp, H., Waidelich, R., Photodynamic diagnosis in urology: state-of-the-art, Eur Urol, 2008. 53: p. 1138-48.
321. Filbeck, T., Pichlmeier, U., Knuechel, R., Wieland, W. F., Roessler, W., Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?, Urology, 2002. 60: p. 1025-8.
322. Walker, L., Liston, T. G., RW, L. Loyd-Davies, Does flexible cystoscopy miss more tumours than rod-lens examination?, Br J Urol, 1993. 72: p. 449-50.
323. Clayman, R. V., Shahin, S., Reddy, P., Fraley, E. E., Transurethral treatment of bladder diverticula. Alternative to open diverticulectomy, Urology, 1984. 23: p. 573-7.
324. Flannigan, G. M., Gelister, J. S., Noble, J. G., Milroy, E. J., Rigid versus flexible cystoscopy. A controlled trial of patient tolerance, Br J Urol, 1988. 62: p. 537-40.
325. Denholm, S. W., Conn, I. G., Newsam, J. E., Chisholm, G. D., Morbidity following cystoscopy: comparison of flexible and rigid techniques, Br J Urol, 1990. 66: p. 152-4.
326. Seklehner, S., Remzi, M., Fajkovic, H., Saratlija-Novakovic, Z., Skopek, M., Resch, I., et.al. Prospective multi-institutional study analyzing pain perception of flexible and rigid cystoscopy in men, Urology, 2015. 85: p. 737-41.
327. Witjes, J. A., Moonen, P. M., van der Heijden, A. G., Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study, Eur Urol, 2005. 47: p. 319-22.
328. Loidl, W, Schmidbauer, J, Susani, M, Marberger, M, Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?, Eur Urol, 2005. 47 (3)(3): p. 323-6., https://pubmed.ncbi.nlm.nih.gov/15716195/
329. Horstmann, M, Banek, S, Gakis, G, Todenhöfer, T, Aufderklamm, S, Hennenlotter, J, et.al. Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study., Springerplus, 2014. 3 (): p. 24., https://pubmed.ncbi.nlm.nih.gov/24478941/
330. Blick, C. G., Nazir, S. A., Mallett, S., Turney, B. W., Onwu, N. N., Roberts, I. S., et.al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic, BJU Int, 2012. 110: p. 84-94.
331. Sharp, V. J., Barnes, K. T., Erickson, B. A., Assessment of asymptomatic microscopic hematuria in adults, Am Fam Physician, 2013. 88: p. 747-54.
332. Sobin LH, Gospodarowicz MK, Wittekind C, TNM Classification of Malignant TumoursWiley-Blackwell, 2009. 7:
333. Lee, R., Droller, M. J., The natural history of bladder cancer. Implications for therapy, Urol Clin North Am, 2000. 27: p. 1-13, vii.
334. Woo, S, Panebianco, V, Narumi, Y, Del Giudice, F, Muglia, VF, Takeuchi, M, et.al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis., Eur Urol Oncol, 2020. 3 (3)(3): p. 306-315., https://pubmed.ncbi.nlm.nih.gov/32199915/
335. Panebianco, V, Pecoraro, M, Del Giudice, F, Takeuchi, M, Muglia, VF, Messina, E, et.al. VI-RADS for Bladder Cancer: Current Applications and Future Developments., J Magn Reson Imaging, 2022. 55 (1)(1): p. 23-36., https://pubmed.ncbi.nlm.nih.gov/32939939/
336. Bryan, RT, Liu, W, Pirrie, SJ, Amir, R, Gallagher, J, Hughes, AI, et.al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study., Eur Urol, 2021. 80 (1)(1): p. 12-15., https://pubmed.ncbi.nlm.nih.gov/33653635/
337. Lai, AL, Law, YM, VI-RADS in bladder cancer: Overview, pearls and pitfalls., Eur J Radiol, 2023. 160 (): p. 110666., https://pubmed.ncbi.nlm.nih.gov/36689790/
338. Goessl, C., Knispel, H. H., Miller, K., Klan, R., Is routine excretory urography necessary at first diagnosis of bladder cancer?, J Urol, 1997. 157: p. 480-1.
339. Herranz-Amo, F, Diez-Cordero, JM, Verdú-Tartajo, F, Bueno-Chomón, G, Leal-Hernández, F, Bielsa-Carrillo, A, Need for intravenous urography in patients with primary transitional carcinoma of the bladder?, Eur Urol, 1999. 36 (3)(3): p. 221-4., https://pubmed.ncbi.nlm.nih.gov/10450006/
340. Palou, J., Rodriguez-Rubio, F., Huguet, J., Segarra, J., Ribal, M. J., Alcaraz, A., et.al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor, J Urol, 2005. 174: p. 859-61; discussion 861.
341. Millan-Rodriguez, F., Chechile-Toniolo, G., Salvador-Bayarri, J., Huguet-Perez, J., Vicente-Rodriguez, J., Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups, J Urol, 2000. 164: p. 1183-7.
342. Van Der Molen, A. J., Cowan, N. C., Mueller-Lisse, U. G., Nolte-Ernsting, C. C., Takahashi, S., Cohan, R. H., et.al. CT urography: definition, indications and techniques. A guideline for clinical practice, Eur Radiol, 2008. 18: p. 4-17.
343. Narumi, Y., Kadota, T., Inoue, E., Kuriyama, K., Fujita, M., Hosomi, N., et.al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging, Radiology, 1993. 187: p. 145-50.
344. Dighe, M. K., Bhargava, P., Wright, J., Urinary bladder masses: techniques, imaging spectrum, and staging, J Comput Assist Tomogr, 2011. 35: p. 411-24.
345. Cowan, N. C., Crew, J. P., Imaging bladder cancer, Curr Opin Urol, 2010. 20: p. 409-13.
346. Tanimoto, A., Yuasa, Y., Imai, Y., Izutsu, M., Hiramatsu, K., Tachibana, M., et.al. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT, Radiology, 1992. 185: p. 741-7.
347. Rajesh, A., Sokhi, H., Fung, R., Mulcahy, K. A., Bankart, M. J., Role of whole-body staging computed tomographic scans for detecting distant metastases in patients with bladder cancer, J Comput Assist Tomogr, 2011. 35: p. 402-5.
348. Green, D. A., Durand, M., Gumpeni, N., Rink, M., Cha, E. K., Karakiewicz, P. I., et.al. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques, BJU Int, 2012. 110: p. 1463-70.
349. Chernyak, V., Novel imaging modalities for lymph node imaging in urologic oncology, Urol Clin North Am, 2011. 38: p. 471-81, vii.
350. Berger, G. L., Sadlowski, R. W., Sharpe, J. R., Finney, R. P., Lack of value of routine preoperative bone and liver scans in cystectomy candidates, J Urol, 1981. 125: p. 637-9.
351. Davey, P., Merrick, M. V., Duncan, W., Redpath, A. T., Bladder cancer: the value of routine bone scintigraphy, Clin Radiol, 1985. 36: p. 77-9.
352. Taher, A. N., Kotb, M. H., Bone metastases in muscle-invasive bladder cancer, J Egypt Natl Canc Inst, 2006. 18: p. 203-8.
353. Shinagare, A. B., Ramaiya, N. H., Jagannathan, J. P., Fennessy, F. M., Taplin, M. E., Van den Abbeele, A. D., Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor, AJR Am J Roentgenol, 2011. 196: p. 117-22.
354. Wallmeroth, A., Wagner, U., Moch, H., Gasser, T. C., Sauter, G., Mihatsch, M. J., Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients, Urol Int, 1999. 62: p. 69-75.
355. Sengelov, L., Kamby, C., von der Maase, H., Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma, J Urol, 1996. 155: p. 111-4.
356. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society, 2010.
357. Bouchelouche, K., Turkbey, B., Choyke, P. L., PET/CT and MRI in Bladder Cancer, J Cancer Sci Ther, 2012. S14:
358. Lu, Y. Y., Chen, J. H., Liang, J. A., Wang, H. Y., Lin, C. C., Lin, W. Y., et.al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis, Eur J Radiol, 2012. 81: p. 2411-6.
359. Richterstetter, M., Wullich, B., Amann, K., Haeberle, L., Engehausen, D. G., Goebell, P. J., et.al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer, BJU Int, 2012. 110: p. E76-9.
360. Langbein S, Badawi K, Haecker A, Weiss C, Hatzinger M, Alken P, Siegsmund M, Persistence, recurrence, and progression rates of superficial bladder tumours after resection using the differentiated technique, Med Princ Pract, 2006. 15: p. 215-8.
361. Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, Mishriki SF, N'Dow J, Grigor KM; Edinburgh Urological Cancer Group, Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking., BJU Int, 2012. 109: p. 1666-73.
362. Del Rosso A, Pace G, Masciovecchio S, Saldutto P, Galatioto GP, Vicentini C, Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: A single center randomized controlled trial, Int J Urol, 2013. 20: p. 399-403.
363. Gupta NP, Saini AK, Dogra PN, Seth A, Kumar R, Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience., BJU Int, 2011. 108: p. 553-6.
364. Matsushima M, Kikuchi E, Hasegawa M, Matsumoto K, Miyajima A, Oya M, Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study., BMC Urol, 2010. 10: p. doi: 10.1186/1471-2490-10-12..
365. Kramer MW, Wolters M, Abdelkawi IF, Merseburger AS, Nagele U, Gross A, Bach T, Kuczyk MA, Herrmann TRW, Transurethrale En-bloc Resektion nicht muskelinvasiver Harnblasenkarzinome- wo stehen wir heute?, Urologe, 2012. 51: p. 798-804.
366. Kramer MW, Bach T, Wolters M, Imkamp F, Abdelkawi IF, Gross A, Kuczyk MA, Merseburger AS, Herrmann TRW, Current evidence for transurethral laser therapy of non-muscle invasive blader cancer, World J Urol, 2011. 29: p. 433-42.
367. Zhong C, Guo S, Tang Y, Clinical observation of 2 micron laser for non-muscle-invasive bladder tumor treatment: single-center experience, World J Urol, 2010. 28: p. 157-61.
368. Zhu Y, Jiang X, Chen W, Shi B, Xu Z, Safety and efficacy of holmium laser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection, Urology, 2008. 72: p. 608-12.
369. Rouprêt M, Yates DR, Varinot J, Phé V, Chartier-Kastler E, Bitker MO, Compérat E, The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience., Can J Urol, 2012. 19: p. 6459-64.
370. Singh W, Sinha RJ, Sankhwar SN, Outcomes of simultaneous transurethral resection of bladder tumor and transurethral resection of the prostate in comparison with the procedures in two separate sittings in patients with bladder tumor and urodynamically proven bladder outflow obstruction, J Endourol, 2009. 23: p. 2007-11.
371. Luo S, Lin Y, Zhang W, Does simultaneous transurethral resection of bladder tumour and prostate affect the recurrence of bladder tumor? A meta-analysis, J Endourol, 2011. 25: p. 291-6.
372. Kausch, I., Sommerauer, M., Montorsi, F., Stenzl, A., Jacqmin, D., Jichlinski, P., et.al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies, Eur Urol, 2010. 57: p. 595-606.
373. Mowatt, G., N'Dow, J., Vale, L., Nabi, G., Boachie, C., Cook, J. A., et.al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis, Int J Technol Assess Health Care, 2011. 27: p. 3-10.
374. Stenzl, A., Penkoff, H., Dajc-Sommerer, E., Zumbraegel, A., Hoeltl, L., Scholz, M., et.al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial, Cancer, 2011. 117: p. 938-47.
375. O'Brien, T., Ray, E., Chatterton, K., Khan, M. S., Chandra, A., Thomas, K., Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer, BJU Int, 2013. 112: p. 1096-104.
376. Geavlete, B., Multescu, R., Georgescu, D., Jecu, M., Stanescu, F., Geavlete, P., Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?, BJU Int, 2012. 109: p. 549-56.
377. Yang, Lily PH, Hexaminolevulinate Blue Light Cystoscopy: A Review of Its Use in the Diagnosis of Bladder Cancer, Molecular diagnosis & therapy, 2014. 18: p. 105-116.
378. Stenzl, A., Burger, M., Fradet, Y., Mynderse, L. A., Soloway, M. S., Witjes, J. A., et.al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer, J Urol, 2010. 184: p. 1907-13.
379. Geavlete, B., Jecu, M., Multescu, R., Georgescu, D., Geavlete, P., HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study, Urology, 2010. 76: p. 664-9.
380. Karaolides, T., Skolarikos, A., Bourdoumis, A., Konandreas, A., Mygdalis, V., Thanos, A., et.al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?, Urology, 2012. 80: p. 354-9.
381. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study, 2011.
382. Yuan, H., Qiu, J., Liu, L., Zheng, S., Yang, L., Liu, Z., et.al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials, PLoS One, 2013. 8: p. e74142.
383. Rink, M., Babjuk, M., Catto, J. W., Jichlinski, P., Shariat, S. F., Stenzl, A., et.al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature, Eur Urol, 2013. 64: p. 624-38.
384. Burger, Maximilian, Stief, Christian G, Zaak, Dirk, Stenzl, Arnulf, Wieland, Wolf F, Jocham, Dieter, et.al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors, Urology, 2009. 74: p. 1282-1286.
385. Burger, M., Grossman, H. B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., et.al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data, Eur Urol, 2013. 64: p. 846-54.
386. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer, 2014.
387. Lapini, A., Minervini, A., Masala, A., Schips, L., Pycha, A., Cindolo, L., et.al. A comparison of hexaminolevulinate (Hexvix((R))) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study, Surg Endosc, 2012. 26: p. 3634-41.
388. Babjuk, Marko, Soukup, Viktor, Petrak, Radko, Jirsa, Milan, Dvoraicek, Jan, 5aminolaevulinic acidinduced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer, BJU international, 2005. 96: p. 798-802.
389. Isfoss, B. L., The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard, BJU Int, 2011. 108: p. 1703-7.
390. Grossman, H. B., Stenzl, A., Fradet, Y., Mynderse, L. A., Kriegmair, M., Witjes, J. A., et.al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy, J Urol, 2012. 188: p. 58-62.
391. Gkritsios, P., Hatzimouratidis, K., Kazantzidis, S., Dimitriadis, G., Ioannidis, E., Katsikas, V., Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial, Int Urol Nephrol, 2014. 46: p. 927-33.
392. Transurethral resection of non–muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study, 2010.
393. Shen, P., Yang, J., Wei, W., Li, Y., Li, D., Zeng, H., et.al. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis, BJU Int, 2012. 110: p. E209-15.
394. Daniltchenko, Dmitry I, Riedl, Claus R, Sachs, Markus D, Koenig, Frank, Daha, Kurosch L, Pflueger, Heinz, et.al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study, The Journal of urology, 2005. 174: p. 2129-2133.
395. Li, K., Lin, T., Fan, X., Duan, Y., Huang, J., Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis, Int J Urol, 2013. 20: p. 602-9.
396. Zheng, C., Lv, Y., Zhong, Q., Wang, R., Jiang, Q., Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis, BJU Int, 2012. 110: p. E680-7.
397. Naselli, A., Introini, C., Timossi, L., Spina, B., Fontana, V., Pezzi, R., et.al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence, Eur Urol, 2012. 61: p. 908-13.
398. Denzinger, S., Rossler, W., Otto, W., [Photodynamic diagnostic of superficial bladder carcinoma], Dtsch Med Wochenschr, 2007. 132: p. 2332-5.
399. Denzinger, S., Wieland, W. F., Otto, W., Filbeck, T., Knuechel, R., Burger, M., Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study, BJU Int, 2008. 101: p. 566-9.
400. Sivalingam, S., Probert, J. L., Schwaibold, H., The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer, BJU Int, 2005. 96: p. 759-62.
401. Schips, L., Augustin, H., Zigeuner, R. E., Galle, G., Habermann, H., Trummer, H., et.al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?, Urology, 2002. 59: p. 220-3.
402. Vogeli, T. A., Grimm, M. O., Simon, X., Ackermann, R., [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma], Urologe A, 2002. 41: p. 470-4.
403. Zurkirchen, MA, Sulser, T, Gaspert, A, Hauri, D, Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists, Urologia internationalis, 2003. 72: p. 99-102.
404. Vianello, A., Costantini, E., Del Zingaro, M., Bini, V., Herr, H. W., Porena, M., Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis, J Endourol, 2011. 25: p. 1703-12.
405. Ali, M. H., Ismail, I. Y., Eltobgy, A., Gobeish, A., Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer, J Endourol, 2010. 24: p. 2047-50.
406. Klan, R., Loy, V., Huland, H., Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder, J Urol, 1991. 146: p. 316-8.
407. Schwaibold, H. E., Sivalingam, S., May, F., Hartung, R., The value of a second transurethral resection for T1 bladder cancer, BJU Int, 2006. 97: p. 1199-201.
408. Lazica, D. A., Bottcher, S., Degener, S., von Rundstedt, F. C., Brandt, A. S., Roth, S., et.al. [T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases], Aktuelle Urol, 2013. 44: p. 124-8.
409. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?, 2007.
410. Divrik, R. T., Sahin, A. F., Yildirim, U., Altok, M., Zorlu, F., Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial, Eur Urol, 2010. 58: p. 185-90.
411. Kim, Wansuk, Song, Cheryn, Park, Sejun, Kim, Jongwon, Park, Jinsung, Kim, Seong Cheol, et.al. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor, Journal of Endourology, 2012. 26: p. 1059-1064.
412. Guevara, A., Salomon, L., Allory, Y., Ploussard, G., de la Taille, A., Paul, A., et.al. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer, J Urol, 2010. 183: p. 2161-4.
413. Takaoka, E., Matsui, Y., Inoue, T., Miyazaki, J., Nakashima, M., Kimura, T., et.al. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era, Jpn J Clin Oncol, 2013. 43: p. 404-9.
414. Okamura, K., Ono, Y., Kinukawa, T., Matsuura, O., Yamada, S., Ando, T., et.al. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma, Cancer, 2002. 94: p. 2363-8.
415. De Nunzio, C., Carbone, A., Albisinni, S., Alpi, G., Cantiani, A., Liberti, M., et.al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial, World J Urol, 2011. 29: p. 517-21.
416. Gudjonsson, S., Adell, L., Merdasa, F., Olsson, R., Larsson, B., Davidsson, T., et.al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study, Eur Urol, 2009. 55: p. 773-80.
417. Saika, T., Tsushima, T., Nasu, Y., Miyaji, Y., Saegusa, M., Takeda, K., et.al. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study, World J Urol, 2010. 28: p. 413-8.
418. Sylvester, R. J., Oosterlinck, W., van der Meijden, A. P., A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials, J Urol, 2004. 171: p. 2186-90, quiz 2435.
419. Abern, M. R., Owusu, R. A., Anderson, M. R., Rampersaud, E. N., Inman, B. A., Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis, J Natl Compr Canc Netw, 2013. 11: p. 477-84.
420. Krege, S., Giani, G., Meyer, R., Otto, T., Rubben, H., A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics, J Urol, 1996. 156: p. 962-6.
421. Solsona, E., Iborra, I., Ricos, J. V., Monros, J. L., Casanova, J., Dumont, R., Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup, J Urol, 1999. 161: p. 1120-3.
422. Sylvester, R. J., Oosterlinck, W., Witjes, J. A., The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials, Eur Urol, 2008. 53: p. 709-19.
423. Serretta, V., Morgia, G., Altieri, V., Di Lallo, A., Ruggiero, G., Salzano, L., et.al. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer, BJU Int, 2010. 106: p. 212-7.
424. EORTC, 2008.
425. Losa, A., Hurle, R., Lembo, A., Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results, J Urol, 2000. 163: p. 68-71; discussion 71-2.
426. Griffiths, T. R., Charlton, M., Neal, D. E., Powell, P. H., Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance, J Urol, 2002. 167: p. 2408-12.
427. Takenaka, A., Yamada, Y., Miyake, H., Hara, I., Fujisawa, M., Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder, Int J Urol, 2008. 15: p. 309-13.
428. Sylvester, R. J., van der, Meijden Ap, Lamm, D. L., Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 2002. 168: p. 1964-70.
429. Sylvester, R. J., Brausi, M. A., Kirkels, W. J., Hoeltl, W., Calais Da Silva, F., Powell, P. H., et.al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder, Eur Urol, 2010. 57: p. 766-73.
430. Malmstrom, P. U., Sylvester, R. J., Crawford, D. E., Friedrich, M., Krege, S., Rintala, E., et.al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer, Eur Urol, 2009. 56: p. 247-56.
431. Shang, P. F., Kwong, J., Wang, Z. P., Tian, J., Jiang, L., Yang, K., et.al. Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer, Cochrane Database Syst Rev, 2011. p. Cd006885.
432. Bohle, A., Bock, P. R., Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression, Urology, 2004. 63: p. 682-6; discussion 686-7.
433. Au, J. L., Badalament, R. A., Wientjes, M. G., Young, D. C., Warner, J. A., Venema, P. L., et.al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial, J Natl Cancer Inst, 2001. 93: p. 597-604.
434. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials., 2006.
435. Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., et.al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer, BJU Int, 2001. 88: p. 209-16.
436. Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., Mason, M. D., Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials, BJU Int, 2004. 93: p. 485-90.
437. Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Pineiro, L., Ojea, A., et.al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables, Eur Urol, 2011. 60: p. 423-30.
438. Zhu, S., Tang, Y., Li, K., Shang, Z., Jiang, N., Nian, X., et.al. Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies, BMC Cancer, 2013. 13: p. 332.
439. Jarvinen, R., Kaasinen, E., Sankila, A., Rintala, E., FinnBladder, Group, Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up, Eur Urol, 2009. 56: p. 260-5.
440. Duchek, M., Johansson, R., Jahnson, S., Mestad, O., Hellstrom, P., Hellsten, S., et.al. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study, Eur Urol, 2010. 57: p. 25-31.
441. Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et.al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance, Eur Urol, 2013. 63: p. 462-72.
442. Bohle, A., Jocham, D., Bock, P. R., Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity, J Urol, 2003. 169: p. 90-5.
443. Friedrich, M. G., Pichlmeier, U., Schwaibold, H., Conrad, S., Huland, H., Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma, Eur Urol, 2007. 52: p. 1123-29.
444. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A., et.al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, 2000. 163: p. 1124-9.
445. Gardmark, T., Jahnson, S., Wahlquist, R., Wijkstrom, H., Malmstrom, P. U., Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer, BJU Int, 2007. 99: p. 817-20.
446. Martinez-Pineiro, L., Portillo, J. A., Fernandez, J. M., Zabala, J. A., Cadierno, I., Moyano, J. L., et.al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013, Eur Urol, 2015. 68: p. 256-62.
447. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis), 2007.
448. Gontero, P., Bohle, A., Malmstrom, P. U., O'Donnell, M. A., Oderda, M., Sylvester, R., et.al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer, Eur Urol, 2010. 57: p. 410-29.
449. Ehdaie, B., Sylvester, R., Herr, H. W., Maintenance bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence, Eur Urol, 2013. 64: p. 579-85.
450. Colombel, M., Saint, F., Chopin, D., Malavaud, B., Nicolas, L., Rischmann, P., The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study, J Urol, 2006. 176: p. 935-9.
451. Martinez-Pineiro, J. A., Martinez-Pineiro, L., Solsona, E., Rodriguez, R. H., Gomez, J. M., Martin, M. G., et.al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial, J Urol, 2005. 174: p. 1242-7.
452. Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et.al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG, Eur Urol, 2014. 65: p. 69-76.
453. van der Meijden, A. P., Brausi, M., Zambon, V., Kirkels, W., de Balincourt, C., Sylvester, R., et.al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial, J Urol, 2001. 166: p. 476-81.
454. Ojea, A., Nogueira, J. L., Solsona, E., Flores, N., Gomez, J. M., Molina, J. R., et.al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C, Eur Urol, 2007. 52: p. 1398-406.
455. Rentsch, C. A., Birkhauser, F. D., Biot, C., Gsponer, J. R., Bisiaux, A., Wetterauer, C., et.al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy, Eur Urol, 2014. 66: p. 677-88.
456. Tilki, D., Reich, O., Svatek, R. S., Karakiewicz, P. I., Kassouf, W., Novara, G., et.al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients, J Urol, 2010. 183: p. 1757-63.
457. Outcomes of patients with clinical CIS-only disease treated with radical cystectomy, 2009.
458. Fritsche, H. M., Burger, M., Dietmaier, W., Denzinger, S., Bach, E., Otto, W., et.al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder, Am J Clin Pathol, 2010. 134: p. 597-603.
459. Burger, M., Oosterlinck, W., Konety, B., Chang, S., Gudjonsson, S., Pruthi, R., et.al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder, Eur Urol, 2013. 63: p. 36-44.
460. ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion., 2013.
461. Bolenz, C., West, A. M., Ortiz, N., Kabbani, W., Lotan, Y., Urinary cytology for the detection of urothelial carcinoma of the bladder-a flawed adjunct to cystoscopy?, Urol Oncol, 2013. 31: p. 366-71.
462. Lerner, S. P., Liu, H., Wu, M. F., Thomas, Y. K., Witjes, J. A., Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder, Urol Oncol, 2012. 30: p. 285-9.
463. Chade, D. C., Shariat, S. F., Adamy, A., Bochner, B. H., Donat, S. M., Herr, H. W., et.al. Clinical outcome of primary versus secondary bladder carcinoma in situ, J Urol, 2010. 184: p. 464-9.
464. Meijer, R. P., van Onna, I. E., Kok, E. T., Bosch, R., The risk profiles of three clinical types of carcinoma in situ of the bladder, BJU Int, 2011. 108: p. 839-43.
465. Gofrit, O. N., Pode, D., Pizov, G., Zorn, K. C., Katz, R., Duvdevani, M., et.al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy, Urol Oncol, 2009. 27: p. 258-62.
466. Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer., 2011.
467. Sengiku, A., Ito, M., Miyazaki, Y., Sawazaki, H., Takahashi, T., Ogura, K., A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer, J Urol, 2013. 190: p. 50-4.
468. Jakse, G., Hall, R., Bono, A., Holtl, W., Carpentier, P., Spaander, J. P., et.al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861, Eur Urol, 2001. 40: p. 144-50.
469. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study, 2003. 43: p. 637-45.
470. Sylvester, R. J., van der Meijden, A. P., Witjes, J. A., Kurth, K., Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials, J Urol, 2005. 174: p. 86-91; discussion 91-2.
471. Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Pineiro, L., Gonzalez, M., et.al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model, J Urol, 2009. 182: p. 2195-203.
472. Porena M, Del Zingaro M, Lazzeri M, Mearini L, Giannantoni A, Bini V, Costantini E, Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study., Urol Int, 2010. 84: p. 23-7.
473. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial., 2010. 116: p. 1893-900.
474. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S., Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance., J Clin Oncol, 2010. 28: p. 543-8.
475. Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, Pavone-Macaluso M, Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma., J Clin Oncol, 2003. 21: p. 4270-6.
476. Colombo R, Brausi M, Da Pozzo L, Salonia A, Montorsi F, Scattoni V, Roscigno M, Rigatti P, Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion., Eur Urol, 2001. 39: p. 95-100.
477. Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P, Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer., J Urol, 1996. 155: p. 1227-32.
478. Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, Colombo R, The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review., Eur Urol, 2011. 60: p. 81-93.
479. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL., Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial., Lancet Oncol., 2006. 7: p. 43-51.
480. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre stud, 2009. 56: p. 495-503.
481. Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG, Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review., BJU Int, 2012. 109: p. 496-505.
482. Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M, Intravesical gemcitabine for non-muscle invasive bladder cancer (Review), The Cochrane Library, 2012.
483. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G, Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study., J Urol, 2003. 170: p. 777-82.
484. Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, Masedu F, Ricci AR, Micali F, Vespasiani G, Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial., Lancet Oncol, 2011. 12: p. 871-9.
485. Fritsche, H. M., Burger, M., Svatek, R. S., Jeldres, C., Karakiewicz, P. I., Novara, G., et.al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort, Eur Urol, 2010. 57: p. 300-9.
486. Palou, J., Sylvester, R. J., Faba, O. R., Parada, R., Pena, J. A., Algaba, F., et.al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin, Eur Urol, 2012. 62: p. 118-25.
487. Badalato, G. M., Gaya, J. M., Hruby, G., Patel, T., Kates, M., Sadeghi, N., et.al. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?, BJU Int, 2012. 110: p. 1471-7.
488. Denzinger, S., Fritsche, H. M., Otto, W., Blana, A., Wieland, W. F., Burger, M., Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?, Eur Urol, 2008. 53: p. 146-52.
489. Thomas, F., Noon, A. P., Rubin, N., Goepel, J. R., Catto, J. W., Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer, Eur Urol, 2013. 63: p. 145-54.
490. Segal, R., Yafi, F. A., Brimo, F., Tanguay, S., Aprikian, A., Kassouf, W., Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?, BJU Int, 2012. 109: p. 1026-30.
491. Amling, C. L., Thrasher, J. B., Frazier, H. A., Dodge, R. K., Robertson, J. E., Paulson, D. F., Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder, J Urol, 1994. 151: p. 31-5; discussion 35-6.
492. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?, 2001.
493. Kamat, A. M., Gee, J. R., Dinney, C. P., Grossman, H. B., Swanson, D. A., Millikan, R. E., et.al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma, J Urol, 2006. 175: p. 881-5.
494. Alkhateeb, S. S., Van Rhijn, B. W., Finelli, A., van der Kwast, T., Evans, A., Hanna, S., et.al. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors, J Urol, 2010. 184: p. 81-6.
495. van den Bosch, S., Alfred Witjes, J., Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review, Eur Urol, 2011. 60: p. 493-500.
496. Palou, J., Rodriguez-Rubio, F., Millan, F., Algaba, F., Rodriguez-Faba, O., Huguet, J., et.al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors, Urology, 2009. 73: p. 1313-7.
497. Shariat, S. F., Palapattu, G. S., Amiel, G. E., Karakiewicz, P. I., Rogers, C. G., Vazina, A., et.al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy, Urology, 2006. 68: p. 538-42.
498. Dalbagni, G., Vora, K., Kaag, M., Cronin, A., Bochner, B., Donat, S. M., et.al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer, Eur Urol, 2009. 56: p. 903-10.
499. May, M., Bastian, P. J., Brookman-May, S., Burger, M., Bolenz, C., Trojan, L., et.al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder, Scand J Urol Nephrol, 2011. 45: p. 251-7.
500. Shariat, S. F., Palapattu, G. S., Karakiewicz, P. I., Rogers, C. G., Vazina, A., Bastian, P. J., et.al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy, Eur Urol, 2007. 51: p. 137-49; discussion 149-51.
501. Svatek, R. S., Shariat, S. F., Novara, G., Skinner, E. C., Fradet, Y., Bastian, P. J., et.al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort, BJU Int, 2011. 107: p. 898-904.
502. Turker, P., Bostrom, P. J., Wroclawski, M. L., van Rhijn, B., Kortekangas, H., Kuk, C., et.al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome, BJU Int, 2012. 110: p. 804-11.
503. Lerner, S. P., Tangen, C. M., Sucharew, H., Wood, D., Crawford, E. D., Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer, Urol Oncol, 2009. 27: p. 155-9.
504. Matsumoto, K., Kikuchi, E., Shirakawa, H., Hayakawa, N., Tanaka, N., Ninomiya, A., et.al. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guerin relapsing non-muscle-invasive bladder cancer, BJU Int, 2012. 110: p. E508-13.
505. Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer, 2012.
506. Huguet, J., Crego, M., Sabate, S., Salvador, J., Palou, J., Villavicencio, H., Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor, Eur Urol, 2005. 48(1): p. 53-9; discussion 59., https://www.ncbi.nlm.nih.gov/pubmed/15967252
507. Shirakawa, H., Kikuchi, E., Tanaka, N., Matsumoto, K., Miyajima, A., Nakamura, S., et.al. Prognostic significance of Bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer, BJU Int, 2012. 110: p. E216-21.
508. Lambert, E. H., Pierorazio, P. M., Olsson, C. A., Benson, M. C., McKiernan, J. M., Poon, S., The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy, BJU Int, 2007. 100: p. 33-6.
509. Thalmann, G. N., Markwalder, R., Shahin, O., Burkhard, F. C., Hochreiter, W. W., Studer, U. E., Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?, J Urol, 2004. 172: p. 70-5.
510. Bostrom, P. J., Alkhateeb, S., van Rhijn, B. W., Kuk, C., Zlotta, A. R., Optimal timing of radical cystectomy in T1 high-grade bladder cancer, Expert Rev Anticancer Ther, 2010. 10: p. 1891-902.
511. Branchereau, J., Larue, S., Vayleux, B., Karam, G., Bouchot, O., Rigaud, J., Prognostic value of the lymphovascular invasion in high-grade stage pT1 bladder cancer, Clin Genitourin Cancer, 2013. 11: p. 182-8.
512. Faba, O. R., Palou, J., Breda, A., Villavicencio, H., High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment, World J Urol, 2012. 30: p. 833-40.
513. Lodde, M., Mayr, R., Martini, T., Comploj, E., Palermo, S., Trenti, E., et.al. Positive urine cytology and carcinoma in situ prior to second transurethral resection of the bladder correlate with positive second resection histology and the need for subsequent cystectomy, World J Urol, 2012. 30: p. 841-6.
514. Bianco, F. J., Jr., Justa, D., Grignon, D. J., Sakr, W. A., Pontes, J. E., Wood, D. P., Jr., Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy, Urol Oncol, 2004. 22: p. 290-4.
515. Chalasani, V., Kassouf, W., Chin, J. L., Fradet, Y., Aprikian, A. G., Fairey, A. S., et.al. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience, Can Urol Assoc J, 2011. 5: p. 83-7.
516. Freeman, J. A., Esrig, D., Stein, J. P., Simoneau, A. R., Skinner, E. C., Chen, S. C., et.al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction, Cancer, 1995. 76: p. 833-9.
517. Ghoneim, M. A., Abdel-Latif, M., el-Mekresh, M., Abol-Enein, H., Mosbah, A., Ashamallah, A., et.al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later, J Urol, 2008. 180: p. 121-7.
518. Madersbacher, S., Hochreiter, W., Burkhard, F., Thalmann, G. N., Danuser, H., Markwalder, R., et.al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy, J Clin Oncol, 2003. 21: p. 690-6.
519. Raj, G. V., Herr, H., Serio, A. M., Donat, S. M., Bochner, B. H., Vickers, A. J., et.al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer, J Urol, 2007. 177: p. 1283-6; discussion 1286.
520. Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A. C., Boyd, S., et.al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, 2001. 19: p. 666-75.
521. Bertz, S., Otto, W., Denzinger, S., Wieland, W. F., Burger, M., Stohr, R., et.al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer, Eur Urol, 2014. 65: p. 218-26.
522. Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Vander Eeckt, K., Serretta, V., et.al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients, Eur Urol, 2015. 67: p. 74-82.
523. Martin-Doyle, W., Leow, J. J., Orsola, A., Chang, S. L., Bellmunt, J., Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients, J Clin Oncol, 2015. 33: p. 643-50.
524. Arends, T. J., van der Heijden, A. G., Witjes, J. A., Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer, J Urol, 2014. 192: p. 708-13.
525. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era, 2006.
526. Simone, G., Gallucci, M., Multimodality treatment versus radical cystectomy: bladder sparing at cost of life?, Eur Urol, 2012. 61: p. 712-3; discussion 713-4.
527. Shariat, S. F., Karakiewicz, P. I., Palapattu, G. S., Lotan, Y., Rogers, C. G., Amiel, G. E., et.al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium, J Urol, 2006. 176: p. 2414-22; discussion 2422.
528. Sandler, H. M., Mirhadi, A. J., Current role of radiation therapy for bladder cancer, Semin Oncol, 2012. 39: p. 583-7.
529. Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., et.al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience, Eur Urol, 2012. 61: p. 705-11.
530. Hussain, S. A., Stocken, D. D., Peake, D. R., Glaholm, J. G., Zarkar, A., Wallace, D. M., et.al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer, Br J Cancer, 2004. 90: p. 2106-11.
531. James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., et.al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 2012. 366: p. 1477-88.
532. Krause, F. S., Walter, B., Ott, O. J., Haberle, L., Weiss, C., Rodel, C., et.al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment, Anticancer Res, 2011. 31: p. 985-90.
533. Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., et.al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233, J Clin Oncol, 2014. 32: p. 3801-9.
534. Rodel, C., Grabenbauer, G. G., Kuhn, R., Papadopoulos, T., Dunst, J., Meyer, M., et.al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results, J Clin Oncol, 2002. 20: p. 3061-71.
535. Rodel, C., Weiss, C., Sauer, R., Combined systemic therapy and radiotherapy for bladder cancer, Strahlenther Onkol, 2007. 183 Spec No 2: p. 29-31.
536. Shipley, W. U., Kaufman, D. S., Zehr, E., Heney, N. M., Lane, S. C., Thakral, H. K., et.al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer, Urology, 2002. 60: p. 62-7; discussion 67-8.
537. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder., 2007.
538. Mulders, P. F., Hoekstra, W. J., Heybroek, R. P., Schapers, E. R., Verbeek, A. L., Oosterhof, G. O., et.al. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group, Eur J Cancer, 1994. 30A: p. 914-7.
539. de Crevoisier, R., Ammor, A., Court, B., Wibault, P., Chirat, E., Fizazi, K., et.al. Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: results of a 28-year single institution experience, Radiother Oncol, 2004. 72: p. 147-57.
540. Koning, C. C., Blank, L. E., Koedooder, C., van Os, R. M., van de Kar, M., Jansen, E., et.al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors, Ann Oncol, 2012. 23: p. 2948-53.
541. Nieuwenhuijzen, J. A., Pos, F., Moonen, L. M., Hart, A. A., Horenblas, S., Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience, Eur Urol, 2005. 48: p. 239-45.
542. van der Werf-Messing, B., Hop, W. C., Carcinoma of the urinary bladder (category T1NxM0) treated either by radium implant or by transurethral resection only, International Journal of Radiation Oncology, Biology, Physics, 1981. 7: p. 299-303.
543. Weiss, C., Wolze, C., Engehausen, D. G., Ott, O. J., Krause, F. S., Schrott, K. M., et.al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?, J Clin Oncol, 2006. 24: p. 2318-24.
544. Denzinger, S., Burger, M., Fritsche, H. M., Ganzer, R., Blana, A., Wieland, W. F., et.al. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?], Aktuelle Urol, 2008. 39: p. 58-61; discussion 62-3.
545. Stockle, M., Alken, P., Engelmann, U., Jacobi, G. H., Riedmiller, H., Hohenfellner, R., Radical cystectomy--often too late?, Eur Urol, 1987. 13: p. 361-7.
546. De Berardinis, E., Busetto, G. M., Antonini, G., Giovannone, R., Gentile, V., T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy, Int Urol Nephrol, 2011. 43: p. 1047-57.
547. Gunlusoy, B., Degirmenci, T., Arslan, M., Nergiz, N., Minareci, S., Ayder, A. R., Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin, Urol Int, 2005. 75: p. 107-13.
548. Kulkarni, J. N., Gupta, R., Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain), BJU Int, 2002. 90: p. 554-7.
549. Shahin, O., Thalmann, G. N., Rentsch, C., Mazzucchelli, L., Studer, U. E., A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival, J Urol, 2003. 169: p. 96-100; discussion 100.
550. Gray, P. J., Fedewa, S. A., Shipley, W. U., Efstathiou, J. A., Lin, C. C., Zietman, A. L., et.al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base, Eur Urol, 2013. 63: p. 823-9.
551. Goossens-Laan, C. A., Gooiker, G. A., van Gijn, W., Post, P. N., Bosch, J. L., Kil, P. J., et.al. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate, Eur Urol, 2011. 59: p. 775-83.
552. Morgan, T. M., Keegan, K. A., Barocas, D. A., Ruhotina, N., Phillips, S. E., Chang, S. S., et.al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy, J Urol, 2011. 186: p. 829-34.
553. Ramani, V. A., Bromage, S. J., Clarke, N. W., A contemporary standard for morbidity and outcome after radical cystectomy, BJU Int, 2009. 104: p. 628-32.
554. Clavien, P. A., Barkun, J., de Oliveira, M. L., Vauthey, J. N., Dindo, D., Schulick, R. D., et.al. The Clavien-Dindo classification of surgical complications: five-year experience, Ann Surg, 2009. 250: p. 187-96.
555. Li, K., Lin, T., Fan, X., Xu, K., Bi, L., Duan, Y., et.al. Systematic review and meta-analysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy, Cancer Treat Rev, 2013. 39: p. 551-60.
556. Ng, C. K., Kauffman, E. C., Lee, M. M., Otto, B. J., Portnoff, A., Ehrlich, J. R., et.al. A comparison of postoperative complications in open versus robotic cystectomy, Eur Urol, 2010. 57: p. 274-81.
557. Sabir, E. F., Holmang, S., Liedberg, F., Ljungberg, B., Malmstrom, P. U., Mansson, W., et.al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden, Scand J Urol, 2013. 47: p. 483-90.
558. Khan, M. S., Elhage, O., Challacombe, B., Rimington, P., Murphy, D., Dasgupta, P., Analysis of early complications of robotic-assisted radical cystectomy using a standardized reporting system, Urology, 2011. 77: p. 357-62.
559. Froehner, M., Brausi, M. A., Herr, H. W., Muto, G., Studer, U. E., Complications following radical cystectomy for bladder cancer in the elderly, Eur Urol, 2009. 56: p. 443-54.
560. Finks, J. F., Osborne, N. H., Birkmeyer, J. D., Trends in hospital volume and operative mortality for high-risk surgery, N Engl J Med, 2011. 364: p. 2128-37.
561. Mayer, E. K., Bottle, A., Darzi, A. W., Athanasiou, T., Vale, J. A., The volume-mortality relation for radical cystectomy in England: retrospective analysis of hospital episode statistics, BMJ, 2010. 340: p. c1128.
562. Morgan, T. M., Barocas, D. A., Keegan, K. A., Cookson, M. S., Chang, S. S., Ni, S., et.al. Volume outcomes of cystectomy--is it the surgeon or the setting?, J Urol, 2012. 188: p. 2139-44.
563. McCabe, J. E., Jibawi, A., Javle, P. M., Radical cystectomy: defining the threshold for a surgeon to achieve optimum outcomes, Postgrad Med J, 2007. 83: p. 556-60.
564. Lessons learned from 1,000 neobladders: the 90-day complication rate., 2010.
565. Novara, G., De Marco, V., Aragona, M., Boscolo-Berto, R., Cavalleri, S., Artibani, W., et.al. Complications and mortality after radical cystectomy for bladder transitional cell cancer, J Urol, 2009. 182: p. 914-21.
566. Stimson, C. J., Chang, S. S., Barocas, D. A., Humphrey, J. E., Patel, S. G., Clark, P. E., et.al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series, J Urol, 2010. 184: p. 1296-300.
567. Takada, N., Abe, T., Shinohara, N., Sazawa, A., Maruyama, S., Shinno, Y., et.al. Peri-operative morbidity and mortality related to radical cystectomy: a multi-institutional retrospective study in Japan, BJU Int, 2012. 110: p. E756-64.
568. Abdollah, F., Sun, M., Schmitges, J., Thuret, R., Djahangirian, O., Jeldres, C., et.al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study, Ann Surg Oncol, 2012. 19: p. 309-17.
569. Aboumarzouk, O. M., Hughes, O., Narahari, K., Drewa, T., Chlosta, P. L., Kynaston, H., Safety and feasibility of laparoscopic radical cystectomy for the treatment of bladder cancer, J Endourol, 2013. 27: p. 1083-95.
570. Clark, P. E., Stein, J. P., Groshen, S. G., Cai, J., Miranda, G., Lieskovsky, G., et.al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients, Cancer, 2005. 104: p. 36-43.
571. 25 years of experience with 1,000 neobladders: long-term complications, 2011.
572. Horovitz, D., Turker, P., Bostrom, P. J., Mirtti, T., Nurmi, M., Kuk, C., et.al. Does patient age affect survival after radical cystectomy?, BJU Int, 2012. 110(11 Pt B): p. E486-93., https://www.ncbi.nlm.nih.gov/pubmed/22551360
573. Johar, R. S., Hayn, M. H., Stegemann, A. P., Ahmed, K., Agarwal, P., Balbay, M. D., et.al. Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium, Eur Urol, 2013. 64: p. 52-7.
574. Mayr, R., May, M., Martini, T., Lodde, M., Comploj, E., Pycha, A., et.al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder, Eur Urol, 2012. 62: p. 662-70.
575. Parekh, D. J., Messer, J., Fitzgerald, J., Ercole, B., Svatek, R., Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy, J Urol, 2013. 189: p. 474-9.
576. Ramani, V. A., Maddineni, S. B., Grey, B. R., Clarke, N. W., Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis, Eur Urol, 2010. 57: p. 1058-63.
577. Karl, A., Buchner, A., Becker, A., Staehler, M., Seitz, M., Khoder, W., et.al. A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study, J Urol, 2014. 191: p. 335-40.
578. Messer, J. C., Shariat, S. F., Dinney, C. P., Novara, G., Fradet, Y., Kassouf, W., et.al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis, Urology, 2014. 83: p. 863-7.
579. Lawrentschuk, N., Colombo, R., Hakenberg, O. W., Lerner, S. P., Mansson, W., Sagalowsky, A., et.al. Prevention and management of complications following radical cystectomy for bladder cancer, Eur Urol, 2010. 57: p. 983-1001.
580. Daabiss, M., American Society of Anaesthesiologists physical status classification, Indian J Anaesth, 2011. 55: p. 111-5.
581. Piccirillo, J. F., Tierney, R. M., Costas, I., Grove, L., Spitznagel, E. L., Jr., Prognostic importance of comorbidity in a hospital-based cancer registry, JAMA, 2004. 291: p. 2441-7.
582. Dindo, D., Demartines, N., Clavien, P. A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 2004. 240: p. 205-13.
583. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use., 2008.
584. Lotan, Y., Bagrodia, A., Passoni, N., Rachakonda, V., Kapur, P., Arriaga, Y., et.al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy, Eur Urol, 2013. 64: p. 465-71.
585. Gore, J. L., Lai, J., Setodji, C. M., Litwin, M. S., Saigal, C. S., Urologic Diseases in America, Project, Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis, Cancer, 2009. 115: p. 988-96.
586. Kulkarni, G. S., Urbach, D. R., Austin, P. C., Fleshner, N. E., Laupacis, A., Longer wait times increase overall mortality in patients with bladder cancer, J Urol, 2009. 182: p. 1318-24.
587. Chromecki, T. F., Mauermann, J., Cha, E. K., Svatek, R. S., Fajkovic, H., Karakiewicz, P. I., et.al. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy, World J Urol, 2012. 30: p. 753-9.
588. Chromecki, T. F., Cha, E. K., Fajkovic, H., Rink, M., Ehdaie, B., Svatek, R. S., et.al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy, BJU Int, 2013. 111: p. 249-55.
589. Weizer, A. Z., Joshi, D., Daignault, S., Kinnaman, M., Hussain, M., Montie, J. E., et.al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer, J Urol, 2007. 177: p. 1287-93.
590. Koppie, T. M., Serio, A. M., Vickers, A. J., Vora, K., Dalbagni, G., Donat, S. M., et.al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer, Cancer, 2008. 112: p. 2384-92.
591. Lughezzani, G., Sun, M., Shariat, S. F., Budaus, L., Thuret, R., Jeldres, C., et.al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer, Cancer, 2011. 117: p. 103-9.
592. Gakis, G., Todenhofer, T., Renninger, M., Schilling, D., Sievert, K. D., Schwentner, C., et.al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score, BJU Int, 2011. 108: p. 1800-5.
593. Bolenz, C., Herrmann, E., Bastian, P. J., Michel, M. S., Wulfing, C., Tiemann, A., et.al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial, BJU Int, 2010. 106: p. 493-9.
594. Shariat, S. F., Svatek, R. S., Tilki, D., Skinner, E., Karakiewicz, P. I., Capitanio, U., et.al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy, BJU Int, 2010. 105: p. 1402-12.
595. Novara, G., Svatek, R. S., Karakiewicz, P. I., Skinner, E., Ficarra, V., Fradet, Y., et.al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients, J Urol, 2010. 183: p. 2165-70.
596. May, M., Herrmann, E., Bolenz, C., Tiemann, A., Brookman-May, S., Fritsche, H. M., et.al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy, Eur Urol, 2011. 59: p. 712-8.
597. Hautmann, R. E., de Petriconi, R. C., Pfeiffer, C., Volkmer, B. G., Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients, Eur Urol, 2012. 61(5): p. 1039-47., https://www.ncbi.nlm.nih.gov/pubmed/22381169
598. Mayr, R., May, M., Martini, T., Lodde, M., Pycha, A., Comploj, E., et.al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder, BJU Int, 2012. 110: p. E222-7.
599. Gakis, G., Schwentner, C., Todenhofer, T., Stenzl, A., Current status of molecular markers for prognostication and outcome in invasive bladder cancer, BJU Int, 2012. 110: p. 233-7.
600. Bochner, B. H., Kattan, M. W., Vora, K. C., Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer, J Clin Oncol, 2006. 24: p. 3967-72.
601. Karakiewicz, P. I., Shariat, S. F., Palapattu, G. S., Gilad, A. E., Lotan, Y., Rogers, C. G., et.al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder, J Urol, 2006. 176: p. 1354-61; discussion 1361-2.
602. Shariat, S. F., Karakiewicz, P. I., Palapattu, G. S., Amiel, G. E., Lotan, Y., Rogers, C. G., et.al. Nomograms provide improved accuracy for predicting survival after radical cystectomy, Clin Cancer Res, 2006. 12: p. 6663-76.
603. Bastian, P. J., Hutterer, G. C., Shariat, S. F., Rogers, C. G., Palapattu, G. S., Lotan, Y., et.al. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival, BJU Int, 2008. 101: p. 450-4.
604. Tilki, D., Reich, O., Karakiewicz, P. I., Novara, G., Kassouf, W., Ergun, S., et.al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome, Eur Urol, 2010. 58: p. 112-7.
605. Tilki, D., Svatek, R. S., Karakiewicz, P. I., Novara, G., Seitz, M., Sonpavde, G., et.al. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder, J Urol, 2010. 184: p. 470-4.
606. Bi, L., Huang, H., Fan, X., Li, K., Xu, K., Jiang, C., et.al. Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies, BJU Int, 2013. 113: p. E39-48.
607. Shariat, S. F., Karakiewicz, P. I., Ashfaq, R., Lerner, S. P., Palapattu, G. S., Cote, R. J., et.al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy, Cancer, 2008. 112: p. 315-25.
608. Stein, J. P., Skinner, D. G., Surgical atlas. Radical cystectomy, BJU Int, 2004. 94: p. 197-221.
609. Prout, G. R., Marshall, V. F., The prognosis with untreated bladder tumors, Cancer, 1956. 9: p. 551-8.
610. Abdollah, F., Sun, M., Schmitges, J., Djahangirian, O., Tian, Z., Jeldres, C., et.al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy, BJU Int, 2012. 109: p. 1147-54.
611. Bochner, B. H., Dalbagni, G., Sjoberg, D. D., Silberstein, J., Keren Paz, G. E., Donat, S. M., et.al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial, Eur Urol, 2015. 67: p. 1042-50.
612. Khan, M. S., Gan, C., Ahmed, K., Ismail, A. F., Watkins, J., Summers, J. A., et.al. A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL), Eur Urol, 2015.
613. Albisinni, S., Oderda, M., Fossion, L., Varca, V., Rassweiler, J., Cathelineau, X., et.al. The morbidity of laparoscopic radical cystectomy: analysis of postoperative complications in a multicenter cohort by the European Association of Urology (EAU)-Section of Uro-Technology, World J Urol, 2016. 34: p. 149-56.
614. Ali-El-Dein, B., Abdel-Latif, M., Mosbah, A., Eraky, I., Shaaban, A. A., Taha, N. M., et.al. Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely?, J Urol, 2004. 172: p. 885-7.
615. Stein, J. P., Penson, D. F., Lee, C., Cai, J., Miranda, G., Skinner, D. G., Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer, J Urol, 2009. 181: p. 2052-8; discussion 2058-9.
616. Djaladat, H., Bruins, H. M., Miranda, G., Cai, J., Skinner, E. C., Daneshmand, S., Reproductive organ involvement in female patients undergoing radical cystectomy for urothelial bladder cancer, J Urol, 2012. 188: p. 2134-8.
617. Zippe, C. D., Raina, R., Shah, A. D., Massanyi, E. Z., Agarwal, A., Ulchaker, J., et.al. Female sexual dysfunction after radical cystectomy: a new outcome measure, Urology, 2004. 63: p. 1153-7.
618. Koie, T., Hatakeyama, S., Yoneyama, T., Hashimoto, Y., Kamimura, N., Ohyama, C., Uterus-, fallopian tube-, ovary-, and vagina-sparing cystectomy followed by U-shaped ileal neobladder construction for female bladder cancer patients: oncological and functional outcomes, Urology, 2010. 75: p. 1499-503.
619. Ali-El-Dein, B., Mosbah, A., Osman, Y., El-Tabey, N., Abdel-Latif, M., Eraky, I., et.al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up, Eur J Surg Oncol, 2013. 39: p. 358-64.
620. Bartsch, G., Daneshmand, S., Skinner, E. C., Syan, S., Skinner, D. G., Penson, D. F., Urinary functional outcomes in female neobladder patients, World J Urol, 2014. 32: p. 221-8.
621. Granberg, C. F., Boorjian, S. A., Crispen, P. L., Tollefson, M. K., Farmer, S. A., Frank, I., et.al. Functional and oncological outcomes after orthotopic neobladder reconstruction in women, BJU Int, 2008. 102: p. 1551-5.
622. Stein, J. P., Cote, R. J., Freeman, J. A., Esrig, D., Elmajian, D. A., Groshen, S., et.al. Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens, J Urol, 1995. 154: p. 1329-33.
623. Stenzl, A., Colleselli, K., Bartsch, G., Update of urethra-sparing approaches in cystectomy in women, World J Urol, 1997. 15: p. 134-8.
624. Ali-El-Dein, B., Oncological outcome after radical cystectomy and orthotopic bladder substitution in women, Eur J Surg Oncol, 2009. 35: p. 320-5.
625. Fan, S., el-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., et.al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents, Cancer Res, 1994. 54: p. 5824-30.
626. Bhatt, A., Nandipati, K., Dhar, N., Ulchaker, J., Jones, S., Rackley, R., et.al. Neurovascular preservation in orthotopic cystectomy: impact on female sexual function, Urology, 2006. 67: p. 742-5.
627. Abou-Elela, A., Outcome of anterior vaginal wall sparing during female radical cystectomy with orthotopic urinary diversion, Eur J Surg Oncol, 2008. 34: p. 115-21.
628. Niver, B. E., Daneshmand, S., Satkunasivam, R., Female reproductive organ-sparing radical cystectomy: contemporary indications, techniques and outcomes, Curr Opin Urol, 2015. 25: p. 105-10.
629. Chade, D. C., Laudone, V. P., Bochner, B. H., Parra, R. O., Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches, J Urol, 2010. 183: p. 862-69.
630. Lin, T., Fan, X., Zhang, C., Xu, K., Liu, H., Zhang, J., et.al. A prospective randomised controlled trial of laparoscopic vs open radical cystectomy for bladder cancer: perioperative and oncologic outcomes with 5-year follow-upT Lin et al, Br J Cancer, 2014. 110: p. 842-9.
631. Aboumarzouk, O. M., Drewa, T., Olejniczak, P., Chlosta, P. L., Laparoscopic versus open radical cystectomy for muscle-invasive bladder cancer: a single institute comparative analysis, Urol Int, 2013. 91: p. 109-12.
632. Chlosta, P., Drewa, T., Siekiera, J., Jaskulski, J., Petrus, A., Kamecki, K., et.al. Lymph node dissection during laparoscopic (LRC) and open (ORC) radical cystectomy due to muscle invasive bladder urothelial cancer (pT2-3, TCC), Wideochir Inne Tech Maloinwazyjne, 2011. 6: p. 127-31.
633. Albisinni, S., Rassweiler, J., Abbou, C. C., Cathelineau, X., Chlosta, P., Fossion, L., et.al. Long-term analysis of oncological outcomes after laparoscopic radical cystectomy in Europe: results from a multicentre study by the European Association of Urology (EAU) section of Uro-technology, BJU Int, 2015. 115: p. 937-45.
634. Albisinni, S., Limani, K., Ingels, L., Kwizera, F., Bollens, R., Hawaux, E., et.al. Long-term evaluation of oncologic and functional outcomes after laparoscopic open-assisted radical cystectomy: a matched-pair analysis, World J Urol, 2014. 32: p. 1455-61.
635. Tang, K., Li, H., Xia, D., Hu, Z., Zhuang, Q., Liu, J., et.al. Laparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studies, PLoS One, 2014. 9: p. e95667.
636. Khan, M. S., Challacombe, B., Elhage, O., Rimington, P., Coker, B., Murphy, D., et.al. A dual-centre, cohort comparison of open, laparoscopic and robotic-assisted radical cystectomy, Int J Clin Pract, 2012. 66: p. 656-62.
637. Cerruto, M. A., D'Elia, C., Siracusano, S., Gedeshi, X., Mariotto, A., Iafrate, M., et.al. Systematic review and meta-analysis of non RCT's on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit, Eur J Surg Oncol, 2015.
638. Goldberg, H., Baniel, J., Mano, R., Rotlevy, G., Kedar, D., Yossepowitch, O., Orthotopic neobladder vs. ileal conduit urinary diversion: A long-term quality-of-life comparison, Urol Oncol, 2015.
639. Abboudi, H., Khan, M. S., Guru, K. A., Froghi, S., de Win, G., Van Poppel, H., et.al. Learning curves for urological procedures: a systematic review, BJU Int, 2013.
640. Aboumarzouk, O. M., Drewa, T., Olejniczak, P., Chlosta, P. L., Laparoscopic radical cystectomy: a 5-year review of a single institute's operative data and complications and a systematic review of the literature, Int Braz J Urol, 2012. 38: p. 330-40.
641. Tang, K., Xia, D., Li, H., Guan, W., Guo, X., Hu, Z., et.al. Robotic vs. open radical cystectomy in bladder cancer: A systematic review and meta-analysis, Eur J Surg Oncol, 2014. 40: p. 1399-411.
642. Nix, J., Smith, A., Kurpad, R., Nielsen, M. E., Wallen, E. M., Pruthi, R. S., Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results, Eur Urol, 2010. 57: p. 196-201.
643. Bochner, B. H., Sjoberg, D. D., Laudone, V. P., A randomized trial of robot-assisted laparoscopic radical cystectomy, N Engl J Med, 2014. 371: p. 389-90.
644. Kader, A. K., Richards, K. A., Krane, L. S., Pettus, J. A., Smith, J. J., Hemal, A. K., Robot-assisted laparoscopic vs open radical cystectomy: comparison of complications and perioperative oncological outcomes in 200 patients, BJU Int, 2013. 112: p. E290-4.
645. Niegisch, G., Albers, P., Rabenalt, R., Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC), Urol Oncol, 2014. 32: p. 966-74.
646. Knox, M. L., El-Galley, R., Busby, J. E., Robotic versus open radical cystectomy: identification of patients who benefit from the robotic approach, J Endourol, 2013. 27: p. 40-4.
647. Ahdoot, M., Almario, L., Araya, H., Busch, J., Conti, S., Gonzalgo, M. L., Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis, World J Urol, 2014. 32: p. 1441-6.
648. Desai, M. M., Gill, I. S., de Castro Abreu, A. L., Hosseini, A., Nyberg, T., Adding, C., et.al. Robotic Intracorporeal Orthotopic Neobladder During Radical Cystectomy in 132 Patients, J Urol, 2014.
649. Snow-Lisy, D. C., Campbell, S. C., Gill, I. S., Hernandez, A. V., Fergany, A., Kaouk, J., et.al. Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes, Eur Urol, 2014. 65: p. 193-200.
650. Xylinas, E., Green, D. A., Otto, B., Jamzadeh, A., Kluth, L., Lee, R. K., et.al. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years, Urology, 2013. 82: p. 1323-9.
651. Does initial learning curve compromise outcomes for robot-assisted radical cystectomy? A critical evaluation of the first 60 cases while establishing a robotics program, 2011.
652. Hayn, M. H., Hussain, A., Mansour, A. M., Andrews, P. E., Carpentier, P., Castle, E., et.al. The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium, Eur Urol, 2010. 58(2): p. 197-202., https://www.ncbi.nlm.nih.gov/pubmed/20434830
653. Collins, J. W., Tyritzis, S., Nyberg, T., Schumacher, M. C., Laurin, O., Adding, C., et.al. Robot-assisted radical cystectomy (RARC) with intracorporeal neobladder - what is the effect of the learning curve on outcomes?, BJU Int, 2014. 113: p. 100-7.
654. Burgers, J. K., Brendler, C. B., Anatomic radical cystoprostatectomy, Urol Clin North Am, 1991. 18: p. 659-76.
655. Lepor, H., Gregerman, M., Crosby, R., Mostofi, F. K., Walsh, P. C., Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis, J Urol, 1985. 133: p. 207-12.
656. Brendler, C. B., Steinberg, G. D., Marshall, F. F., Mostwin, J. L., Walsh, P. C., Local recurrence and survival following nerve-sparing radical cystoprostatectomy, The Journal of urology, 1990. 144: p. 1137-40; discussion 1140-1.
657. Kessler, T. M., Burkhard, F. C., Studer, U. E., Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer, The Urologic clinics of North America, 2005. 32: p. 165-75.
658. Schoenberg, M. P., Walsh, P. C., Breazeale, D. R., Marshall, F. F., Mostwin, J. L., Brendler, C. B., Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup, The Journal of urology, 1996. 155: p. 490-4.
659. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience, 2002.
660. Hautmann, R. E., de Petriconi, R., Gottfried, H. W., Kleinschmidt, K., Mattes, R., Paiss, T., The ileal neobladder: complications and functional results in 363 patients after 11 years of followup, J Urol, 1999. 161(2): p. 422-7; discussion 427-8., https://www.ncbi.nlm.nih.gov/pubmed/9915417
661. Kessler, T. M., Burkhard, F. C., Perimenis, P., Danuser, H., Thalmann, G. N., Hochreiter, W. W., et.al. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution, J Urol, 2004. 172: p. 1323-7.
662. Mills, R. D., Studer, U. E., Female orthotopic bladder substitution: a good operation in the right circumstances, The Journal of urology, 2000. 163: p. 1501-4.
663. Ali-El-Dein, B., Gomha, M., Ghoneim, M. A., Critical evaluation of the problem of chronic urinary retention after orthotopic bladder substitution in women, The Journal of urology, 2002. 168: p. 587-92.
664. Lee, C. T., Hafez, K. S., Sheffield, J. H., Joshi, D. P., Montie, J. E., Orthotopic bladder substitution in women: nontraditional applications, J Urol, 2004. 171: p. 1585-8.
665. Stenzl, A., Jarolim, L., Coloby, P., Golia, S., Bartsch, G., Babjuk, M., et.al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors, Cancer, 2001. 92: p. 1864-71.
666. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist, 2009.
667. Holzbeierlein, J. M., Lopez-Corona, E., Bochner, B. H., Herr, H. W., Donat, S. M., Russo, P., et.al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection, J Urol, 2004. 172(3): p. 878-81., https://www.ncbi.nlm.nih.gov/pubmed/15310988
668. Knoedler, J. J., Boorjian, S. A., Kim, S. P., Weight, C. J., Thapa, P., Tarrell, R. F., et.al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis, J Urol, 2012. 188: p. 1115-9.
669. Smaldone, M. C., Jacobs, B. L., Smaldone, A. M., Hrebinko, R. L., Jr., Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma, Urology, 2008. 72: p. 613-6.
670. Kassouf, W., Swanson, D., Kamat, A. M., Leibovici, D., Siefker-Radtke, A., Munsell, M. F., et.al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience, J Urol, 2006. 175: p. 2058-62.
671. Capitanio, U., Isbarn, H., Shariat, S. F., Jeldres, C., Zini, L., Saad, F., et.al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist, Urology, 2009. 74: p. 858-64.
672. Colombo, J. R., Jr., Haber, G. P., Gill, I. S., Laparoscopic partial nephrectomy in patients with compromised renal function, Urology, 2008. 71: p. 1043-8.
673. Milhoua, P. M., Knoll, A., Bleustein, C. B., Ghavamian, R., Laparoscopic partial cystectomy for treatment of adenocarcinoma of the urachus, Urology, 2006. 67: p. 423 e15-423 e17.
674. Spiess, P. E., Correa, J. J., Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma, Int Braz J Urol, 2009. 35: p. 609.
675. Tai, H. C., Chung, S. D., Wang, S. M., Chueh, S. C., Yu, H. J., Laparoscopic partial cystectomy for various bladder pathologies, BJU Int, 2007. 100: p. 382-5.
676. Wadhwa, P., Kolla, S. B., Hemal, A. K., Laparoscopic en bloc partial cystectomy with bilateral pelvic lymphadenectomy for urachal adenocarcinoma, Urology, 2006. 67: p. 837-43.
677. Ashley, R. A., Inman, B. A., Sebo, T. J., Leibovich, B. C., Blute, M. L., Kwon, E. D., et.al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy, Cancer, 2006. 107: p. 712-20.
678. Urachal cancer: role of conservative surgery, 1993.
679. Herr, H. W., Bochner, B. H., Sharp, D., Dalbagni, G., Reuter, V. E., Urachal carcinoma: contemporary surgical outcomes, J Urol, 2007. 178(1): p. 74-8; discussion 78., https://www.ncbi.nlm.nih.gov/pubmed/17499279
680. Siefker-Radtke, A. O., Gee, J., Shen, Y., Wen, S., Daliani, D., Millikan, R. E., et.al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience, J Urol, 2003. 169: p. 1295-8.
681. Chan, E. S., Ng, C. F., Chui, K. L., Lo, K. L., Hou, S. M., Yip, S. K., Novel approach of laparoscopic transperitoneal en bloc resection of urachal tumor and umbilectomy with a comparison of various techniques, Journal of laparoendoscopic & advanced surgical techniques. Part A, 2009. 19: p. 423-6.
682. Hong, S. H., Kim, J. C., Hwang, T. K., Laparoscopic partial cystectomy with en bloc resection of the urachus for urachal adenocarcinoma, Int J Urol, 2007. 14(10): p. 963-5., https://www.ncbi.nlm.nih.gov/pubmed/17880303
683. Golijanin, D., Yossepowitch, O., Beck, S. D., Sogani, P., Dalbagni, G., Carcinoma in a bladder diverticulum: presentation and treatment outcome, The Journal of urology, 2003. 170: p. 1761-4.
684. Tamas, E. F., Stephenson, A. J., Campbell, S. C., Montague, D. K., Trusty, D. C., Hansel, D. E., Histopathologic features and clinical outcomes in 71 cases of bladder diverticula, Arch Pathol Lab Med, 2009. 133: p. 791-6.
685. Tabibi, A., Simforoosh, N., Basiri, A., Ezzatnejad, M., Abdi, H., Farrokhi, F., Bowel preparation versus no preparation before ileal urinary diversion, Urology, 2007. 70: p. 654-8.
686. Xu, R., Zhao, X., Zhong, Z., Zhang, L., No advantage is gained by preoperative bowel preparation in radical cystectomy and ileal conduit: a randomized controlled trial of 86 patients, Int Urol Nephrol, 2010. 42: p. 947-50.
687. Aslan, G., Baltaci, S., Akdogan, B., Kuyumcuoglu, U., Kaplan, M., Cal, C., et.al. A prospective randomized multicenter study of Turkish Society of Urooncology comparing two different mechanical bowel preparation methods for radical cystectomy, Urol Oncol, 2013. 31: p. 664-70.
688. Donat, S. M., Slaton, J. W., Pisters, L. L., Swanson, D. A., Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion, J Urol, 1999. 162: p. 1599-602.
689. Inman, B. A., Harel, F., Tiguert, R., Lacombe, L., Fradet, Y., Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients, J Urol, 2003. 170: p. 1888-91.
690. Adamakis, I., Tyritzis, S. I., Koutalellis, G., Tokas, T., Stravodimos, K. G., Mitropoulos, D., et.al. Early removal of nasogastric tube is beneficial for patients undergoing radical cystectomy with urinary diversion, International braz j urol : official journal of the Brazilian Society of Urology, 2011. 37: p. 42-8.
691. Roth, B., Birkhauser, F. D., Zehnder, P., Thalmann, G. N., Huwyler, M., Burkhard, F. C., et.al. Parenteral nutrition does not improve postoperative recovery from radical cystectomy: results of a prospective randomised trial, Eur Urol, 2013. 63: p. 475-82.
692. Cerantola, Y., Valerio, M., Persson, B., Jichlinski, P., Ljungqvist, O., Hubner, M., et.al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS((R))) society recommendations, Clin Nutr, 2013. 32: p. 879-87.
693. Choi, H., Kang, S. H., Yoon, D. K., Kang, S. G., Ko, H. Y., Moon du, G., et.al. Chewing gum has a stimulatory effect on bowel motility in patients after open or robotic radical cystectomy for bladder cancer: a prospective randomized comparative study, Urology, 2011. 77: p. 884-90.
694. Pruthi, R. S., Nielsen, M., Smith, A., Nix, J., Schultz, H., Wallen, E. M., Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients, Journal of the American College of Surgeons, 2010. 210: p. 93-9.
695. Hashad, M. M., Atta, M., Elabbady, A., Elfiky, S., Khattab, A., Kotb, A., Safety of no bowel preparation before ileal urinary diversion, BJU Int, 2012. 110(11 Pt C): p. E1109-13., https://www.ncbi.nlm.nih.gov/pubmed/23167296
696. Large, M. C., Kiriluk, K. J., DeCastro, G. J., Patel, A. R., Prasad, S., Jayram, G., et.al. The impact of mechanical bowel preparation on postoperative complications for patients undergoing cystectomy and urinary diversion, The Journal of urology, 2012. 188: p. 1801-5.
697. Raynor, M. C., Lavien, G., Nielsen, M., Wallen, E. M., Pruthi, R. S., Elimination of preoperative mechanical bowel preparation in patients undergoing cystectomy and urinary diversion, Urol Oncol, 2013. 31: p. 32-5.
698. Shafii, M., Murphy, D. M., Donovan, M. G., Hickey, D. P., Is mechanical bowel preparation necessary in patients undergoing cystectomy and urinary diversion?, BJU Int, 2002. 89: p. 879-81.
699. Arumainayagam, N., McGrath, J., Jefferson, K. P., Gillatt, D. A., Introduction of an enhanced recovery protocol for radical cystectomy, BJU Int, 2008. 101: p. 698-701.
700. Dutton, T. J., Daugherty, M. O., Mason, R. G., McGrath, J. S., Implementation of the Exeter enhanced recovery programme for patients undergoing radical cystectomy, BJU Int, 2014. 113: p. 719-25.
701. Maffezzini, M., Gerbi, G., Campodonico, F., Parodi, D., Multimodal perioperative plan for radical cystectomy and intestinal urinary diversion. I. Effect on recovery of intestinal function and occurrence of complications, Urology, 2007. 69: p. 1107-11.
702. Maffezzini, M., Gerbi, G., Campodonico, F., Parodi, D., Capponi, G., Spina, A., et.al. Peri-operative management of ablative and reconstructive surgery for invasive bladder cancer in the elderly, Surgical oncology, 2004. 13: p. 197-200.
703. Mukhtar, S., Ayres, B. E., Issa, R., Swinn, M. J., Perry, M. J., Challenging boundaries: an enhanced recovery programme for radical cystectomy, Ann R Coll Surg Engl, 2013. 95: p. 200-6.
704. Saar, M., Ohlmann, C. H., Siemer, S., Lehmann, J., Becker, F., Stockle, M., et.al. Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery, BJU Int, 2013. 112: p. E99-106.
705. Shah, A. D., Abaza, R., Clinical pathway for 3-day stay after robot-assisted cystectomy, J Endourol, 2011. 25: p. 1253-8.
706. Park, H. K., Kwak, C., Byun, S. S., Lee, E., Lee, S. E., Early removal of nasogastric tube after cystectomy with urinary diversion: does postoperative ileus risk increase?, Urology, 2005. 65: p. 905-8.
707. de Vries, R. R., Kauer, P., van Tinteren, H., van der Poel, H. G., Bex, A., Meinhardt, W., et.al. Short-term outcome after cystectomy: comparison of two different perioperative protocols, Urol Int, 2012. 88: p. 383-9.
708. Pruthi, R. S., Chun, J., Richman, M., Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy using a perioperative care plan, Urology, 2003. 62: p. 661-5; discussion 665-6.
709. Nelson, R., Edwards, S., Tse, B., Prophylactic nasogastric decompression after abdominal surgery, The Cochrane database of systematic reviews, 2007. p. CD004929.
710. Cerruto, M. A., De Marco, V., D'Elia, C., Bizzotto, L., De Marchi, D., Cavalleri, S., et.al. Fast track surgery to reduce short-term complications following radical cystectomy and intestinal urinary diversion with Vescica Ileale Padovana neobladder: proposal for a tailored enhanced recovery protocol and preliminary report from a pilot study, Urol Int, 2014. 92: p. 41-9.
711. Pham, K. N., Schwartz, L. W., Garg, T., Langenstroer, P., Guralnick, M. L., See, W. A., et.al. Immediate total parenteral nutrition after radical cystectomy and urinary diversion, WMJ : official publication of the State Medical Society of Wisconsin, 2014. 113: p. 20-3.
712. A multimodal perioperative plan for radical cystectomy and urinary intestinal diversion: effects, limits and complications of early artificial nutrition, 2006.
713. The effect of nutritional status and support on morbidity and mortality of bladder cancer patients treated by radical cystectomy, 1987.
714. Kouba, E. J., Wallen, E. M., Pruthi, R. S., Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion, Urology, 2007. 70: p. 1053-6.
715. Abdollah, F., Sun, M., Shariat, S. F., Schmitges, J., Djahangirian, O., Tian, Z., et.al. The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment, J Urol, 2011. 185: p. 2078-84.
716. Gray, P. J., Lin, C. C., Jemal, A., Shipley, W. U., Fedewa, S. A., Kibel, A. S., et.al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base, Int J Radiat Oncol Biol Phys, 2014. 88: p. 1048-56.
717. Nishiyama, H., Habuchi, T., Watanabe, J., Teramukai, S., Tada, H., Ono, Y., et.al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan, Eur Urol, 2004. 45: p. 176-81.
718. Power, N. E., Kassouf, W., Bell, D., Aprikian, A. G., Fradet, Y., Lacombe, L., et.al. Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort, Can Urol Assoc J, 2012. 6: p. E217-23.
719. Rink, M., Shariat, S. F., Xylinas, E., Fitzgerald, J. P., Hansen, J., Green, D. A., et.al. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?, World J Urol, 2012. 30: p. 807-14.
720. Yafi, F. A., Aprikian, A. G., Chin, J. L., Fradet, Y., Izawa, J., Estey, E., et.al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience, BJU Int, 2011. 108: p. 539-45.
721. Herr, H., Lee, C., Chang, S., Lerner, S., Bladder Cancer Collaborative, Group, Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report, J Urol, 2004. 171(5): p. 1823-8; discussion 1827-8., https://www.ncbi.nlm.nih.gov/pubmed/15076285
722. Herr, H. W., Faulkner, J. R., Grossman, H. B., Natale, R. B., deVere White, R., Sarosdy, M. F., et.al. Surgical factors influence bladder cancer outcomes: a cooperative group report, J Clin Oncol, 2004. 22(14): p. 2781-9., https://www.ncbi.nlm.nih.gov/pubmed/15199091
723. Dhar, N. B., Klein, E. A., Reuther, A. M., Thalmann, G. N., Madersbacher, S., Studer, U. E., Outcome after radical cystectomy with limited or extended pelvic lymph node dissection, J Urol, 2008. 179: p. 873-8; discussion 878.
724. Karl, A., Carroll, P. R., Gschwend, J. E., Knuchel, R., Montorsi, F., Stief, C. G., et.al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer, Eur Urol, 2009. 55: p. 826-35.
725. Kondo, T., Tanabe, K., Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract, Int J Urol, 2012. 19: p. 710-21.
726. Bi, L., Huang, H., Fan, X., Li, K., Xu, K., Jiang, C., et.al. Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies, BJU Int, 2014. 113: p. E39-48.
727. May, M., Herrmann, E., Bolenz, C., Brookman-May, S., Tiemann, A., Moritz, R., et.al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy, Ann Surg Oncol, 2011. 18: p. 2018-25.
728. Simone, G., Papalia, R., Ferriero, M., Guaglianone, S., Castelli, E., Collura, D., et.al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy, Int J Urol, 2013. 20: p. 390-7.
729. Dhar, N. B., Campbell, S. C., Zippe, C. D., Derweesh, I. H., Reuther, A. M., Fergany, A., et.al. Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection, BJU Int, 2006. 98: p. 1172-5.
730. Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference?, 2009.
731. Jensen, J. B., Ulhoi, B. P., Jensen, K. M., Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival, Int J Urol, 2012. 19(1): p. 39-47., https://www.ncbi.nlm.nih.gov/pubmed/22050425
732. Mills, R. D., Turner, W. H., Fleischmann, A., Markwalder, R., Thalmann, G. N., Studer, U. E., Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy, J Urol, 2001. 166: p. 19-23.
733. Leissner, J., Ghoneim, M. A., Abol-Enein, H., Thuroff, J. W., Franzaring, L., Fisch, M., et.al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study, J Urol, 2004. 171: p. 139-44.
734. Abol-Enein, H., El-Baz, M., Abd El-Hameed, M. A., Abdel-Latif, M., Ghoneim, M. A., Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study--a single center experience, J Urol, 2004. 172: p. 1818-21.
735. Weisbach, L., Dahlem, R., Simone, G., Hansen, J., Soave, A., Engel, O., et.al. Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent, Int Urol Nephrol, 2013. 45: p. 1561-7.
736. Kitamura, H., Masumori, N., Tsukamoto, T., Role of lymph node dissection in management of bladder cancer, Int J Clin Oncol, 2011. 16: p. 179-85.
737. Herr, H. W., Bochner, B. H., Dalbagni, G., Donat, S. M., Reuter, V. E., Bajorin, D. F., Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer, J Urol, 2002. 167(3): p. 1295-8., https://www.ncbi.nlm.nih.gov/pubmed/11832716
738. Brunocilla, E., Pernetti, R., Schiavina, R., Borghesi, M., Vagnoni, V., Rocca, G. C., et.al. The number of nodes removed as well as the template of the dissection is independently correlated to cancer-specific survival after radical cystectomy for muscle-invasive bladder cancer, Int Urol Nephrol, 2013. 45: p. 711-9.
739. Dharaskar, A., Kumar, V., Kapoor, R., Jain, M., Mandhani, A., Does extended lymph node dissection affect the lymph node density and survival after radical cystectomy?, Indian J Cancer, 2011. 48: p. 230-3.
740. Fang, A. C., Ahmad, A. E., Whitson, J. M., Ferrell, L. D., Carroll, P. R., Konety, B. R., Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer, Cancer, 2010. 116: p. 1901-8.
741. Honma, I., Masumori, N., Sato, E., Maeda, T., Hirobe, M., Kitamura, H., et.al. Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer--analysis of role of pelvic lymph node dissection, Urology, 2006. 68(3): p. 543-8., https://www.ncbi.nlm.nih.gov/pubmed/16979723
742. Jeong, I. G., Park, J., Song, K., Ro, J. Y., Song, C., Hong, J. H., et.al. Comparison of 2002 TNM nodal status with lymph node density in node-positive patients after radical cystectomy for bladder cancer: analysis by the number of lymph nodes removed, Urol Oncol, 2011. 29: p. 199-204.
743. Karadeniz, T., Baran, C., Topsakal, M., Kavukcu, E., Importance of the number of retreived lymph nodes during cystectomy, Urol J, 2011. 8: p. 197-202.
744. Kassouf, W., Leibovici, D., Munsell, M. F., Dinney, C. P., Grossman, H. B., Kamat, A. M., Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy, J Urol, 2006. 176: p. 53-7; discussion 57.
745. Knap, M. M., Lundbeck, F., Overgaard, J., The role of pelvic lymph node dissection as a predictive and prognostic factor in bladder cancer, Eur J Cancer, 2003. 39: p. 604-13.
746. Konety, B. R., Joslyn, S. A., O'Donnell, M. A., Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base, J Urol, 2003. 169: p. 946-50.
747. Morgan, T. M., Barocas, D. A., Penson, D. F., Chang, S. S., Ni, S., Clark, P. E., et.al. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients, Urology, 2012. 80: p. 632-40.
748. Park, J., Kim, S., Jeong, I. G., Song, C., Hong, J. H., Kim, C. S., et.al. Does the greater number of lymph nodes removed during standard lymph node dissection predict better patient survival following radical cystectomy?, World J Urol, 2011. 29: p. 443-9.
749. Shirotake, S., Kikuchi, E., Matsumoto, K., Yazawa, S., Kosaka, T., Miyajima, A., et.al. Role of pelvic lymph node dissection in lymph node-negative patients with invasive bladder cancer, Jpn J Clin Oncol, 2010. 40: p. 247-51.
750. Stein, J. P., Cai, J., Groshen, S., Skinner, D. G., Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density, J Urol, 2003. 170: p. 35-41.
751. Bensalah, K., Roupret, M., Xylinas, E., Shariat, S., The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?, World J Urol, 2013. 31: p. 1369-76.
752. Brunocilla, E., Pernetti, R., Martorana, G., The role of pelvic lymph node dissection during radical cystectomy for bladder cancer, Anticancer Res, 2011. 31: p. 271-5.
753. Hurle, R., Naspro, R., Pelvic lymphadenectomy during radical cystectomy: a review of the literature, Surg Oncol, 2010. 19: p. 208-20.
754. Yafi, F. A., Duclos, M., Correa, J. A., Tanguay, S., Aprikian, A. G., Cury, F., et.al. Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer, Urol Oncol, 2011. 29: p. 309-13.
755. Bruins, H. M., Veskimae, E., Hernandez, V., Imamura, M., Neuberger, M. M., Dahm, P., et.al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review, Eur Urol, 2014. 66: p. 1065-77.
756. Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract, 2012.
757. Abol-Enein, H., Tilki, D., Mosbah, A., El-Baz, M., Shokeir, A., Nabeeh, A., et.al. Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study, Eur Urol, 2011. 60: p. 572-7.
758. Brossner, C., Pycha, A., Toth, A., Mian, C., Kuber, W., Does extended lymphadenectomy increase the morbidity of radical cystectomy?, BJU Int, 2004. 93: p. 64-6.
759. Poulsen, A. L., Horn, T., Steven, K., Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall, J Urol, 1998. 160: p. 2015-9; discussion 2020.
760. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study, 2011.
761. Koppie, T. M., Vickers, A. J., Vora, K., Dalbagni, G., Bochner, B. H., Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?, Cancer, 2006. 107: p. 2368-74.
762. Stein, J. P., Penson, D. F., Cai, J., Miranda, G., Skinner, E. C., Dunn, M. A., et.al. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer, J Urol, 2007. 177: p. 876-81; discussion 881-2.
763. Bochner, B. H., Herr, H. W., Reuter, V. E., Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens, J Urol, 2001. 166: p. 2295-6.
764. Leissner, J., Hohenfellner, R., Thuroff, J. W., Wolf, H. K., Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis, BJU Int, 2000. 85: p. 817-23.
765. Herr, H. W., Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy, Urology, 2003. 61(1): p. 105-8., https://www.ncbi.nlm.nih.gov/pubmed/12559278
766. Wright, J. L., Lin, D. W., Porter, M. P., The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy, Cancer, 2008. 112: p. 2401-8.
767. Stein, J. P., Skinner, D. G., Results with radical cystectomy for treating bladder cancer: a 'reference standard' for high-grade, invasive bladder cancer, BJU Int, 2003. 92: p. 12-7.
768. Herr, H. W., Superiority of ratio based lymph node staging for bladder cancer, J Urol, 2003. 169(3): p. 943-5., https://www.ncbi.nlm.nih.gov/pubmed/12576818
769. Stein, J. P., Penson, D. F., Wu, S. D., Skinner, D. G., Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature, J Urol, 2007. 178: p. 756-60.
770. Stenzl, A., Draxl, H., Posch, B., Colleselli, K., Falk, M., Bartsch, G., The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract?, J Urol, 1995. 153: p. 950-5.
771. Coloby, P. J., Kakizoe, T., Tobisu, K., Sakamoto, M., Urethral involvement in female bladder cancer patients: mapping of 47 consecutive cysto-urethrectomy specimens, J Urol, 1994. 152: p. 1438-42.
772. Maralani, S., Wood, D. P., Jr., Grignon, D., Banerjee, M., Sakr, W., Pontes, J. E., Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study, Urology, 1997. 50: p. 537-41.
773. Stein, J. P., Esrig, D., Freeman, J. A., Grossfeld, G. D., Ginsberg, D. A., Cote, R. J., et.al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women, Urology, 1998. 51: p. 951-5.
774. Urethral recurrence in women with orthotopic bladder substitutes: A multi-institutional study, 2015.
775. Gakis, G., Ali-El-Dein, B., Babjuk, M., Hrbacek, J., Macek, P., Burkhard, F. C., et.al. Urethral recurrence in women with orthotopic bladder substitutes: A multi-institutional study, Urol Oncol, 2015. 33: p. 204.e17-23.
776. Jentzmik, F., Schrader, A. J., de Petriconi, R., Hefty, R., Mueller, J., Doetterl, J., et.al. The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome, World J Urol, 2012. 30: p. 733-9.
777. Ali-el-Dein, B., Abdel-Latif, M., Ashamallah, A., Abdel-Rahim, M., Ghoneim, M., Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study, J Urol, 2004. 171: p. 275-8.
778. Chen, M. E., Pisters, L. L., Malpica, A., Pettaway, C. A., Dinney, C. P., Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center, J Urol, 1997. 157: p. 2120-3.
779. Jentzmik, F., Schrader, M., de Petriconi, R., Hefty, R., Doetterl, J., Eickhoff, A., et.al. [Radical cystectomy and ileal neobladder reconstruction in elderly female patients over 70 years old: morbidity, functional and oncological long-term results], Urologe A, 2012. 51: p. 1419-23.
780. Levinson, A. K., Johnson, D. E., Wishnow, K. I., Indications for urethrectomy in an era of continent urinary diversion, J Urol, 1990. 144: p. 73-5.
781. Van Poppel, H., Sorgeloose, T., Radical cystectomy with or without urethrectomy?, Crit Rev Oncol Hematol, 2003. 47: p. 141-5.
782. Clark, P. E., Hall, M. C., Contemporary management of the urethra in patients after radical cystectomy for bladder cancer, Urol Clin North Am, 2005. 32: p. 199-206.
783. Urethral recurrence in patients with orthotopic ileal neobladders, 1996.
784. Risk factors and outcomes of urethral recurrence following radical cystectomy, 2011.
785. Hardeman, S. W., Soloway, M. S., Urethral recurrence following radical cystectomy, J Urol, 1990. 144(3): p. 666-9., https://www.ncbi.nlm.nih.gov/pubmed/2388323
786. Varol, C., Thalmann, G. N., Burkhard, F. C., Studer, U. E., Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution, J Urol, 2004. 172: p. 937-42.
787. Stein, J. P., Clark, P., Miranda, G., Cai, J., Groshen, S., Skinner, D. G., Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients, J Urol, 2005. 173: p. 1163-8.
788. Urethral recurrence in patients following orthotopic urinary diversion, 2004.
789. Shariat, S. F., Palapattu, G. S., Karakiewicz, P. I., Rogers, C. G., Vazina, A., Bastian, P. J., et.al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy, Eur Urol, 2007. 51: p. 152-60.
790. Nixon, R. G., Chang, S. S., Lafleur, B. J., Smith, Ja Ja, Cookson, M. S., Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder, J Urol, 2002. 167: p. 502-5.
791. Huguet, J., [Management of the male urethra before and after cystectomy: from the prophylactic urethrectomy to the intraoperative frozen section biopsy of the urethral margin], Actas Urol Esp, 2011. 35(9): p. 552-8., https://www.ncbi.nlm.nih.gov/pubmed/21715049
792. Freeman, J. A., Esrig, D., Stein, J. P., Skinner, D. G., Management of the patient with bladder cancer. Urethral recurrence, Urol Clin North Am, 1994. 21: p. 645-51.
793. Stenzl, A., Bartsch, G., Rogatsch, H., The remnant urothelium after reconstructive bladder surgery, Eur Urol, 2002. 41: p. 124-31.
794. Huguet, J., Monllau, V., Sabate, S., Rodriguez-Faba, O., Algaba, F., Palou, J., et.al. Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients, Eur Urol, 2008. 53(4): p. 785-92 discussion 792-3., https://www.ncbi.nlm.nih.gov/pubmed/17629611
795. Ichihara, K., Kitamura, H., Masumori, N., Fukuta, F., Tsukamoto, T., Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in patients with bladder cancer, Int J Clin Oncol, 2013. 18: p. 75-80.
796. Lebret, T., Herve, J. M., Barre, P., Gaudez, F., Lugagne, P. M., Barbagelatta, M., et.al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy, Eur Urol, 1998. 33: p. 170-4.
797. Osman, Y., Mansour, A., El-Tabey, N., Abdel-Latif, M., Mosbah, A., Hekal, I., et.al. Value of routine frozen section analysis of urethral margin in male patients undergoing radical cystectomy in predicting prostatic involvement, Int Urol Nephrol, 2012. 44: p. 1721-5.
798. Spiess, P. E., Kassouf, W., Brown, G., Highshaw, R., Wang, X., Do, K. A., et.al. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?, Urology, 2006. 67: p. 466-71.
799. Nelles, J. L., Konety, B. R., Saigal, C., Pace, J., Lai, J., Urologic Diseases in America, Project, Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival, J Urol, 2008. 180: p. 1933-6; discussion 1936-7.
800. Clark, P. E., Stein, J. P., Groshen, S. G., Miranda, G., Cai, J., Lieskovsky, G., et.al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer, J Urol, 2004. 172: p. 1342-7.
801. Lin, D. W., Herr, H. W., Dalbagni, G., Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy, J Urol, 2003. 169: p. 961-3.
802. Fahmy, N. M., Mahmud, S., Aprikian, A. G., Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature, Eur Urol, 2006. 50: p. 1176-82.
803. Lee, C. T., Madii, R., Daignault, S., Dunn, R. L., Zhang, Y., Montie, J. E., et.al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival, J Urol, 2006. 175: p. 1262-7; discussion 1267.
804. Nielsen, M. E., Palapattu, G. S., Karakiewicz, P. I., Lotan, Y., Bastian, P. J., Lerner, S. P., et.al. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome, BJU Int, 2007. 100: p. 1015-20.
805. Fahmy, N., Kassouf, W., Jeyaganth, S., Amin, M., Mahmud, S., Steinberg, J., et.al. An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec, Can Urol Assoc J, 2008. 2: p. 102-8.
806. Tracey, E., Watt, H., Currow, D., Young, J., Armstrong, B., Investigation of poorer bladder cancer survival in women in NSW, Australia: a data linkage study, BJU Int, 2014. 113: p. 437-48.
807. Sanchez-Ortiz, R. F., Huang, W. C., Mick, R., Van Arsdalen, K. N., Wein, A. J., Malkowicz, S. B., An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma, J Urol, 2003. 169: p. 110-5; discussion 115.
808. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder, 2004.
809. Chen, R. C., Shipley, W. U., Efstathiou, J. A., Zietman, A. L., Trimodality bladder preservation therapy for muscle-invasive bladder cancer, J Natl Compr Canc Netw, 2013. 11: p. 952-60.
810. Rodel, C., Weiss, C., Sauer, R., Trimodality treatment and selective organ preservation for bladder cancer, J Clin Oncol, 2006. 24: p. 5536-44.
811. Weiss, C., Wittlinger, M., Engehausen, D. G., Krause, F. S., Ott, O. J., Dunst, J., et.al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy, Int J Radiat Oncol Biol Phys, 2008. 70: p. 1502-6.
812. Zietman, A. L., Grocela, J., Zehr, E., Kaufman, D. S., Young, R. H., Althausen, A. F., et.al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder, Urology, 2001. 58: p. 380-5.
813. Mahlknecht, P.; Nussbaumer, B.; Sommer I.; Gartlehner G., Evidenzbericht, 2014.
814. Huddart, R. A., Hall, E., Lewis, R., Birtle, A., Group, Spare Trial Management, Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed, BJU Int, 2010. 106(6): p. 753-5., https://www.ncbi.nlm.nih.gov/pubmed/20707796
815. Asadauskiene, J., Aleknavicius, E., Pipiriene-Zelviene, T., Jankevicius, F., The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer, Medicina (Kaunas), 2010. 46: p. 305-14.
816. Gakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., et.al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder, Eur Urol, 2013. 63: p. 45-57.
817. Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rodel, C. M., et.al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review, Eur Urol, 2014. 66: p. 120-37.
818. Milosevic, M., Gospodarowicz, M., Zietman, A., Abbas, F., Haustermans, K., Moonen, L., et.al. Radiotherapy for bladder cancer, Urology, 2007. 69: p. 80-92.
819. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer, 2012.
820. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients, 2015.
821. van der Steen-Banasik, E., Ploeg, M., Witjes, J. A., van Rey, F. S., Idema, J. G., Heijbroek, R. P., et.al. Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study, Radiother Oncol, 2009. 93: p. 352-7.
822. Caffo, O., Fellin, G., Graffer, U., Luciani, L., Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire, Cancer, 1996. 78: p. 1089-97.
823. Efstathiou, S., Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience., 2012.
824. Lagrange, J. L., Bascoul-Mollevi, C., Geoffrois, L., Beckendorf, V., Ferrero, J. M., Joly, F., et.al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015), Int J Radiat Oncol Biol Phys, 2011. 79: p. 172-8.
825. Neuromonitoring in thyroid surgery: prospective evaluation of intraoperative electrophysiological responses for the prediction of recurrent laryngeal nerve injury, 2004.
826. Herman, J. M., Smith, D. C., Montie, J., Hayman, J. A., Sullivan, M. A., Kent, E., et.al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy, Urology, 2004. 64(1): p. 69-73., https://www.ncbi.nlm.nih.gov/pubmed/15245938
827. Tester, W., Porter, A., Asbell, S., Coughlin, C., Heaney, J., Krall, J., et.al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12, Int J Radiat Oncol Biol Phys, 1993. 25: p. 783-90.
828. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802, 1996.
829. Shipley, W. U., Winter, K. A., Kaufman, D. S., Lee, W. R., Heney, N. M., Tester, W. R., et.al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03, J Clin Oncol, 1998. 16: p. 3576-83.
830. Kaufman, D. S., Winter, K. A., Shipley, W. U., Heney, N. M., Chetner, M. P., Souhami, L., et.al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response, Oncologist, 2000. 5: p. 471-6.
831. Hagan, M. P., Winter, K. A., Kaufman, D. S., Wajsman, Z., Zietman, A. L., Heney, N. M., et.al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy, Int J Radiat Oncol Biol Phys, 2003. 57(3): p. 665-72., https://www.ncbi.nlm.nih.gov/pubmed/14529770
832. Kaufman, D. S., Winter, K. A., Shipley, W. U., Heney, N. M., Wallace, H. J., 3rd, Toonkel, L. M., et.al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy, Urology, 2009. 73: p. 833-7.
833. Mitin, T., Hunt, D., Shipley, W. U., Kaufman, D. S., Uzzo, R., Wu, C. L., et.al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial, Lancet Oncol, 2013. 14: p. 863-72.
834. Housset M, Dufour B, Maulard–Durdux C, Chretien Y, Mejean A., Concomitant fluorouracil (5-fu)–cisplatin (cddp) and bifractionated split course radiation therapy (bscrt) for invasive bladder cancerProc Am Soc Clin Oncol., 1997. 15:
835. Danesi, D. T., Arcangeli, G., Cruciani, E., Altavista, P., Mecozzi, A., Saracino, B., et.al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results, Cancer, 2004. 101: p. 2540-8.
836. Tunio, M. A., Hashmi, A., Qayyum, A., Mohsin, R., Zaeem, A., Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience, Int J Radiat Oncol Biol Phys, 2012. 82: p. e457-62.
837. James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., et.al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 2012. 366: p. 1477-88.
838. Arias, F., Dominguez, M. A., Martinez, E., Illarramendi, J. J., Miquelez, S., Pascual, I., et.al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program, Int J Radiat Oncol Biol Phys, 2000. 47: p. 373-8.
839. Coen, J. J., Paly, J. J., Niemierko, A., Kaufman, D. S., Heney, N. M., Spiegel, D. Y., et.al. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer, Int J Radiat Oncol Biol Phys, 2013. 86: p. 311-6.
840. Given, R. W., Parsons, J. T., McCarley, D., Wajsman, Z., Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up, Urology, 1995. 46: p. 499-504; discussion 504-5.
841. Oh, K. S., Soto, D. E., Smith, D. C., Montie, J. E., Lee, C. T., Sandler, H. M., Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial, Int J Radiat Oncol Biol Phys, 2009. 74: p. 511-7.
842. Perdona, S., Autorino, R., Damiano, R., De Sio, M., Morrica, B., Gallo, L., et.al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience, Cancer, 2008. 112: p. 75-83.
843. Dunst, J., Sauer, R., Schrott, K. M., Kuhn, R., Wittekind, C., Altendorf-Hofmann, A., Organ-sparing treatment of advanced bladder cancer: a 10-year experience, Int J Radiat Oncol Biol Phys, 1994. 30: p. 261-6.
844. Maarouf, A. M., Khalil, S., Salem, E. A., ElAdl, M., Nawar, N., Zaiton, F., Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer, BJU Int, 2011. 107: p. 1605-10.
845. Coppin, C. M., Gospodarowicz, M. K., James, K., Tannock, I. F., Zee, B., Carson, J., et.al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 1996. 14: p. 2901-7.
846. Challenging treatment decision-making in older urologic cancer patients, 2014.
847. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines, 2014.
848. Caffo, O., Fellin, G., Graffer, U., Mussari, S., Tomio, L., Galligioni, E., Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies, Cancer, 2011. 117: p. 1190-6.
849. Choudhury, A., Cowan, R., Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer, BJU Int, 2011. 108: p. E313.
850. Choudhury, A., Swindell, R., Logue, J. P., Elliott, P. A., Livsey, J. E., Wise, M., et.al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer, J Clin Oncol, 2011. 29: p. 733-8.
851. Wittlinger, M., Rodel, C. M., Weiss, C., Krause, S. F., Kuhn, R., Fietkau, R., et.al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia, Radiother Oncol, 2009. 93: p. 358-63.
852. Hoskin, P. J., Rojas, A. M., Bentzen, S. M., Saunders, M. I., Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma, J Clin Oncol, 2010. 28(33): p. 4912-8., https://www.ncbi.nlm.nih.gov/pubmed/20956620
853. Horwich, A., Dearnaley, D., Huddart, R., Graham, J., Bessell, E., Mason, M., et.al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer, Radiother Oncol, 2005. 75(1): p. 34-43., https://www.ncbi.nlm.nih.gov/pubmed/15878099
854. Maciejewski, B., Majewski, S., Dose fractionation and tumour repopulation in radiotherapy for bladder cancer, Radiother Oncol, 1991. 21: p. 163-70.
855. De Neve, W., Lybeert, M. L., Goor, C., Crommelin, M. A., Ribot, J. G., Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time, Radiother Oncol, 1995. 36: p. 183-8.
856. Gamal El-Deen, H. S., Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation, J Egypt Natl Canc Inst, 2007. 19: p. 133-46.
857. Chung, P. W., Bristow, R. G., Milosevic, M. F., Yi, Q. L., Jewett, M. A., Warde, P. R., et.al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer, Urol Oncol, 2007. 25: p. 303-9.
858. Lin, C. C., Hsu, C. H., Cheng, J. C., Huang, C. Y., Tsai, Y. C., Hsu, F. M., et.al. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer, Int J Radiat Oncol Biol Phys, 2009. 75: p. 442-8.
859. George, L., Bladou, F., Bardou, V. J., Gravis, G., Tallet, A., Alzieu, C., et.al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy, Urology, 2004. 64: p. 488-93.
860. Turgeon, G. A., Souhami, L., Cury, F. L., Faria, S. L., Duclos, M., Sturgeon, J., et.al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer, Int J Radiat Oncol Biol Phys, 2014. 88: p. 326-31.
861. Eswara, J. R., Efstathiou, J. A., Heney, N. M., Paly, J., Kaufman, D. S., McDougal, W. S., et.al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer, J Urol, 2012. 187: p. 463-8.
862. Sapre, N., Anderson, P., Foroudi, F., Management of local recurrences in the irradiated bladder: a systematic review, BJU Int, 2012. 110 Suppl 4: p. 51-7.
863. Cooke, P. W., Dunn, J. A., Latief, T., Bathers, S., James, N. D., Wallace, D. M., Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer, Eur Urol, 2000. 38: p. 279-86.
864. Nagele, U., Anastasiadis, A. G., Merseburger, A. S., Corvin, S., Hennenlotter, J., Adam, M., et.al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer, World J Urol, 2007. 25: p. 401-5.
865. Zebic, N., Weinknecht, S., Kroepfl, D., Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent, BJU Int, 2005. 95: p. 1211-4.
866. Large, M. C., Malik, R., Cohn, J. A., Richards, K. A., Ganshert, C., Kunnavakkum, R., et.al. Prospective health-related quality of life analysis for patients undergoing radical cystectomy and urinary diversion, Urology, 2014. 84: p. 808-13.
867. Stein, R., Hohenfellner, M., Pahernik, S., Roth, S., Thuroff, J. W., Rubben, H., Urinary diversion--approaches and consequences, Dtsch Arztebl Int, 2012. 109: p. 617-22.
868. Cody, J. D., Nabi, G., Dublin, N., McClinton, S., Neal, D. E., Pickard, R., et.al. Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy, Cochrane Database Syst Rev, 2012. 2: p. Cd003306.
869. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit?, 2005.
870. Kristjansson, A., Bajc, M., Wallin, L., Willner, J., Mansson, W., Renal function up to 16 years after conduit (refluxing or anti-reflux anastomosis) or continent urinary diversion. 2. Renal scarring and location of bacteriuria, Br J Urol, 1995. 76: p. 546-50.
871. Nieuwenhuijzen, J. A., de Vries, R. R., Bex, A., van der Poel, H. G., Meinhardt, W., Antonini, N., et.al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions, Eur Urol, 2008. 53: p. 834-42; discussion 842-4.
872. Madersbacher, S., Schmidt, J., Eberle, J. M., Thoeny, H. C., Burkhard, F., Hochreiter, W., et.al. Long-term outcome of ileal conduit diversion, J Urol, 2003. 169: p. 985-90.
873. Lee, R. K., Abol-Enein, H., Artibani, W., Bochner, B., Dalbagni, G., Daneshmand, S., et.al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes, BJU Int, 2014. 113: p. 11-23.
874. Studer, U. E., Zingg, E. J., Ileal orthotopic bladder substitutes. What we have learned from 12 years' experience with 200 patients, Urol Clin North Am, 1997. 24: p. 781-93.
875. Benson, M. C., Olsson, C. A., Continent urinary diversion, Urol Clin North Am, 1999. 26: p. 125-47, ix.
876. Gerharz, E. W., Kohl, U. N., Melekos, M. D., Bonfig, R., Weingartner, K., Riedmiller, H., Ten years' experience with the submucosally embedded in situ appendix in continent cutaneous diversion, Eur Urol, 2001. 40: p. 625-31.
877. Jonsson, O., Olofsson, G., Lindholm, E., Tornqvist, H., Long-time experience with the Kock ileal reservoir for continent urinary diversion, Eur Urol, 2001. 40: p. 632-40.
878. Wiesner, C., Bonfig, R., Stein, R., Gerharz, E. W., Pahernik, S., Riedmiller, H., et.al. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs, World J Urol, 2006. 24: p. 315-8.
879. EAUN, Incontinent Urostomy, 2009.
880. EAUN, Incontinent Urostomy, 2010.
881. Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., et.al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines, Eur Urol, 2011. 59: p. 1009-18.
882. Studer, U. E., Hautmann, R. E., Hohenfellner, M., Mills, R. D., Okada, Y., Rowland, R. G., et.al. Indications for continent diversion after cystectomy and factors affecting long-term results, Urol Oncol, 1998. 4: p. 172-82.
883. Skinner, E. C., Fairey, A. S., Groshen, S., Daneshmand, S., Cai, J., Miranda, G., et.al. Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer, J Urol, 2015. 194: p. 433-9.
884. Abol-Enein, H., Ghoneim, M. A., Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients, J Urol, 2001. 165: p. 1427-32.
885. Gakis, G., Abdelhafez, M. F., Stenzl, A., The "I-Pouch": Results of a new ileal neobladder technique, Scand J Urol, 2015. 49: p. 400-6.
886. Stein, J. P., Dunn, M. D., Quek, M. L., Miranda, G., Skinner, D. G., The orthotopic T pouch ileal neobladder: experience with 209 patients, J Urol, 2004. 172: p. 584-7.
887. Studer, U. E., Burkhard, F. C., Schumacher, M., Kessler, T. M., Thoeny, H., Fleischmann, A., et.al. Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned, J Urol, 2006. 176: p. 161-6.
888. Kristjansson, A., Wallin, L., Mansson, W., Renal function up to 16 years after conduit (refluxing or anti-reflux anastomosis) or continent urinary diversion. 1. Glomerular filtration rate and patency of uretero-intestinal anastomosis, Br J Urol, 1995. 76: p. 539-45.
889. Studer, U. E., Danuser, H., Thalmann, G. N., Springer, J. P., Turner, W. H., Antireflux nipples or afferent tubular segments in 70 patients with ileal low pressure bladder substitutes: long-term results of a prospective randomized trial, J Urol, 1996. 156: p. 1913-7.
890. Shaaban, A. A., Abdel-Latif, M., Mosbah, A., Gad, H., Eraky, I., Ali-El-Dein, B., et.al. A randomized study comparing an antireflux system with a direct ureteric anastomosis in patients with orthotopic ileal neobladders, BJU Int, 2006. 97: p. 1057-62.
891. Leilinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3 Leilinie Kolorektales Karzinom, Langversion 1.0, 2013.
892. Millan, M., Tegido, M., Biondo, S., Garcia-Granero, E., Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units, Colorectal Dis, 2010. 12: p. e88-92.
893. Leilinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3 Leilinie Kolorektales Karzinom, Langversion 1.0, 2013.
894. Bass, E. M., Del Pino, A., Tan, A., Pearl, R. K., Orsay, C. P., Abcarian, H., Does preoperative stoma marking and education by the enterostomal therapist affect outcome?, Dis Colon Rectum, 1997. 40: p. 440-2.
895. Colwell, J. C., Gray, M., Does preoperative teaching and stoma site marking affect surgical outcomes in patients undergoing ostomy surgery?, J Wound Ostomy Continence Nurs, 2007. 34: p. 492-6.
896. Chaudhri, S., Brown, L., Hassan, I., Horgan, A. F., Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial, Dis Colon Rectum, 2005. 48: p. 504-9.
897. Schwenk, Moderne perioperative Behandlung, in Moderne Chirurgie des Rektumkarzinoms, Kreis M. E., Straßburg J. , Editor. 2015, Springer: Berlin.
898. Glatzle J., Longin I., Stomaanlage und Stomatherapie, in Moderne Chirurgie des Rektumkarzinoms, Kreis M. E., Straßburg J. , Editor. 2015, Springer: Berlin.
899. G., Gruber, Handlungsanweisung "präoperative Markierung", 2012. 2015:
900. Patientenedukation, in Pflege von Menschen mit chronischen Wunden - Lehrbuch für Pflegende und Wundexperten, 2010.
901. Droste, W. & Gruber, G., Sektorenübergreifender Leitfaden Stomatherapie für Krankenhäuser, die ambulante Homecare-Versorgung und RehabilitationsklinikenSchlütersche Verlagsgesellschaft mbH & Co. KG, 2010.
902. Fünftes Buch Sozialgesetzgebung 2015:
903. Nazmy, M., Yuh, B., Kawachi, M., Lau, C. S., Linehan, J., Ruel, N. H., et.al. Early and late complications of robot-assisted radical cystectomy: a standardized analysis by urinary diversion type, J Urol, 2014. 191: p. 681-7.
904. Torrey, R. R., Chan, K. G., Yip, W., Josephson, D. Y., Lau, C. S., Ruel, N. H., et.al. Functional outcomes and complications in patients with bladder cancer undergoing robotic-assisted radical cystectomy with extracorporeal Indiana pouch continent cutaneous urinary diversion, Urology, 2012. 79: p. 1073-8.
905. Pruthi, R. S., Nix, J., McRackan, D., Hickerson, A., Nielsen, M. E., Raynor, M., et.al. Robotic-assisted laparoscopic intracorporeal urinary diversion, Eur Urol, 2010. 57: p. 1013-21.
906. Haber, G. P., Campbell, S. C., Colombo, J. R., Jr., Fergany, A. F., Aron, M., Kaouk, J., et.al. Perioperative outcomes with laparoscopic radical cystectomy: "pure laparoscopic" and "open-assisted laparoscopic" approaches, Urology, 2007. 70(5): p. 910-5., https://www.ncbi.nlm.nih.gov/pubmed/18068447
907. Guru, K., Seixas-Mikelus, S. A., Hussain, A., Blumenfeld, A. J., Nyquist, J., Chandrasekhar, R., et.al. Robot-assisted intracorporeal ileal conduit: Marionette technique and initial experience at Roswell Park Cancer Institute, Urology, 2010. 76: p. 866-71.
908. Azzouni, F. S., Din, R., Rehman, S., Khan, A., Shi, Y., Stegemann, A., et.al. The first 100 consecutive, robot-assisted, intracorporeal ileal conduits: evolution of technique and 90-day outcomes, Eur Urol, 2013. 63: p. 637-43.
909. Schumacher, M. C., Jonsson, M. N., Hosseini, A., Nyberg, T., Poulakis, V., Pardalidis, N. P., et.al. Surgery-related complications of robot-assisted radical cystectomy with intracorporeal urinary diversion, Urology, 2011. 77: p. 871-6.
910. Jonsson, M. N., Adding, L. C., Hosseini, A., Schumacher, M. C., Volz, D., Nilsson, A., et.al. Robot-assisted radical cystectomy with intracorporeal urinary diversion in patients with transitional cell carcinoma of the bladder, Eur Urol, 2011. 60: p. 1066-73.
911. Tyritzis, S. I., Hosseini, A., Collins, J., Nyberg, T., Jonsson, M. N., Laurin, O., et.al. Oncologic, functional, and complications outcomes of robot-assisted radical cystectomy with totally intracorporeal neobladder diversion, Eur Urol, 2013. 64: p. 734-41.
912. Ahmed, K., Khan, S. A., Hayn, M. H., Agarwal, P. K., Badani, K. K., Balbay, M. D., et.al. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium, Eur Urol, 2014. 65: p. 340-7.
913. Aboumohamed, A. A., Raza, S. J., Al-Daghmin, A., Tallman, C., Creighton, T., Crossley, H., et.al. Health-related quality of life outcomes after robot-assisted and open radical cystectomy using a validated bladder-specific instrument: a multi-institutional study, Urology, 2014. 83: p. 1300-8.
914. Specchia, ML, Frisicale, EM, Carini, E, Di Pilla, A, Cappa, D, Barbara, A, et.al. The impact of tumor board on cancer care: evidence from an umbrella review., BMC Health Serv Res, 2020. 20 (1)(1): p. 73., https://pubmed.ncbi.nlm.nih.gov/32005232/
915. Takata, R., Katagiri, T., Kanehira, M., Tsunoda, T., Shuin, T., Miki, T., et.al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling, Clin Cancer Res, 2005. 11: p. 2625-36.
916. Pinho, M. B., Costas, F., Sellos, J., Dienstmann, R., Andrade, P. B., Herchenhorn, D., et.al. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy, Urol Oncol, 2009. 27: p. 382-90.
917. Font, A., Taron, M., Gago, J. L., Costa, C., Sanchez, J. J., Carrato, C., et.al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer, Ann Oncol, 2011. 22: p. 139-44.
918. Sun, J. M., Sung, J. Y., Park, S. H., Kwon, G. Y., Jeong, B. C., Seo, S. I., et.al. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy, BMC Cancer, 2012. 12: p. 187.
919. Takata, R., Katagiri, T., Kanehira, M., Shuin, T., Miki, T., Namiki, M., et.al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy, Cancer Sci, 2007. 98: p. 113-7.
920. Hoffmann, A. C., Wild, P., Leicht, C., Bertz, S., Danenberg, K. D., Danenberg, P. V., et.al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy, Neoplasia, 2010. 12(8): p. 628-36., https://www.ncbi.nlm.nih.gov/pubmed/20689757
921. Laukhtina, E, Pradere, B, Mori, K, Schuettfort, VM, Quhal, F, Mostafaei, H, et.al. Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review., Urol Oncol, 2021. 39 (3)(3): p. 180-190., https://pubmed.ncbi.nlm.nih.gov/33423937/
922. de Kruijff, IE, Beije, N, Martens, JWM, de Wit, R, Boormans, JL, Sleijfer, S, Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review., Eur Urol Oncol, 2021. 4 (2)(2): p. 204-214., https://pubmed.ncbi.nlm.nih.gov/32059957/
923. Bajorin, DF, Witjes, JA, Gschwend, JE, Schenker, M, Valderrama, BP, Tomita, Y, et.al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma., N Engl J Med, 2021. 384 (22)(22): p. 2102-2114., https://pubmed.ncbi.nlm.nih.gov/34077643/
924. Bellmunt, J., Gonzalez-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., et.al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity, Ann Oncol, 2011. 22: p. 2646-53.
925. Powles, T, Assaf, ZJ, Davarpanah, N, Banchereau, R, Szabados, BE, Yuen, KC, et.al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma., Nature, 2021. 595 (7867)(7867): p. 432-437., https://pubmed.ncbi.nlm.nih.gov/34135506/
926. EAU guidelines on muscle-invasive and metastatic bladder cancer, EAU Annual Congress 2021, 2021.
927. Wang, Y, Song, Y, Qin, C, Zhang, C, Du, Y, Xu, T, Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis., Ann Med, 2023. 55 (2)(2): p. 2281654., https://pubmed.ncbi.nlm.nih.gov/37963224/
928. Pfister, C, Gravis, G, Flechon, A, Chevreau, C, Mahammedi, H, Laguerre, B, et.al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study., Lancet Oncol, 2024. 25 (2)(2): p. 255-264., https://pubmed.ncbi.nlm.nih.gov/38142702/
929. Pfister, C, Gravis, G, Fléchon, A, Chevreau, C, Mahammedi, H, Laguerre, B, et.al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial., J Clin Oncol, 2022. 40 (18)(18): p. 2013-2022., https://pubmed.ncbi.nlm.nih.gov/35254888/
930. Flaig, TW, Tangen, CM, Daneshmand, S, Alva, A, Lerner, SP, Lucia, MS, et.al. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)., Clin Cancer Res, 2021. 27 (9)(9): p. 2435-2441., https://pubmed.ncbi.nlm.nih.gov/33568346/
931. Liu, T, Jiang, G, A systematic review and meta-analysis of neoadjuvant chemotherapy for bladder cancer between ddMVAC and GC regimen., Urol Oncol, 2022. 40 (5)(5): p. 195.e19-195.e25., https://pubmed.ncbi.nlm.nih.gov/34949512/
932. Leilinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Harnblasenkarzinom, Langversion 1.0, 2016.
933. Mahlknecht, P.; Nussbaumer, B.; Sommer I.; Gartlehner G., Subgruppeneffekte der Wirksamkeit und Sicherheit von organerhaltenden, adjuvanten und neoadjuvanten Therapien des muskelinvasiven Urothelkarzinoms der Harnblase - Systematische Übersichtsarbeit und Subgruppenanalyse, 2014.
934. Cortesi, E., Italian Randomised Trial of Neoadjuvant MVEC in Locally Advanced Bladder Cancer, unpublished.
935. Wallace, D. M., Raghavan, D., Kelly, K. A., Sandeman, T. F., Conn, I. G., Teriana, N., et.al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder, Br J Urol, 1991. 67: p. 608-15.
936. Martinez-Pineiro, J. A., Gonzalez Martin, M., Arocena, F., Flores, N., Roncero, C. R., Portillo, J. A., et.al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study, J Urol, 1995. 153: p. 964-73.
937. Malmstrom, P. U., Rintala, E., Wahlqvist, R., Hellstrom, P., Hellsten, S., Hannisdal, E., Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group, J Urol, 1996. 155: p. 1903-6.
938. Bassi, P., Ferrante, G. D., Piazza, N., Spinadin, R., Carando, R., Pappagallo, G., et.al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort, J Urol, 1999. 161: p. 1494-7.
939. Bassi, P.; Pappagallo, GL, Sperandio, P., Neoadjuvant MVAC chemotherapy of invasive bladder cancer: results of a multicentre phase III trial, Journal of Urology, 1999. p. 161(264a).
940. Grossman, HB, Natale, RB, Tangen, CM, Speights, VO, Vogelzang, NJ, Trump, DL, et.al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer., N Engl J Med, 2003. 349 (9)(9): p. 859-66., https://pubmed.ncbi.nlm.nih.gov/12944571/
941. Griffiths, G., Hall, R., Sylvester, R., Raghavan, D., Parmar, M. K., International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial, J Clin Oncol, 2011. 29: p. 2171-7.
942. Sengelov, L., von der Maase, H., Lundbeck, F., Barlebo, H., Colstrup, H., Engelholm, S. A., et.al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours, Acta Oncol, 2002. 41: p. 447-56.
943. Sherif, A., Rintala, E., Mestad, O., Nilsson, J., Holmberg, L., Nilsson, S., et.al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2, Scand J Urol Nephrol, 2002. 36: p. 419-25.
944. Kitamura, H., Tsukamoto, T., Shibata, T., Masumori, N., Fujimoto, H., Hirao, Y., et.al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209, Ann Oncol, 2014. 25: p. 1192-8.
945. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists, Lancet, 1999. 354: p. 533-40.
946. Guyatt, GH, Oxman, AD, Vist, GE, Kunz, R, Falck-Ytter, Y, Alonso-Coello, P, et.al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations., BMJ, 2008. 336 (7650)(7650): p. 924-6., https://pubmed.ncbi.nlm.nih.gov/18436948/
947. Orsatti, M, Curotto, A, Canobbio, L, Guarneri, D, Scarpati, D, Venturini, M, et.al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach., Int J Radiat Oncol Biol Phys, 1995. 33 (1)(1): p. 173-8., https://pubmed.ncbi.nlm.nih.gov/7642415/
948. Abol-Enein H, et al, Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study., 1997. 79: p. 174.
949. Rintala, E, Hannisdahl, E, Fosså, SD, Hellsten, S, Sander, S, Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I., Scand J Urol Nephrol, 1993. 27 (3)(3): p. 355-62., https://pubmed.ncbi.nlm.nih.gov/8290916/
950. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis., Lancet, 2003. 361 (9373)(9373): p. 1927-34., https://pubmed.ncbi.nlm.nih.gov/12801735/
951. Winquist, E, Kirchner, TS, Segal, R, Chin, J, Lukka, H, Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis., J Urol, 2004. 171 (2 Pt 1)(2 Pt 1): p. 561-9., https://pubmed.ncbi.nlm.nih.gov/14713760/
952. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration., Eur Urol, 2005. 48 (2)(2): p. 202-5; discussion 205-6., https://pubmed.ncbi.nlm.nih.gov/15939524/
953. Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, HA, et.al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis., Oncologist, 2016. 21 (6)(6): p. 708-15., https://pubmed.ncbi.nlm.nih.gov/27053504/
954. Choueiri, TK, Jacobus, S, Bellmunt, J, Qu, A, Appleman, LJ, Tretter, C, et.al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates., J Clin Oncol, 2014. 32 (18)(18): p. 1889-94., https://pubmed.ncbi.nlm.nih.gov/24821883/
955. Plimack, ER, Hoffman-Censits, JH, Viterbo, R, Trabulsi, EJ, Ross, EA, Greenberg, RE, et.al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity., J Clin Oncol, 2014. 32 (18)(18): p. 1895-901., https://pubmed.ncbi.nlm.nih.gov/24821881/
956. Hussain, SA, Lester, JF, Jackson, R, Gornall, M, Qureshi, M, Elliott, A, et.al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial., Lancet Oncol, 2022. 23 (5)(5): p. 650-658., https://pubmed.ncbi.nlm.nih.gov/35421369/
957. Ghoneim, MA, el-Mekresh, MM, el-Baz, MA, el-Attar, IA, Ashamallah, A, Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases., J Urol, 1997. 158 (2)(2): p. 393-9., https://pubmed.ncbi.nlm.nih.gov/9224310/
958. Galsky, MD, Pal, SK, Chowdhury, S, Harshman, LC, Crabb, SJ, Wong, YN, et.al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer., Cancer, 2015. 121 (15)(15): p. 2586-93., https://pubmed.ncbi.nlm.nih.gov/25872978/
959. Yuh, BE, Ruel, N, Wilson, TG, Vogelzang, N, Pal, SK, Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer., J Urol, 2013. 189 (5)(5): p. 1682-6., https://pubmed.ncbi.nlm.nih.gov/23123547/
960. Lee, FC, Harris, W, Cheng, HH, Shenoi, J, Zhao, S, Wang, J, et.al. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer., Adv Urol, 2013. 2013 (): p. 317190., https://pubmed.ncbi.nlm.nih.gov/24382958/
961. Dash, A, Pettus, JA, Herr, HW, Bochner, BH, Dalbagni, G, Donat, SM, et.al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience., Cancer, 2008. 113 (9)(9): p. 2471-7., https://pubmed.ncbi.nlm.nih.gov/18823036/
962. Peyton, CC, Tang, D, Reich, RR, Azizi, M, Chipollini, J, Pow-Sang, JM, et.al. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer., JAMA Oncol, 2018. 4 (11)(11): p. 1535-1542., https://pubmed.ncbi.nlm.nih.gov/30178038/
963. Osterman, CK, Babu, DS, Geynisman, DM, Lewis, B, Somer, RA, Balar, AV, et.al. Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer., Oncologist, 2019. 24 (5)(5): p. 688-690., https://pubmed.ncbi.nlm.nih.gov/30728277/
964. D'Andrea, D, Shariat, SF, Soria, F, Mari, A, Mertens, LS, Di Trapani, E, et.al. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy., Eur Urol Open Sci, 2022. 41 (): p. 74-80., https://pubmed.ncbi.nlm.nih.gov/35813257/
965. Aydh, A, Sari Motlagh, R, Alamri, A, Yanagisawa, T, Ayed, A, Rajwa, P, et.al. Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes., World J Urol, 2023. 41 (8)(8): p. 2185-2194., https://pubmed.ncbi.nlm.nih.gov/37347252/
966. Wu, T, Wu, Y, Chen, S, Wu, J, Zhu, W, Liu, H, et.al. Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis., Front Oncol, 2021. 11 (): p. 678896., https://pubmed.ncbi.nlm.nih.gov/34900663/
967. Flaig, TW, Tangen, CM, Daneshmand, S, Alva, AS, Lucia, MS, McConkey, DJ, et.al. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)., Eur Urol, 2023. 84 (3)(3): p. 341-347., https://pubmed.ncbi.nlm.nih.gov/37414705/
968. van Valkenhoef, G, Lu, G, de Brock, B, Hillege, H, Ades, AE, Welton, NJ, Automating network meta-analysis., Res Synth Methods, 2012. 3 (4)(4): p. 285-99., https://pubmed.ncbi.nlm.nih.gov/26053422/
969. Leilinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Harnblasenkarzinom, Langversion 2.0, 2020.
970. Zargar-Shoshtari, K, Kongnyuy, M, Sharma, P, Fishman, MN, Gilbert, SM, Poch, MA, et.al. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy., World J Urol, 2016. 34 (11)(11): p. 1567-1573., https://pubmed.ncbi.nlm.nih.gov/27072536/
971. Seisen, T, Jamzadeh, A, Leow, JJ, Rouprêt, M, Cole, AP, Lipsitz, SR, et.al. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy., JAMA Oncol, 2018. 4 (2)(2): p. 225-229., https://pubmed.ncbi.nlm.nih.gov/28837718/
972. Krajewski, W, Nowak, Ł, Moschini, M, Poletajew, S, Chorbińska, J, Necchi, A, et.al. Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis., J Clin Med, 2021. 10 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/33567656/
973. Cai, Z, Jin, H, Chen, J, Hu, J, Li, H, Yi, Z, et.al. Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis., Transl Androl Urol, 2021. 10 (1)(1): p. 283-291., https://pubmed.ncbi.nlm.nih.gov/33532317/
974. Freiha, F., Reese, J., Torti, F. M., A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer, J Urol, 1996. 155: p. 495-9; discussion 499-500.
975. Stöckle, M, Meyenburg, W, Wellek, S, Voges, GE, Rossmann, M, Gertenbach, U, et.al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience., J Urol, 1995. 153 (1)(1): p. 47-52., https://pubmed.ncbi.nlm.nih.gov/7966789/
976. Studer, U. E., Bacchi, M., Biedermann, C., Jaeger, P., Kraft, R., Mazzucchelli, L., et.al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial, J Urol, 1994. 152: p. 81-4.
977. Skinner, DG, Daniels, JR, Russell, CA, Lieskovsky, G, Boyd, SD, Krailo, M, et.al. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer., Semin Urol, 1990. 8 (4)(4): p. 279-84., https://pubmed.ncbi.nlm.nih.gov/2284533/
978. Cognetti, F., Ruggeri, E. M., Felici, A., Gallucci, M., Muto, G., Pollera, C. F., et.al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial, Ann Oncol, 2012. 23: p. 695-700.
979. Paz-Ares, LG; Solsona, E; Esteban, E, Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study, J Clin Oncol 28:18s, 2010 (suppl; abstr LBA4518), 2010.
980. Stadler, W. M., Lerner, S. P., Groshen, S., Stein, J. P., Shi, S. R., Raghavan, D., et.al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status, J Clin Oncol, 2011. 29: p. 3443-9.
981. Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., et.al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial, Lancet Oncol, 2015. 16: p. 76-86.
982. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration., Eur Urol, 2005. 48 (2)(2): p. 189-199; discussion 199-201., https://pubmed.ncbi.nlm.nih.gov/15939530/
983. Leow, J. J., Martin-Doyle, W., Rajagopal, P. S., Patel, C. G., Anderson, E. M., Rothman, A. T., et.al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials, Eur Urol, 2014. 66: p. 42-54.
984. Svatek, RS, Shariat, SF, Lasky, RE, Skinner, EC, Novara, G, Lerner, SP, et.al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder., Clin Cancer Res, 2010. 16 (17)(17): p. 4461-7., https://pubmed.ncbi.nlm.nih.gov/20651056/
985. Galsky, MD, Stensland, KD, Moshier, E, Sfakianos, JP, McBride, RB, Tsao, CK, et.al. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer., J Clin Oncol, 2016. 34 (8)(8): p. 825-32., https://pubmed.ncbi.nlm.nih.gov/26786930/
986. Berg, S, D'Andrea, D, Vetterlein, MW, Cole, AP, Fletcher, SA, Krimphove, MJ, et.al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?, Cancer, 2019. 125 (9)(9): p. 1449-1458., https://pubmed.ncbi.nlm.nih.gov/30620387/
987. Zamboni, S, Afferi, L, Soria, F, Aziz, A, Abufaraj, M, Poyet, C, et.al. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent., World J Urol, 2021. 39 (6)(6): p. 1947-1953., https://pubmed.ncbi.nlm.nih.gov/32712850/
988. Zaghloul, M. S., Awwad, H. K., Akoush, H. H., Omar, S., Soliman, O., el Attar, I., Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control, Int J Radiat Oncol Biol Phys, 1992. 23: p. 511-7.
989. El-Monim, H. A., El-Baradie, M. M., Younis, A., Ragab, Y., Labib, A., El-Attar, I., A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer, Urol Oncol, 2013. 31: p. 359-65.
990. Powles, T, Kockx, M, Rodriguez-Vida, A, Duran, I, Crabb, SJ, Van Der Heijden, MS, et.al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial., Nat Med, 2019. 25 (11)(11): p. 1706-1714., https://pubmed.ncbi.nlm.nih.gov/31686036/
991. Szabados, B, Rodriguez-Vida, A, Durán, I, Crabb, SJ, Van Der Heijden, MS, Pous, AF, et.al. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial., Eur Urol Oncol, 2021. 4 (3)(3): p. 456-463., https://pubmed.ncbi.nlm.nih.gov/33612455/
992. Necchi, A, Anichini, A, Raggi, D, Briganti, A, Massa, S, Lucianò, R, et.al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study., J Clin Oncol, 2018. 36 (34)(34): p. 3353-3360., https://pubmed.ncbi.nlm.nih.gov/30343614/
993. Necchi, A, Raggi, D, Gallina, A, Madison, R, Colecchia, M, Lucianò, R, et.al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies., Eur Urol, 2020. 77 (4)(4): p. 439-446., https://pubmed.ncbi.nlm.nih.gov/31708296/
994. Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., et.al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 2014. 515(7528): p. 558-62., https://www.ncbi.nlm.nih.gov/pubmed/25428503
995. van Dijk, N, Gil-Jimenez, A, Silina, K, Hendricksen, K, Smit, LA, de Feijter, JM, et.al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial., Nat Med, 2020. 26 (12)(12): p. 1839-1844., https://pubmed.ncbi.nlm.nih.gov/33046870/
996. van Dorp, J, Pipinikas, C, Suelmann, BBM, Mehra, N, van Dijk, N, Marsico, G, et.al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial., Nat Med, 2023. 29 (3)(3): p. 588-592., https://pubmed.ncbi.nlm.nih.gov/36732628/
997. Rose, TL, Harrison, MR, Deal, AM, Ramalingam, S, Whang, YE, Brower, B, et.al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer., J Clin Oncol, 2021. 39 (28)(28): p. 3140-3148., https://pubmed.ncbi.nlm.nih.gov/34428076/
998. Bellmunt, J, Hussain, M, Gschwend, JE, Albers, P, Oudard, S, Castellano, D, et.al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2021. 22 (4)(4): p. 525-537., https://pubmed.ncbi.nlm.nih.gov/33721560/
999. Zaghloul, MS, Christodouleas, JP, Smith, A, Abdallah, A, William, H, Khaled, HM, et.al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial., JAMA Surg, 2018. 153 (1)(1): p. e174591., https://pubmed.ncbi.nlm.nih.gov/29188298/
1000. Iwata, T, Kimura, S, Abufaraj, M, Janisch, F, Karakiewicz, PI, Seebacher, V, et.al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review., Urol Oncol, 2019. 37 (10)(10): p. 659-671., https://pubmed.ncbi.nlm.nih.gov/31255542/
1001. Slack, NH, Bross, ID, Prout, GR, Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder., J Surg Oncol, 1977. 9 (4)(4): p. 393-405., https://pubmed.ncbi.nlm.nih.gov/330958/
1002. Smith, JA, Crawford, ED, Paradelo, JC, Blumenstein, B, Herschman, BR, Grossman, HB, et.al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study., J Urol, 1997. 157 (3)(3): p. 805-7; discussion 807-8., https://pubmed.ncbi.nlm.nih.gov/9072571/
1003. Ghoneim, MA, Ashamallah, AK, Awaad, HK, Whitmore, WF, Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder., J Urol, 1985. 134 (2)(2): p. 266-8., https://pubmed.ncbi.nlm.nih.gov/3894693/
1004. Anderström, C, Johansson, S, Nilsson, S, Unsgaard, B, Wahlqvist, L, A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma., Eur Urol, 1983. 9 (3)(3): p. 142-7., https://pubmed.ncbi.nlm.nih.gov/6861819/
1005. Blackard, CE, Byar, DP, Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder., J Urol, 1972. 108 (6)(6): p. 875-8., https://pubmed.ncbi.nlm.nih.gov/5082739/
1006. Huncharek, M, Muscat, J, Geschwind, JF, Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis., Anticancer Res, 1998. 18 (3B)(3B): p. 1931-4., https://pubmed.ncbi.nlm.nih.gov/9677446/
1007. Hermans, TJN, Voskuilen, CS, Deelen, M, Mertens, LS, Horenblas, S, Meijer, RP, et.al. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer., Int J Cancer, 2019. 144 (6)(6): p. 1453-1459., https://pubmed.ncbi.nlm.nih.gov/30155893/
1008. Bateni, ZH, Pearce, SM, Zainfeld, D, Ballas, L, Djaladat, H, Schuckman, AK, et.al. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013., Eur Urol Oncol, 2020. 3 (3)(3): p. 343-350., https://pubmed.ncbi.nlm.nih.gov/31317867/
1009. Fischer-Valuck, BW, Michalski, JM, Mitra, N, Christodouleas, JP, DeWees, TA, Kim, E, et.al. Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer., Cancer Med, 2019. 8 (8)(8): p. 3698-3709., https://pubmed.ncbi.nlm.nih.gov/31119885/
1010. Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., et.al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987, J Clin Oncol, 2012. 30: p. 1107-13.
1011. Bajorin, D. F., Dodd, P. M., Mazumdar, M., Fazzari, M., McCaffrey, J. A., Scher, H. I., et.al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J Clin Oncol, 1999. 17: p. 3173-81.
1012. Bellmunt, J., Albanell, J., Paz-Ares, L., Climent, M. A., Gonzalez-Larriba, J. L., Carles, J., et.al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine, Cancer, 2002. 95: p. 751-7.
1013. De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., et.al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986, J Clin Oncol, 2012. 30: p. 191-9.
1014. Loehrer, P. J., Sr., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., et.al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J Clin Oncol, 1992. 10: p. 1066-73.
1015. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., et.al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, 2000. 18: p. 3068-77.
1016. Sternberg, C. N., de Mulder, P. H., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., et.al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924, J Clin Oncol, 2001. 19: p. 2638-46.
1017. Bellmunt, J., Orsola, A., Leow, J. J., Wiegel, T., De Santis, M., Horwich, A., Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2014. 25 Suppl 3: p. iii40-8.
1018. Bellmunt, J., Theodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., et.al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract, J Clin Oncol, 2009. 27: p. 4454-61.
1019. Bellmunt, J., Fougeray, R., Rosenberg, J. E., von der Maase, H., Schutz, F. A., Salhi, Y., et.al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy, Ann Oncol, 2013. 24: p. 1466-72.
1020. Sonpavde, G., Pond, G. R., Fougeray, R., Choueiri, T. K., Qu, A. Q., Vaughn, D. J., et.al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials, Eur Urol, 2013. 63: p. 717-23.
1021. Niegisch, G., Fimmers, R., Siener, R., Park, S. I., Albers, P., Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99), Eur Urol, 2011. 60: p. 1087-96.
1022. Pond, G. R., Bellmunt, J., Fougeray, R., Choueiri, T. K., Qu, A. Q., Niegisch, G., et.al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design, Clin Genitourin Cancer, 2013. 11: p. 495-500.
1023. Pond, G. R., Bellmunt, J., Rosenberg, J. E., Bajorin, D. F., Regazzi, A. M., Choueiri, T. K., et.al. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design, Clin Genitourin Cancer, 2015. 13: p. 71-9.
1024. Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., et.al. Comprehensive Characterization of Cancer Driver Genes and Mutations, Cell, 2018. 173(2): p. 371-385 e18., https://www.ncbi.nlm.nih.gov/pubmed/29625053
1025. Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., et.al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers, Eur Urol, 2013. 63: p. 4-15.
1026. Li, S., Wu, J., Chen, Y., Tang, W., Peng, Q., Deng, Y., et.al. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis, Anticancer Drugs, 2014. 25: p. 106-14.
1027. Nordentoft, I., Dyrskjot, L., Bodker, J. S., Wild, P. J., Hartmann, A., Bertz, S., et.al. Increased expression of transcription factor TFAP2alpha correlates with chemosensitivity in advanced bladder cancer, BMC Cancer, 2011. 11: p. 135.
1028. Matsumura, N., Nakamura, Y., Kohjimoto, Y., Inagaki, T., Nanpo, Y., Yasuoka, H., et.al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy, BJU Int, 2011. 108: p. E110-6.
1029. Nickerson, M. L., Dancik, G. M., Im, K. M., Edwards, M. G., Turan, S., Brown, J., et.al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer, Clin Cancer Res, 2014. 20: p. 4935-48.
1030. Groenendijk, F. H., de Jong, J., Fransen van de Putte, E. E., Michaut, M., Schlicker, A., Peters, D., et.al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy, Eur Urol, 2015.
1031. Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., et.al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy, Mod Pathol, 2014. 27: p. 271-80.
1032. Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., et.al. Genome sequencing identifies a basis for everolimus sensitivity, Science, 2012. 338: p. 221.
1033. Chatterjee, S. J., Datar, R., Youssefzadeh, D., George, B., Goebell, P. J., Stein, J. P., et.al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma, J Clin Oncol, 2004. 22: p. 1007-13.
1034. Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., et.al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer, Cell, 2017. 171(3): p. 540-556 e25., https://www.ncbi.nlm.nih.gov/pubmed/28988769
1035. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., et.al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, 2017. 18(3): p. 312-322., http://www.ncbi.nlm.nih.gov/pubmed/28131785
1036. Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., et.al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 2016. 387(10031): p. 1909-20., http://www.ncbi.nlm.nih.gov/pubmed/26952546
1037. Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., et.al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 2017. 389(10064): p. 67-76., http://www.ncbi.nlm.nih.gov/pubmed/27939400
1038. Powles, T., Duran, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., et.al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 2018. 391(10122): p. 748-757., http://www.ncbi.nlm.nih.gov/pubmed/29268948
1039. Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., et.al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 2017. 18(11): p. 1483-1492., http://www.ncbi.nlm.nih.gov/pubmed/28967485
1040. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., et.al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N Engl J Med, 2017. 376(11): p. 1015-1026., http://www.ncbi.nlm.nih.gov/pubmed/28212060
1041. K. Schwamborn, R. Knüchel, A. Hartmann, G. Baretton, F. Lasitschka, P. Schirmacher, T. Braunschweig, R. Tauber, F. Erlmeier, S. Hieke-Schulz, J. Ammann1, W. Weichert., Comparability-of-programmed-death-ligand-1-PD-L1-expression-on-tumor infiltrating-immune-cells-IC-and-tumor-cells-TC-in-advanced-urothelial-bladder-cancer-UBC-using-clinically-relevant-immunohistochemistry-IHC assays., Annals of Oncology, 2017. 28(suppl_5): p. v403-v427.
1042. Marcus, L, Lemery, SJ, Keegan, P, Pazdur, R, FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors., Clin Cancer Res, 2019. 25 (13)(13): p. 3753-3758., https://pubmed.ncbi.nlm.nih.gov/30787022/
1043. Hartmann, A., Zanardo, L., Bocker-Edmonston, T., Blaszyk, H., Dietmaier, W., Stoehr, R., et.al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract, Cancer Res, 2002. 62(23): p. 6796-802., https://www.ncbi.nlm.nih.gov/pubmed/12460887
1044. Mead, G. M., Russell, M., Clark, P., Harland, S. J., Harper, P. G., Cowan, R., et.al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party, Br J Cancer, 1998. 78: p. 1067-75.
1045. Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Geller, N., Herr, H. W., et.al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse, Cancer, 1989. 64: p. 2448-58.
1046. Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., et.al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours, Eur J Cancer, 2006. 42: p. 50-4.
1047. Bamias, A., Dafni, U., Karadimou, A., Timotheadou, E., Aravantinos, G., Psyrri, A., et.al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03), Ann Oncol, 2013. 24: p. 1011-7.
1048. Roberts, J. T., von der Maase, H., Sengelov, L., Conte, P. F., Dogliotti, L., Oliver, T., et.al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer, Ann Oncol, 2006. 17 Suppl 5: p. v118-22.
1049. Bamias, A., Aravantinos, G., Deliveliotis, C., Bafaloukos, D., Kalofonos, C., Xiros, N., et.al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group, J Clin Oncol, 2004. 22: p. 220-8.
1050. Galsky, M. D., Chen, G. J., Oh, W. K., Bellmunt, J., Roth, B. J., Petrioli, R., et.al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma, Ann Oncol, 2012. 23: p. 406-10.
1051. Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., et.al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy, J Clin Oncol, 2011. 29: p. 2432-8.
1052. Dash, A., Galsky, M. D., Vickers, A. J., Serio, A. M., Koppie, T. M., Dalbagni, G., et.al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder, Cancer, 2006. 107: p. 506-13.
1053. Hussain, S. A., Palmer, D. H., Lloyd, B., Collins, S. I., Barton, D., Ansari, J., et.al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer, Oncol Lett, 2012. 3: p. 855-859.
1054. Hussain, S. A., Stocken, D. D., Riley, P., Palmer, D. H., Peake, D. R., Geh, J. I., et.al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer, Br J Cancer, 2004. 91: p. 844-9.
1055. Lippe, P., Tummarello, D., Monterubbianesi, M. C., Silva, R. R., Giuliodori, L., Mari, D., et.al. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study, Ann Oncol, 1999. 10: p. 217-21.
1056. Berardi, R., Porfiri, E., Scartozzi, M., Lippe, P., Silva, R. R., Nacciarriti, D., et.al. Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine, Oncology, 2003. 65: p. 198-203.
1057. Balar, A. V., Apolo, A. B., Ostrovnaya, I., Mironov, S., Iasonos, A., Trout, A., et.al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer, J Clin Oncol, 2013. 31: p. 724-30.
1058. Culine, S., Flechon, A., Guillot, A., Le Moulec, S., Pouessel, D., Rolland, F., et.al. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01), Eur Urol, 2011. 60: p. 1251-7.
1059. Bamias, A., Efstathiou, E., Moulopoulos, L. A., Gika, D., Hamilos, G., Zorzou, M. P., et.al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy, Ann Oncol, 2005. 16: p. 307-13.
1060. Bamias, A., Moulopoulos, L. A., Koutras, A., Aravantinos, G., Fountzilas, G., Pectasides, D., et.al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group, Cancer, 2006. 106: p. 297-303.
1061. Bhattacharyya, M., Powles, T., Mutsvangwa, K., Wilson, P., Oliver, T., Shamash, J., A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder, Urol Oncol, 2013. 31: p. 878-82.
1062. Carles, J., Nogue, M., Domenech, M., Perez, C., Saigi, E., Villadiego, K., et.al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function, Oncology, 2000. 59: p. 24-7.
1063. Carles, J., Esteban, E., Climent, M., Font, A., Gonzalez-Larriba, J. L., Berrocal, A., et.al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer, Ann Oncol, 2007. 18: p. 1359-62.
1064. Castagneto, B., Zai, S., Marenco, D., Bertetto, O., Repetto, L., Scaltriti, L., et.al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment, Oncology, 2004. 67: p. 27-32.
1065. Dreicer, R., Manola, J., Roth, B. J., See, W. A., Kuross, S., Edelman, M. J., et.al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium, Cancer, 2004. 100: p. 1639-45.
1066. Dreicer, R., Li, H., Cooney, M. M., Wilding, G., Roth, B. J., Eastern Cooperative Oncology, Group, Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group, Cancer, 2008. 112: p. 2671-5.
1067. Galsky, M. D., Iasonos, A., Mironov, S., Scattergood, J., Boyle, M. G., Bajorin, D. F., Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function, Cancer, 2007. 109: p. 549-55.
1068. Hainsworth, J. D., Meluch, A. A., Litchy, S., Schnell, F. M., Bearden, J. D., Yost, K., et.al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium, Cancer, 2005. 103(11): p. 2298-303., http://www.ncbi.nlm.nih.gov/pubmed/15856431
1069. Hussain, M. H., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Jr., et.al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial, J Clin Oncol, 2007. 25: p. 2218-24.
1070. Hussain, M., Vaishampayan, U., Du, W., Redman, B., Smith, D. C., Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer, J Clin Oncol, 2001. 19: p. 2527-33.
1071. Lara, P. N., Jr., Meyers, F. J., Law, L. Y., Dawson, N. A., Houston, J., Lauder, I., et.al. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma, Cancer, 2004. 100: p. 82-8.
1072. Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M. J., et.al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study, J Clin Oncol, 2005. 23: p. 1185-91.
1073. Linardou, H., Aravantinos, G., Efstathiou, E., Kalofonos, C., Anagnostopoulos, A., Deliveliotis, C., et.al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group, Urology, 2004. 64: p. 479-84.
1074. Neri, B., Vannini, L., Giordano, C., Grifoni, R., Pantaleo, P., Baldazzi, V., et.al. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study, Anticancer Drugs, 2007. 18: p. 1207-11.
1075. Dumez, H., Martens, M., Selleslach, J., Guetens, G., De Boeck, G., Aerts, R., et.al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study, Anticancer Drugs, 2007. 18: p. 211-8.
1076. Sridhar, S. S., Winquist, E., Eisen, A., Hotte, S. J., McWhirter, E., Tannock, I. F., et.al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium, Invest New Drugs, 2011. 29: p. 1045-9.
1077. Theodore, C., Bidault, F., Bouvet-Forteau, N., Abdelatif, M., Fizazi, K., di Palma, M., et.al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract, Ann Oncol, 2006. 17: p. 990-4.
1078. Tsavaris, N., Kosmas, C., Skopelitis, H., Dimitrakopoulos, A., Kopterides, P., Bougas, D., et.al. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study, J Chemother, 2005. 17: p. 441-8.
1079. Tsuruta, H., Inoue, T., Narita, S., Horikawa, Y., Saito, M., Obara, T., et.al. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma, Int J Clin Oncol, 2011. 16: p. 533-8.
1080. von der Maase, H., Lehmann, J., Gravis, G., Joensuu, H., Geertsen, P. F., Gough, J., et.al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium, Ann Oncol, 2006. 17: p. 1533-8.
1081. Xu, N., Zhang, X. C., Xiong, J. P., Fang, W. J., Yu, L. F., Qian, J., et.al. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium, BMC Cancer, 2007. 7: p. 98.
1082. De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., et.al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986, J Clin Oncol, 2009. 27: p. 5634-9.
1083. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group., 2006.
1084. Dreicer, R., Magi-Galluzzi, C., Zhou, M., Rothaermel, J., Reuther, A., Ulchaker, J., et.al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer, Urology, 2004. 63: p. 1138-42.
1085. Hussain, R. A., Habib, O. S., Incidence of cancer in Basrah: results of a household survey, Asian Pac J Cancer Prev, 2015. 16: p. 163-7.
1086. Dogliotti, L., Carteni, G., Siena, S., Bertetto, O., Martoni, A., Bono, A., et.al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial, Eur Urol, 2007. 52: p. 134-41.
1087. Bellmunt, J., de Wit, R., Albanell, J., Baselga, J., A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer, Eur J Cancer, 2001. 37: p. 2212-5.
1088. Petrioli, R., Frediani, B., Manganelli, A., Barbanti, G., De Capua, B., De Lauretis, A., et.al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study, Cancer, 1996. 77: p. 344-51.
1089. Bellmunt, J., Albiol, S., Chemotherapy for metastatic or unresectable bladder cancer, Semin Oncol, 2007. 34: p. 135-44.
1090. De Santis, M., Wiechno, P. J., Bellmunt, J., Lucas, C., Su, W. C., Albiges, L., et.al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1), Ann Oncol, 2016. 27(3): p. 449-54., https://www.ncbi.nlm.nih.gov/pubmed/26673352
1091. Bamias, A., Lainakis, G., Kastritis, E., Antoniou, N., Alivizatos, G., Koureas, A., et.al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment, Oncology, 2007. 73: p. 290-7.
1092. Vaughn, D. J., Manola, J., Dreicer, R., See, W., Levitt, R., Wilding, G., Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group, Cancer, 2002. 95: p. 1022-7.
1093. Calabro, F., Lorusso, V., Rosati, G., Manzione, L., Frassineti, L., Sava, T., et.al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma, Cancer, 2009. 115: p. 2652-9.
1094. Ricci, S., Galli, L., Chioni, A., Iannopollo, M., Antonuzzo, A., Francesca, F., et.al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens, Cancer, 2002. 95: p. 1444-50.
1095. Eroglu, Z., Fruehauf, J. P., A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder, Cancer Chemother Pharmacol, 2013. 72: p. 263-7.
1096. Necchi A., Mariani L., Lo Vullo S., Raggi D., Giannatempo P., Bamias A., Crabb S., Bellmunt J., Yu E., Niegisch G., Vaishampayan U., Theodore C., Berthold D., Srinivas S., Sridhar S., Plimack E., Rosenberg J., Powles T., Galsky M., Sonpavde G., Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma,, European Urology Supplements, 2018. 17(2 Abstract 89): p. Pages e131-e132.
1097. EMA, EMA restricts use of Keytruda and Tecentriq in bladder cancer, 2018., http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/05/news_detail_002964.jsp&mid=WC0b01ac058004d5c1
1098. Schreiber, R. D., Old, L. J., Smyth, M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 2011. 331(6024): p. 1565-70., https://www.ncbi.nlm.nih.gov/pubmed/21436444
1099. Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self, Nat Immunol, 2005. 6(4): p. 345-52., https://www.ncbi.nlm.nih.gov/pubmed/15785760
1100. Blank, C., Gajewski, T. F., Mackensen, A., Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy, Cancer Immunol Immunother, 2005. 54(4): p. 307-14., https://www.ncbi.nlm.nih.gov/pubmed/15599732
1101. Egen, J. G., Kuhns, M. S., Allison, J. P., CTLA-4: new insights into its biological function and use in tumor immunotherapy, Nat Immunol, 2002. 3(7): p. 611-8., https://www.ncbi.nlm.nih.gov/pubmed/12087419
1102. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et.al. Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 2010. 363(8): p. 711-23., https://www.ncbi.nlm.nih.gov/pubmed/20525992
1103. Ruof, Jörg, Flückiger, Olivier, Andre, Niko, Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?, Drugs in R&D, 2015. 15:
1104. Staab, T. R., Dintsios, Charalabos-Markos, Graf von der Schulenburg, Johann-Matthias, Ruof, J., Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?, Value in Health, 2016. 19: p. A466-A467.
1105. FDA, FDA Alerts Health Care Professionals and Oncology Clinical Investigators about an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1, 2018., https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm
1106. Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., Chandra, A. B., Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy, Front Pharmacol, 2017. 8: p. 49., http://www.ncbi.nlm.nih.gov/pubmed/28228726
1107. Postow MA, Sidlow R, Hellmann MD., Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy., N Engl J Med., 2018.
1108. Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., 3rd, Brogdon, C., Dadu, R., et.al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J Immunother Cancer, 2017. 5(1): p. 95., http://www.ncbi.nlm.nih.gov/pubmed/29162153
1109. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., et.al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2018. 36(17): p. 1714-1768., http://www.ncbi.nlm.nih.gov/pubmed/29442540
1110. Postow, M. A., Sidlow, R., Hellmann, M. D., Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N Engl J Med, 2018. 378(2): p. 158-168., http://www.ncbi.nlm.nih.gov/pubmed/29320654
1111. Albers, P., Park, S. I., Niegisch, G., Fechner, G., Steiner, U., Lehmann, J., et.al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99], Ann Oncol, 2011. 22: p. 288-94.
1112. Akaza, H., Naito, S., Usami, M., Miki, T., Miyanaga, N., Taniai, H., et.al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience, Jpn J Clin Oncol, 2007. 37: p. 201-6.
1113. Joly, F., Houede, N., Noal, S., Chevreau, C., Priou, F., Chinet-Charrot, P., et.al. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study, Clin Genitourin Cancer, 2009. 7: p. E28-33.
1114. Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., et.al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer, J Clin Oncol, 2016. 34(26): p. 3119-25., http://www.ncbi.nlm.nih.gov/pubmed/27269937
1115. Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., et.al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial, Lancet Oncol, 2016. 17(11): p. 1590-1598., http://www.ncbi.nlm.nih.gov/pubmed/27733243
1116. Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., et.al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 2014. 515(7528): p. 558-62., https://www.ncbi.nlm.nih.gov/pubmed/25428503
1117. Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q., Juco, J., et.al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study, Lancet Oncol, 2017. 18(2): p. 212-220., http://www.ncbi.nlm.nih.gov/pubmed/28081914
1118. Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., et.al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial, Lancet Oncol, 2018. 19(1): p. 51-64., http://www.ncbi.nlm.nih.gov/pubmed/29217288
1119. Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H. T., Friedlander, T. W., Hoimes, C. J., et.al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study, JAMA Oncol, 2017. 3(9): p. e172411., http://www.ncbi.nlm.nih.gov/pubmed/28817753
1120. Bellmunt, J., Kerst, J. M., Vazquez, F., Morales-Barrera, R., Grande, E., Medina, A., et.al. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN), Ann Oncol, 2017. 28(7): p. 1517-1522., http://www.ncbi.nlm.nih.gov/pubmed/28419193
1121. Bambury, R. M., Benjamin, D. J., Chaim, J. L., Zabor, E. C., Sullivan, J., Garcia-Grossman, I. R., et.al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience, Oncologist, 2015. 20: p. 508-15.
1122. Sonpavde, G., Pond, G. R., Choueiri, T. K., Mullane, S., Niegisch, G., Albers, P., et.al. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma, Eur Urol, 2016. 69(4): p. 634-641., http://www.ncbi.nlm.nih.gov/pubmed/26264159
1123. Thomas Powles, Syed A. Hussain, Andrew Protheroe, Alison Birtle, Prabir R Chakraborti, Robert Huddart, Satinder Jagdev, Amit Bahl, Andrew Stockdale, Santhanam Sundar, Simon J. Crabb, Judith Dixon-Hughes, Laura Alexander, Caroline A Bray, Jamie Stobo, Akhila Ganeshi Wimalasingham, Charlotte Ackerman, James Paul, and Rob Jones., PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours., Journal of Clinical Oncology, 2016. 34:2_suppl: p. 430-430.
1124. Jones, R. J., Hussain, S. A., Protheroe, A. S., Birtle, A., Chakraborti, P., Huddart, R. A., et.al. Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer, J Clin Oncol, 2017. 35(16): p. 1770-1777., http://www.ncbi.nlm.nih.gov/pubmed/28402747
1125. Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., et.al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial, Lancet, 2017. 390(10109): p. 2266-2277., http://www.ncbi.nlm.nih.gov/pubmed/28916371
1126. Bajorin, D. F., Halabi, S., Small, E., Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903), Clin Genitourin Cancer, 2009. 7: p. E66-70.
1127. Hoffman-Censits, J.; Vaughn, D.; Lin, J.; et al, A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy., A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy., 2014. 32(A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy.):
1128. McCaffrey, J. A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W. K., Scher, H. I., et.al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma, J Clin Oncol, 1997. 15: p. 1853-7.
1129. Kim YS, Choi MK, Hong JY, et al, A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma, A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma, 2013. 31: p. suppl; abstr e15613.
1130. Logothetis, C. J., Hossan, E., Sella, A., Dexeus, F. H., Amato, R. J., Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors, J Natl Cancer Inst, 1991. 83: p. 285-8.
1131. Huan, S. D., Aitken, S. E., Stewart, D. J., A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer, Ann Oncol, 1995. 6(8): p. 836-7., https://www.ncbi.nlm.nih.gov/pubmed/8589024
1132. Lorusso, V., Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., et.al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer, Eur J Cancer, 1998. 34: p. 1208-12.
1133. Gebbia, V., Testa, A., Borsellino, N., Mauceri, G., Varvara, F., Tirrito, M. L., et.al. Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study, Clin Ter, 1999. 150: p. 11-5.
1134. Albers, P., Siener, R., Hartlein, M., Fallahi, M., Haeutle, D., Perabo, F. G., et.al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life, Onkologie, 2002. 25: p. 47-52.
1135. Lee, J. L., Ahn, J. H., Park, S. H., Lim, H. Y., Kwon, J. H., Ahn, S., et.al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum, Invest New Drugs, 2012. 30: p. 1984-90.
1136. Witte, R. S., Elson, P., Bono, B., Knop, R., Richardson, R. R., Dreicer, R., et.al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma, J Clin Oncol, 1997. 15: p. 589-93.
1137. Pronzato, P., Vigani, A., Pensa, F., Vanoli, M., Tani, F., Vaira, F., Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer, Am J Clin Oncol, 1997. 20: p. 519-21.
1138. Kim, J., Millikan, R. E., Smith, T. L., Tu, S. M., Pagliaro, L. C., Logothetis, C. J., Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study, Urol Oncol, 2003. 21: p. 21-6.
1139. Beer, T. M., Goldman, B., Nichols, C. R., Petrylak, D. P., Agarwal, M., Ryan, C. W., et.al. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy, Clin Genitourin Cancer, 2008. 6: p. 36-9.
1140. Dreicer, R., Li, S., Manola, J., Haas, N. B., Roth, B. J., Wilding, G., et.al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group, Cancer, 2007. 110: p. 759-63.
1141. Moore M, Winquist E and Vokes E, Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional carcinoma of the urothelial tract (TCC) who have recieved prior chemotherapy, Moore M, Winquist E and Vokes E, 2003. p. suppl; abstr 1638..
1142. Winquist, E., Vokes, E., Moore, M. J., Schumm, L. P., Hoving, K., Stadler, W. M., A Phase II study of oxaliplatin in urothelial cancer, Urol Oncol, 2005. 23: p. 150-4.
1143. Papamichael, D., Gallagher, C. J., Oliver, R. T., Johnson, P. W., Waxman, J., Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter, Br J Cancer, 1997. 75: p. 606-7.
1144. Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., Markowitz, A. B., Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer, J Clin Oncol, 2002. 20: p. 937-40.
1145. Ko, Y. J., Canil, C. M., Mukherjee, S. D., Winquist, E., Elser, C., Eisen, A., et.al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study, Lancet Oncol, 2013. 14: p. 769-76.
1146. Sweeney, C. J., Roth, B. J., Kabbinavar, F. F., Vaughn, D. J., Arning, M., Curiel, R. E., et.al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium, J Clin Oncol, 2006. 24: p. 3451-7.
1147. Galsky, M. D., Mironov, S., Iasonos, A., Scattergood, J., Boyle, M. G., Bajorin, D. F., Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma, Invest New Drugs, 2007. 25: p. 265-70.
1148. Khorsand, M., Lange, J., Feun, L., Clendeninn, N. J., Collier, M., Wilding, G., Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder, Invest New Drugs, 1997. 15: p. 157-63.
1149. Roth, B. J., Manola, J., Dreicer, R., Graham, D., Wilding, G., Eastern Cooperative Oncology, Group, Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group, Invest New Drugs, 2002. 20: p. 425-9.
1150. Lassiter, L. K., Tummala, M. K., Hussain, M. H., Stadler, W. M., Petrylak, D. P., Carducci, M. A., Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy, Clin Genitourin Cancer, 2008. 6: p. 31-5.
1151. Castellano, D. E., Bellmunt, J., Maroto, J. P., Font-Pous, A., Morales-Barrera, R., Ghanem, I., et.al. Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen, Cancer Chemother Pharmacol, 2014. 73: p. 857-67.
1152. Loriot Y, Fizazi K, Carles J, et al, Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder, J Clin Oncol, 2012. 30: p. suppl; abstr 4574.
1153. Dodd, P. M., McCaffrey, J. A., Mazumdar, M., Icasiano, E., Higgins, G., Herr, H., et.al. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma, Invest New Drugs, 2000. 18: p. 247-51.
1154. Galsky, M. D., Seng, S., Camacho, L. H., Chiorean, E. G., Mulkerin, D., Hong, D. S., et.al. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy, Clin Genitourin Cancer, 2011. 9: p. 27-30.
1155. Witte, R. S., Manola, J., Burch, P. A., Kuzel, T., Weinshel, E. L., Loehrer, P. J., Sr., Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial, Invest New Drugs, 1998. 16: p. 191-5.
1156. Culine, S., Theodore, C., De Santis, M., Bui, B., Demkow, T., Lorenz, J., et.al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen, Br J Cancer, 2006. 94: p. 1395-401.
1157. Vaughn, D. J., Srinivas, S., Stadler, W. M., Pili, R., Petrylak, D., Sternberg, C. N., et.al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study, Cancer, 2009. 115: p. 4110-7.
1158. Hegele, A., Goebell, P., Matz, U., Neuhaus, T., Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data, Urol Int, 2014. 92(2): p. 174-9., https://www.ncbi.nlm.nih.gov/pubmed/24334998
1159. Kattan, J., Culine, S., Theodore, C., Droz, J. P., Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer, Ann Oncol, 1993. 4: p. 793-4.
1160. Han, K. S., Joung, J. Y., Kim, T. S., Jeong, I. G., Seo, H. K., Chung, J., et.al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy, Br J Cancer, 2008. 98(1): p. 86-90., https://www.ncbi.nlm.nih.gov/pubmed/18087289
1161. Karadimou, A., Lianos, E., Pectasides, D., Dimopoulos, M. A., Bamias, A., Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis, Open Access J Urol, 2010. 2: p. 193-9.
1162. Edeline, J., Loriot, Y., Culine, S., Massard, C., Albiges, L., Blesius, A., et.al. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen, Eur J Cancer, 2012. 48: p. 1141-6.
1163. Lee, J. H., Kang, S. G., Kim, S. T., Kang, S. H., Choi, I. K., Park, Y. J., et.al. Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment, Cancer Res Treat, 2014. 46: p. 172-7.
1164. Logothetis CJ, Dieringer P and Ellerhorst J, A 61% response rate with 5-fluorouracil, interferon-a 2b and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma, Proc Am Assoc Cancer Res, 1992. 33: p. 221.
1165. De Mulder, P. H., Theodore, C., Sella, A., Koriakine, O., Sternberg, C. N., Collette, L., et.al. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract, Ann Oncol, 2000. 11: p. 1391-4.
1166. Tu, S. M., Hossan, E., Amato, R., Kilbourn, R., Logothetis, C. J., Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies, J Urol, 1995. 154: p. 1719-22.
1167. Pagliaro, L. C., Millikan, R. E., Tu, S. M., Williams, D., Daliani, D., Papandreou, C. N., et.al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma, J Clin Oncol, 2002. 20: p. 2965-70.
1168. Kakutani, S., Fukuhara, H., Taguchi, S., Nagata, M., Niimi, A., Hattori, M., et.al. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma, Jpn J Clin Oncol, 2015. 45: p. 281-5.
1169. Pectasides, D., Aravantinos, G., Kalofonos, H., Kiamouris, C., Bafaloukos, D., Xiros, N., et.al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group, Ann Oncol, 2001. 12: p. 1417-22.
1170. Lin, C. C., Hsu, C. H., Huang, C. Y., Keng, H. Y., Tsai, Y. C., Huang, K. H., et.al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study, Anticancer Drugs, 2007. 18: p. 487-91.
1171. Bellmunt, J., Cos, J., Cleries, R., Perez, M., Ribas, A., Eres, N., et.al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer, Cancer Invest, 2002. 20: p. 673-85.
1172. Halim, A., Abotouk, N., Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study, Asia Pac J Clin Oncol, 2013. 9(1): p. 60-5., https://www.ncbi.nlm.nih.gov/pubmed/22897883
1173. Rozzi, A., Salerno, M., Bordin, F., De Marco, F., Di Nicola, S., Lanzetta, G., Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study, Med Oncol, 2011. 28 Suppl 1: p. S426-32.
1174. Sweeney, C. J., Williams, S. D., Finch, D. E., Bihrle, R., Foster, R. S., Collins, M., et.al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium, Cancer, 1999. 86: p. 514-8.
1175. Kitamura, H., Taguchi, K., Kunishima, Y., Yanase, M., Takahashi, A., Shigyo, M., et.al. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group, Cancer Sci, 2011. 102: p. 1171-5.
1176. Di Lorenzo, G., Montesarchio, V., Autorino, R., Bellelli, T., Longo, N., Imbimbo, C., et.al. Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients, Cancer, 2009. 115: p. 517-23.
1177. Park, J. H., Lee, J. L., Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum, Cancer Chemother Pharmacol, 2015. 75: p. 247-54.
1178. Kaya, A. O., Coskun, U., Ozkan, M., Sevinc, A., Yilmaz, A. U., Gumus, M., et.al. Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy, Onkologie, 2012. 35: p. 576-80.
1179. Otto, T., Bex, A., Krege, S., Walz, P. H., Rubben, H., Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study, Cancer, 1997. 80: p. 465-70.
1180. Vaishampayan, U. N., Faulkner, J. R., Small, E. J., Redman, B. G., Keiser, W. L., Petrylak, D. P., et.al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study, Cancer, 2005. 104: p. 1627-32.
1181. Soga, N., Onishi, T., Arima, K., Sugimura, Y., Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases, Int J Urol, 2007. 14: p. 828-32.
1182. Kouno, T., Ando, M., Yonemori, K., Matsumoto, K., Shimizu, C., Katsumata, N., et.al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen, Eur Urol, 2007. 52: p. 1115-22.
1183. Terakawa, T., Miyake, H., Yokoyama, N., Miyazaki, A., Tanaka, H., Inoue, T., et.al. Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin, Urol Int, 2014. 92: p. 180-5.
1184. Ito, H., Aoki, Y., Oyama, N., Miwa, Y., Akino, H., Yokoyama, O., [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy], Gan To Kagaku Ryoho, 2011. 38: p. 481-4.
1185. Meluch, A. A., Greco, F. A., Burris, H. A., 3rd, O'Rourke, T., Ortega, G., Steis, R. G., et.al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network, J Clin Oncol, 2001. 19: p. 3018-24.
1186. Sternberg, C. N., Calabro, F., Pizzocaro, G., Marini, L., Schnetzer, S., Sella, A., Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy, Cancer, 2001. 92: p. 2993-8.
1187. Fechner, G., Siener, R., Reimann, M., Kobalz, L., Albers, P., German Association Of Urologic Oncology Bladder Cancer Study, Group, Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99), Int J Clin Pract, 2006. 60: p. 27-31.
1188. Takahashi, T., Higashi, S., Nishiyama, H., Segawa, T., Nakamura, E., Kinoshita, H., et.al. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen, Jpn J Clin Oncol, 2006. 36: p. 104-8.
1189. Matsumoto, K., Irie, A., Satoh, T., Okazaki, M., Iwamura, M., Baba, S., Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma, Int J Urol, 2007. 14: p. 1000-4; discussion 1004.
1190. Kanai, K., Kikuchi, E., Ohigashi, T., Miyajima, A., Nakagawa, K., Nakashima, J., et.al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy, Int J Clin Oncol, 2008. 13: p. 510-4.
1191. Suyama, T., Ueda, T., Fukasawa, S., Imamura, Y., Nakamura, K., Miyasaka, K., et.al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma, Jpn J Clin Oncol, 2009. 39: p. 244-50.
1192. Ikeda, M., Matsumoto, K., Tabata, K., Minamida, S., Fujita, T., Satoh, T., et.al. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy, Jpn J Clin Oncol, 2011. 41: p. 1214-20.
1193. Di Lorenzo, G., Autorino, R., Giordano, A., Giuliano, M., D'Armiento, M., Bianco, A. R., et.al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder, Jpn J Clin Oncol, 2004. 34: p. 747-50.
1194. Srinivas, S., Harshman, L. C., A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma, Chemotherapy, 2009. 55: p. 321-6.
1195. Krege, S., Rembrink, V., Borgermann, C., Otto, T., Rubben, H., Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study, J Urol, 2001. 165: p. 67-71.
1196. Twardowski, P., Stadler, W. M., Frankel, P., Lara, P. N., Ruel, C., Chatta, G., et.al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial, Urology, 2010. 76: p. 923-6.
1197. Jones, R., Vuky, J., Elliott, T., Mead, G., Arranz, J. A., Chester, J., et.al. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer, Invest New Drugs, 2013. 31: p. 1001-7.
1198. Sridhar SS, Stadler W, Le L, et al, Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium, J Clin Oncol, 2005. 25: p. suppl; abstr 4677.
1199. Gomez-Abuin, G., Winquist, E., Stadler, W. M., Pond, G., Degendorfer, P., Wright, J., et.al. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia, Invest New Drugs, 2007. 25: p. 181-5.
1200. Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., et.al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207, Ann Oncol, 2008. 19: p. 946-50.
1201. Apolo A, Parnes H, Madan R, et al, A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC), 2014. 2014:
1202. Milowsky MI, Dittrich C, Martinez ID, et al, Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3, 2013. 31: p. suppl 6; abstr 255.
1203. Petrylak, D. P., Tangen, C. M., Van Veldhuizen, P. J., Jr., Goodwin, J. W., Twardowski, P. W., Atkins, J. N., et.al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium, BJU Int, 2010. 105: p. 317-21.
1204. Wulfing, C., Machiels, J. P., Richel, D. J., Grimm, M. O., Treiber, U., De Groot, M. R., et.al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma, Cancer, 2009. 115: p. 2881-90.
1205. Necchi, A., Mariani, L., Zaffaroni, N., Schwartz, L. H., Giannatempo, P., Crippa, F., et.al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial, Lancet Oncol, 2012. 13: p. 810-6.
1206. Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., et.al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer, Clin Genitourin Cancer, 2013. 11: p. 477-83.
1207. Necchi, A., Giannatempo, P., Mariani, L., Fare, E., Raggi, D., Pennati, M., et.al. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGFbeta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial, Invest New Drugs, 2014. 32: p. 555-60.
1208. Dumez, H., Gallardo, E., Culine, S., Galceran, J. C., Schoffski, P., Droz, J. P., et.al. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium, Mar Drugs, 2009. 7: p. 451-63.
1209. Dreicer, R., Li, H., Stein, M., DiPaola, R., Eleff, M., Roth, B. J., et.al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group, Cancer, 2009. 115: p. 4090-5.
1210. Gallagher, D. J., Milowsky, M. I., Gerst, S. R., Ishill, N., Riches, J., Regazzi, A., et.al. Phase II study of sunitinib in patients with metastatic urothelial cancer, J Clin Oncol, 2010. 28: p. 1373-9.
1211. Lerner SP, Sternberg C, Younes M, et al, Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy, 2012. 30: p. suppl; abstr e15003.
1212. Gerullis, H., Eimer, C., Ecke, T. H., Georgas, E., Freitas, C., Kastenholz, S., et.al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer, Med Oncol, 2012. 29: p. 2870-6.
1213. Stadler, W. M., Vaughn, D. J., Sonpavde, G., Vogelzang, N. J., Tagawa, S. T., Petrylak, D. P., et.al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer, Cancer, 2014. 120: p. 976-82.
1214. Cheung EM, Quinn DI, Tsao-Wei DD, et al, Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy -- California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial, J Clin Oncol, 2008. p. suppl; abstr 16058.
1215. Niegisch G, Retz M, Thalgott MK, et al, Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09). J Clin Oncol 2012http://meetinglibrary.asco.org/content/99372-114, 2012. 2015:
1216. Wong, Y. N., Litwin, S., Vaughn, D., Cohen, S., Plimack, E. R., Lee, J., et.al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma, J Clin Oncol, 2012. 30: p. 3545-51.
1217. Culine, S., Sellam, Z., Bouaita, L., Assaf, E., Delbaldo, C., Verlinde-Carvalho, M., et.al. Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series, Anticancer Res, 2012. 32: p. 3949-52.
1218. Srinivas S, Narayanan S, Harshman L, et al, Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC), J Clin Oncol, 2014. 32: p. abstr 299.
1219. Theodore, C., Geoffrois, L., Vermorken, J. B., Caponigro, F., Fiedler, W., Chollet, P., et.al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers, Eur J Cancer, 2005. 41: p. 1150-7.
1220. Choueiri, T. K., Ross, R. W., Jacobus, S., Vaishampayan, U., Yu, E. Y., Quinn, D. I., et.al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer, J Clin Oncol, 2012. 30: p. 507-12.
1221. Szabados, B., van Dijk, N., Tang, Y. Z., van der Heijden, M. S., Wimalasingham, A., Gomez de Liano, A., et.al. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer, Eur Urol, 2018. 73(2): p. 149-152., http://www.ncbi.nlm.nih.gov/pubmed/28917596
1222. Abe, T., Kitamura, H., Obara, W., Matsumura, N., Tsukamoto, T., Fujioka, T., et.al. Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan, J Urol, 2014. 191: p. 932-6.
1223. Abe, T., Shinohara, N., Harabayashi, T., Sazawa, A., Maruyama, S., Suzuki, S., et.al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer, Eur Urol, 2007. 52: p. 1106-13.
1224. Lehmann, J., Suttmann, H., Albers, P., Volkmer, B., Gschwend, J. E., Fechner, G., et.al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05), Eur Urol, 2009. 55: p. 1293-9.
1225. Otto, T., Krege, S., Suhr, J., Rubben, H., Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial, Urology, 2001. 57: p. 55-9.
1226. Siefker-Radtke, A. O., Walsh, G. L., Pisters, L. L., Shen, Y., Swanson, D. A., Logothetis, C. J., et.al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience, J Urol, 2004. 171: p. 145-8.
1227. Herr, H. W., Donat, S. M., Bajorin, D. F., Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer, J Urol, 2001. 165(3): p. 811-4., https://www.ncbi.nlm.nih.gov/pubmed/11176475
1228. Sweeney, P., Millikan, R., Donat, M., Wood, C. G., Radtke, A. S., Pettaway, C. A., et.al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?, J Urol, 2003. 169: p. 2113-7.
1229. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., et.al. Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 2012. 367: p. 1187-97.
1230. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., et.al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 2011. 377: p. 813-22.
1231. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):, Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, 2014.
1232. AWMF, Leitlinie Bisphosphonat-assoziierte Kiefernekrosen, 2012.
1233. Lutz, S., Berk, L., Chang, E., Chow, E., Hahn, C., Hoskin, P., et.al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, Int J Radiat Oncol Biol Phys, 2011. 79: p. 965-76.
1234. Zaghloul, M. S., Boutrus, R., El-Hossieny, H., Kader, Y. A., El-Attar, I., Nazmy, M., A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer, Int J Clin Oncol, 2010. 15: p. 382-9.
1235. Hirsh, V, Tchekmedyian, NS, Rosen, LS, Zheng, M, Hei, YJ, Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications., Clin Lung Cancer, 2004. 6 (3)(3): p. 170-4., https://pubmed.ncbi.nlm.nih.gov/15555218/
1236. Coleman, R. E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treat Rev, 2001. 27: p. 165-76.
1237. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):, Leitlinie Supportive Therapie, 2013.
1238. Rosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., et.al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, J Clin Oncol, 2003. 21: p. 3150-7.
1239. Cassinello Espinosa, J., Gonzalez Del Alba Baamonde, A., Rivera Herrero, F., Holgado Martin, E., Seom, SEOM guidelines for the treatment of bone metastases from solid tumours, Clin Transl Oncol, 2012. 14: p. 505-11.
1240. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., et.al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 2010. 376: p. 1147-54.
1241. George, R., Jeba, J., Ramkumar, G., Chacko, A. G., Leng, M., Tharyan, P., Interventions for the treatment of metastatic extradural spinal cord compression in adults, Cochrane Database Syst Rev, 2008. p. CD006716.
1242. Carlin, B. I., Andriole, G. L., The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma, Cancer, 2000. 88: p. 2989-94.
1243. Saad, F., Chen, Y. M., Gleason, D. M., Chin, J., Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases, Clin Genitourin Cancer, 2007. 5: p. 390-6.
1244. Henry, DH, Costa, L, Goldwasser, F, Hirsh, V, Hungria, V, Prausova, J, et.al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma., J Clin Oncol, 2011. 29 (9)(9): p. 1125-32., https://pubmed.ncbi.nlm.nih.gov/21343556/
1245. Eaton, C. L., Coleman, R. E., Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment, Cancer Treat Rev, 2003. 29: p. 189-98.
1246. Dearnaley, D. P., Sydes, M. R., Mason, M. D., Stott, M., Powell, C. S., Robinson, A. C., et.al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial), J Natl Cancer Inst, 2003. 95: p. 1300-11.
1247. Ruggiero, S. L., Bisphosphonate-related osteonecrosis of the jaw: an overview, Ann N Y Acad Sci, 2011. 1218: p. 38-46.
1248. Chow, E., Harris, K., Fan, G., Tsao, M., Sze, W. M., Palliative radiotherapy trials for bone metastases: a systematic review, J Clin Oncol, 2007. 25: p. 1423-36.
1249. Falkmer, U., Jarhult, J., Wersall, P., Cavallin-Stahl, E., A systematic overview of radiation therapy effects in skeletal metastases, Acta Oncol, 2003. 42: p. 620-33.
1250. Dennis, K., Makhani, L., Zeng, L., Lam, H., Chow, E., Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials, Radiother Oncol, 2013. 106: p. 5-14.
1251. Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., Lutz, S., Update on the systematic review of palliative radiotherapy trials for bone metastases, Clin Oncol (R Coll Radiol), 2012. 24: p. 112-24.
1252. Howell, DD, James, JL, Hartsell, WF, Suntharalingam, M, Machtay, M, Suh, JH, et.al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14., Cancer, 2013. 119 (4)(4): p. 888-96., https://pubmed.ncbi.nlm.nih.gov/23165743/
1253. Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366: p. 643-8.
1254. Rades, D., Huttenlocher, S., Dunst, J., Bajrovic, A., Karstens, J. H., Rudat, V., et.al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression, J Clin Oncol, 2010. 28: p. 3597-604.
1255. Huisman, M, van den Bosch, MA, Wijlemans, JW, van Vulpen, M, van der Linden, YM, Verkooijen, HM, Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis., Int J Radiat Oncol Biol Phys, 2012. 84 (1)(1): p. 8-14., https://pubmed.ncbi.nlm.nih.gov/22300568/
1256. Chow, E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., et.al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial, Lancet Oncol, 2014. 15: p. 164-71.
1257. D'Angelo, G., Sciuto, R., Salvatori, M., Sperduti, I., Mantini, G., Maini, C. L., et.al. Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis, Q J Nucl Med Mol Imaging, 2012. 56: p. 538-43.
1258. Brady, D., Parker, C. C., O'Sullivan, J. M., Bone-targeting radiopharmaceuticals including radium-223, Cancer J, 2013. 19: p. 71-8.
1259. Zertifizierung, Qualitätsmanagement, Checklisten, Formulare, FAQs zur Rehabilitation, 2023., www.bar-frankfurt.de
1260. Müller, G.; Borrusch, H.; Otto, U., Rehabilitation. Allgemeine Grundlagen, in Uroonkologie, Heidelberg, Springer-Verlag Berlin , Editor. 2014, Springer Verlag: Berlin Heidelberg. 6. Auflage: p. 64-83.
1261. Sökeland, J.; Roth, S., Harnableitung, Deutsches Ärzteblatt, 1996. 93:
1262. Urologie, Deutsche Gesellschaft für, Leitlinie zur Nachsorge von Patienten mit Harnableitung unter Verwendung von Darmsegmenten Leitlinien der Deutschen Gesellschaft für UrologieSpringer Verlag, 2000.
1263. Nach:, S3-Leitlinie: Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, 2015. p. 82-85.
1264. Dombo, O.; Otto, U., Stress-Inkontinenz beim Mann: Anamtomische und funktionelle Besonderheiten, J. Urol Gynaecol, 2004. 1: p. 7-12.
1265. Dorschner, W., Stolzenburg, J. U., Neuhaus, J., [Anatomic principles of urinary incontinence], Urologe A, 2001. 40: p. 223-33.
1266. Müller, G.;Brock, O.; Otto, U., Wie effektiv ist die fachspezifische stationäre Anschlussheilbehandlung (AHB) nach Zystektomie mit Anlage einer Ileum Neoblase?, Urologe, 2014. 53 (Suppl.):
1267. AWMF, S3-Leitlinie Kolorektales Karzinom, 2013. 2014:
1268. Sailer, M., Patientenedukation, in Pflege von Menschen mit chronischen Wunden - Lehrbuch für Pflegende und Wundexperten, Schröder, Panfil & , Editor. 2010, Verlag Hans Huber: Bern.
1269. EAUN, Kontinente Harnableitungen, 2010.
1270. Fukushima, T, Tsuji, T, Sano, Y, Miyata, C, Kamisako, M, Hohri, H, et.al. Immediate effects of active exercise with compression therapy on lower-limb lymphedema., Support Care Cancer, 2017. 25 (8)(8): p. 2603-2610., https://pubmed.ncbi.nlm.nih.gov/28386788/
1271. Robert Koch Institut, u.d. G. d. e. K. i. D. e. V., Krebs in Deutschland, 2013. 9:
1272. ESMO, Rehabilitation Issus during cancer treatment and follow up, 2014. 2015:
1273. Rehabilitation, Bundesarbeitsgemeinschaft für, Arbeitshilfe für die Rehabilitation und Teilhabe von Menschen mit Krebserkrankung, 2013.
1274. Berger, A. M., Mooney, K., Alvarez-Perez, A., Breitbart, W. S., Carpenter, K. M., Cella, D., et.al. Cancer-Related Fatigue, Version 2.2015, J Natl Compr Canc Netw, 2015. 13: p. 1012-39.
1275. Weis, J., Cancer-related fatigue: prevalence, assessment and treatment strategies, Expert Rev Pharmacoecon Outcomes Res, 2011. 11: p. 441-6.
1276. Cella, D., Peterman, A., Passik, S., Jacobsen, P., Breitbart, W., Progress toward guidelines for the management of fatigue, Oncology (Williston Park), 1998. 12: p. 369-77.
1277. Fischer, I; Kuhnt, S., Psychodiagnostik und neuropsychologische Diagnostik, in Fatigue bei Krebserkrankungen, Heim, ME; Weis J. , Editor. 2015, Schattauer: Stuttgart. p. 110-119.
1278. Heim, ME; Weis J., Somatische und psychosoziale Einflussfaktoren: experimentelle, präklinische u. klinische Forschungsdaten, in Fatigue bei Krebserkrankungen, Heim, ME; Weis J. , Editor. 2015, Schattauer: Stuttgart. p. 51-68.
1279. NCCN, Cancer-Related Fatigue, NCCN guidelines for supportive care, 2013. 3.2013:
1280. S3-Leitlinie Komplementärmedizin in der Behandlung onkologischer PatientInnen, 2021., https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin
1281. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):, Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, 2020.
1282. Fradet, Y, Bellmunt, J, Vaughn, DJ, Lee, JL, Fong, L, Vogelzang, NJ, et.al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up., Ann Oncol, 2019. 30 (6)(6): p. 970-976., https://pubmed.ncbi.nlm.nih.gov/31050707/
1283. Laukhtina, E, Mori, K, Mostafaei, H, Merseburger, AS, Nyirady, P, Moschini, M, et.al. Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis., Immunotherapy, 2021. 13 (11)(11): p. 917-929., https://pubmed.ncbi.nlm.nih.gov/34078134/
1284. Rammant, E, Decaestecker, K, Bultijnck, R, Sundahl, N, Ost, P, Pauwels, NS, et.al. A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy., Clin Rehabil, 2018. 32 (5)(5): p. 594-606., https://pubmed.ncbi.nlm.nih.gov/29231044/
1285. Arnaud-Coffin, P, Maillet, D, Gan, HK, Stelmes, JJ, You, B, Dalle, S, et.al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors., Int J Cancer, 2019. 145 (3)(3): p. 639-648., https://pubmed.ncbi.nlm.nih.gov/30653255/
1286. Benner, C., Greenberg, M., Shepard, N., Meng, M. V., Rabow, M. W., The natural history of symptoms and distress in patients and families following cystectomy for treatment of muscle invasive bladder cancer, J Urol, 2014. 191: p. 937-42.
1287. Chasen, M., Bhargava, R., Dalzell, C., Pereira, J. L., Attitudes of oncologists towards palliative care and the Edmonton Symptom Assessment System (ESAS) at an Ontario cancer center in Canada, Support Care Cancer, 2015. 23: p. 769-78.
1288. Kangas, M., Bovbjerg, D. H., Montgomery, G. H., Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients, Psychol Bull, 2008. 134: p. 700-41.
1289. Dudgeon, D., King, S., Howell, D., Green, E., Gilbert, J., Hughes, E., et.al. Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening, Psychooncology, 2012. 21: p. 357-64.
1290. Velikova, G., Keding, A., Harley, C., Cocks, K., Booth, L., Smith, A. B., et.al. Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial, Eur J Cancer, 2010. 46: p. 2381-8.
1291. Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et.al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial, J Clin Oncol, 2004. 22: p. 714-24.
1292. Chen, J., Ou, L., Hollis, S. J., A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting, BMC Health Serv Res, 2013. 13: p. 211.
1293. Mehnert, A.; et al, Die deutsche Version des NCCN Distress-Thermometers ZPPP 54, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 2006.
1294. Stiel, S., Matthes, M. E., Bertram, L., Ostgathe, C., Elsner, F., Radbruch, L., [Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS)], Schmerz, 2010. 24: p. 596-604.
1295. Bausewein, C., Fegg, M., Radbruch, L., Nauck, F., von Mackensen, S., Borasio, G. D., et.al. Validation and clinical application of the german version of the palliative care outcome scale, J Pain Symptom Manage, 2005. 30: p. 51-62.
1296. Bausewein, C., Le Grice, C., Simon, S., Higginson, I., Prisma, The use of two common palliative outcome measures in clinical care and research: a systematic review of POS and STAS, Palliat Med, 2011. 25: p. 304-13.
1297. Murtagh, FE, Ramsenthaler, C, Firth, A, Groeneveld, EI, Lovell, N, Simon, ST, et.al. A brief, patient- and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS)., Palliat Med, 2019. 33 (8)(8): p. 1045-1057., https://pubmed.ncbi.nlm.nih.gov/31185804/
1298. Singer, S., Ziegler, C., Schwalenberg, T., Hinz, A., Gotze, H., Schulte, T., Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer, Support Care Cancer, 2013. 21: p. 1383-93.
1299. Botteman, M. F., Pashos, C. L., Hauser, R. S., Laskin, B. L., Redaelli, A., Quality of life aspects of bladder cancer: a review of the literature, Qual Life Res, 2003. 12: p. 675-88.
1300. Johannsen, C., Psychosocial Factors, in Pscho-Oncology, Holland, JCBreitbart, WSJacobsen, PBLederberg, MSLoscalzo, MJ and Corkle, R, Editors. 2010, Oxford University Press. p. 57-71.
1301. Ahles, T. A., Saykin, A. J., Noll, W. W., Furstenberg, C. T., Guerin, S., Cole, B., et.al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy, Psychooncology, 2003. 12: p. 612-9.
1302. Koch, U, Weis, J, Psychoonkologie. Eine Disziplin in Entwicklung.Hogrefe Verlag, Jahrbuch der Medizinischen Psychologie, 2009.
1303. Roth, A.; Gonzáles-Resetrepo, A., Genitourinary Malignancies, in Psycho-Oncology, Holland, J.; Breitbart, W.; Jacobsen, P.; Lederberg, M.; Loscalczo, M.; Corkle, R. , Editor. 2010, Oxford University Press. 2: p. 160-165.
1304. Roth, AJ, Carter, J, CJ, Nelson, Sexuality after Cancer, in Pscho-Oncology, Holland, JCBreitbart, WSJacobsen, PBLederberg, MSLoscalzo, MJ and Corkle, R, Editors. 2010, Oxford University Press. p. 245-250.
1305. Mehnert, A., Employment and work-related issues in cancer survivors, Crit Rev Oncol Hematol, 2011. 77: p. 109-30.
1306. Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P., The unmet supportive care needs of patients with cancer. Supportive Care Review Group, Cancer, 2000. 88: p. 226-37.
1307. Fallowfield, L., Jenkins, V., Communicating sad, bad, and difficult news in medicine, Lancet, 2004. 363: p. 312-9.
1308. Doctor-patient communication and cancer patients' quality of life and satisfaction, 2000.
1309. de Haes, H., Teunissen, S., Communication in palliative care: a review of recent literature, Curr Opin Oncol, 2005. 17: p. 345-50.
1310. Fukui, S., Ogawa, K., Ohtsuka, M., Fukui, N., A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer, Cancer, 2008. 113: p. 1462-70.
1311. Baile, W. F., Aaron, J., Patient-physician communication in oncology: past, present, and future, Curr Opin Oncol, 2005. 17: p. 331-5.
1312. Von Ah, D., Carpenter, J. S., Saykin, A., Monahan, P., Wu, J., Yu, M., et.al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial, Breast Cancer Res Treat, 2012. 135: p. 799-809.
1313. EAUN, Kontinente Harnableitung, 2010.
1314. Hayder-Beichel, D., Sexualität und Patnerschaft – Ein tabuisiertes Beratungsfeld der professionellen Pflege, in Interdisziplinäre Kontinenzberatung, 2013, Kohlhammer: Stuttgart.
1315. S3-Leitlinie Supportive Therapie bei Onkologischen Patienten Version 1.3, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/
1316. Jordan, B, Margulies, A, Cardoso, F, Cavaletti, G, Haugnes, HS, Jahn, P, et.al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up., Ann Oncol, 2020. 31 (10)(10): p. 1306-1319., https://pubmed.ncbi.nlm.nih.gov/32739407/
1317. Beijers, AJM, Bonhof, CS, Mols, F, Ophorst, J, de Vos-Geelen, J, Jacobs, EMG, et.al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy., Ann Oncol, 2020. 31 (1)(1): p. 131-136., https://pubmed.ncbi.nlm.nih.gov/31912787/
1318. Tsuyuki, S, Senda, N, Kanng, Y, Yamaguchi, A, Yoshibayashi, H, Kikawa, Y, et.al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group., Breast Cancer Res Treat, 2016. 160 (1)(1): p. 61-67., https://pubmed.ncbi.nlm.nih.gov/27620884/
1319. Kanbayashi, Y, Sakaguchi, K, Ishikawa, T, Ouchi, Y, Nakatsukasa, K, Tabuchi, Y, et.al. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial., Breast, 2020. 49 (): p. 219-224., https://pubmed.ncbi.nlm.nih.gov/31901783/
1320. Kruck, P., Das Kurzdarmsyndrom - wenn Dünndarm fehlt, ILCO-Praxis, 2015. 1-15: p. 38-50.
1321. Radbruch, Lukas, SA, Payne, White paper on standards and norms for hospice and palliative care in Europe: Part 1, 2010/01/01. 17: p. 22 - 33.
1322. Cosentino, M, Palou, J, Gaya, JM, Breda, A, Rodriguez-Faba, O, Villavicencio-Mavrich, H, Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma., World J Urol, 2013. 31 (1)(1): p. 141-5., https://pubmed.ncbi.nlm.nih.gov/22552732/
1323. Tanaka, T, Shindo, T, Hashimoto, K, Kobayashi, K, Masumori, N, Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience., Int J Urol, 2022. 29 (9)(9): p. 1046-1053., https://pubmed.ncbi.nlm.nih.gov/35772732/
1324. Maisch, P, Lunger, L, Düwel, C, Schmid, SC, Horn, T, Gschwend, JE, et.al. Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer., Urol Oncol, 2021. 39 (6)(6): p. 368.e11-368.e17., https://pubmed.ncbi.nlm.nih.gov/33431328/
1325. Burger, M., Catto, J. W., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., et.al. Epidemiology and risk factors of urothelial bladder cancer, Eur Urol, 2013. 63: p. 234-41.
1326. Steinmaus, C., Ferreccio, C., Acevedo, J., Yuan, Y., Liaw, J., Duran, V., et.al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure, Cancer Epidemiol Biomarkers Prev, 2014. 23: p. 1529-38.
1327. NICE, Bladder cancer: diagnosis and management, 2015.
1328. Altieri, V. M., Castellucci, R., Palumbo, P., Verratti, V., Sut, M., Olivieri, R., et.al. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables, Urol Int, 2012. 89: p. 61-6.
1329. van Rhijn, B. W., Zuiverloon, T. C., Vis, A. N., Radvanyi, F., van Leenders, G. J., Ooms, B. C., et.al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer, Eur Urol, 2010. 58: p. 433-41.
1330. Xu, T., Zhu, Z., Zhang, X., Wang, X., Zhong, S., Zhang, M., et.al. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models, Urology, 2013. 82: p. 387-93.
1331. Hernandez, V., De La Pena, E., Martin, M. D., Blazquez, C., Diaz, F. J., Llorente, C., External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer, World J Urol, 2011. 29(4): p. 409-14., https://www.ncbi.nlm.nih.gov/pubmed/21190023
1332. Seo, K. W., Kim, B. H., Park, C. H., Kim, C. I., Chang, H. S., The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation, Korean J Urol, 2010. 51: p. 165-70.
1333. Lammers, R. J., Palou, J., Witjes, W. P., Janzing-Pastors, M. H., Caris, C. T., Witjes, J. A., Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy, BJU Int, 2014. 114: p. 193-201.
1334. Bolenz, C., Auer, M., Strobel, P., Heinzelbecker, J., Schubert, C., Trojan, L., The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value, Urol Oncol, 2013. 31: p. 1606-14.
1335. Brimo, F., Wu, C., Zeizafoun, N., Tanguay, S., Aprikian, A., Mansure, J. J., et.al. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion, Hum Pathol, 2013. 44: p. 95-102.
1336. Scosyrev, E., Yao, J., Messing, E., Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?, Urology, 2009. 73: p. 822-7.
1337. Alkibay, T., Sozen, S., Gurocak, S., Isik Gonul, I., Poyraz, A., Ure, I., Micropapillary pattern in urothelial carcinoma: a clinicopathological analysis, Urol Int, 2009. 83: p. 300-5.
1338. Kaimakliotis, H. Z., Monn, M. F., Cary, K. C., Pedrosa, J. A., Rice, K., Masterson, T. A., et.al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?, Urol Oncol, 2014. 32: p. 833-8.
1339. Pasquier, D., Barney, B., Sundar, S., Poortmans, P., Villa, S., Nasrallah, H., et.al. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients, Int J Radiat Oncol Biol Phys, 2015. 92: p. 904-10.
1340. Olsen, L. H., Genster, H. G., Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial, Scand J Urol Nephrol Suppl, 1995. 172: p. 33-6.
1341. Mariappan, P., Smith, G., A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database, J Urol, 2005. 173: p. 1108-11.
1342. Zieger, K., Wolf, H., Olsen, P. R., Hojgaard, K., Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression, BJU Int, 2000. 85: p. 824-8.
1343. Leblanc, B., Duclos, A. J., Benard, F., Cote, J., Valiquette, L., Paquin, J. M., et.al. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder, J Urol, 1999. 162: p. 1946-50.
1344. Thompson, R. A., Jr., Campbell, E. W., Jr., Kramer, H. C., Jacobs, S. C., Naslund, M. J., Late invasive recurrence despite long-term surveillance for superficial bladder cancer, J Urol, 1993. 149: p. 1010-1.
1345. Soloway, M. S., Bruck, D. S., Kim, S. S., Expectant management of small, recurrent, noninvasive papillary bladder tumors, J Urol, 2003. 170: p. 438-41.
1346. Messing, E. M., Teot, L., Korman, H., Underhill, E., Barker, E., Stork, B., et.al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States, J Urol, 2005. 174: p. 1238-41.
1347. Comploj, E., Mian, C., Ambrosini-Spaltro, A., Dechet, C., Palermo, S., Trenti, E., et.al. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses, Cancer Cytopathol, 2013. 121: p. 392-7.
1348. Zellweger, T., Benz, G., Cathomas, G., Mihatsch, M. J., Sulser, T., Gasser, T. C., et.al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer, Int J Cancer, 2006. 119: p. 1660-5.
1349. Savic, S., Zlobec, I., Thalmann, G. N., Engeler, D., Schmauss, M., Lehmann, K., et.al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy, Int J Cancer, 2009. 124: p. 2899-904.
1350. Bubendorf, L., Grilli, B., Sauter, G., Mihatsch, M. J., Gasser, T. C., Dalquen, P., Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings, Am J Clin Pathol, 2001. 116: p. 79-86.
1351. Maffezzini, M., Campodonico, F., Capponi, G., Canepa, G., Casazza, S., Bandelloni, R., et.al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer, Anticancer Res, 2010. 30: p. 4761-5.
1352. Skacel, M., Fahmy, M., Brainard, J. A., Pettay, J. D., Biscotti, C. V., Liou, L. S., et.al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology, J Urol, 2003. 169: p. 2101-5.
1353. Gofrit, O. N., Zorn, K. C., Silvestre, J., Shalhav, A. L., Zagaja, G. P., Msezane, L. P., et.al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer, Urol Oncol, 2008. 26: p. 246-9.
1354. Aharony, S., Baniel, J., Yossepowitch, O., Clinically unconfirmed positive urinary cytology: diagnostic implications and oncological outcomes, BJU Int, 2011. 108: p. E179-83.
1355. Kamat, A. M., Karam, J. A., Grossman, H. B., Kader, A. K., Munsell, M., Dinney, C. P., Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity, BJU Int, 2011. 108: p. 1119-23.
1356. Need for intravenous urography in patients with primary transitional carcinoma of the bladder?, 1999.
1357. Miyake, M., Hirao, S., Mibu, H., Tanaka, M., Takashima, K., Shimada, K., et.al. Clinical significance of subepithelial growth patterns in non-muscle invasive bladder cancer, BMC Urol, 2011. 11: p. 17.
1358. Canales, B. K., Anderson, J. K., Premoli, J., Slaton, J. W., Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer, J Urol, 2006. 175: p. 74-7.
1359. Moses, K. A., Zhang, J., Hricak, H., Bochner, B. H., Bladder cancer imaging: an update, Curr Opin Urol, 2011. 21: p. 393-7.
1360. Solsona, E., Iborra, I., Rubio, J., Casanova, J., Almenar, S., The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour, BJU Int, 2004. 94: p. 1258-62.
1361. Donat, S. M., Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?, World J Urol, 2006. 24: p. 557-64.
1362. Huguet, J., Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors, Actas Urol Esp, 2013. 37(6): p. 376-82., https://www.ncbi.nlm.nih.gov/pubmed/23611464
1363. Tongaonkar, H. B., Dalal, A. V., Kulkarni, J. N., Kamat, M. R., Urethral recurrences following radical cystectomy for invasive transitional cell carcinoma of the bladder, Br J Urol, 1993. 72: p. 910-4.
1364. Nieder, A. M., Sved, P. D., Gomez, P., Kim, S. S., Manoharan, M., Soloway, M. S., Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring, Urology, 2004. 64: p. 950-4.
1365. Soukup, V., Babjuk, M., Bellmunt, J., Dalbagni, G., Giannarini, G., Hakenberg, O. W., et.al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature, Eur Urol, 2012. 62: p. 290-302.
1366. Picozzi, S., Ricci, C., Gaeta, M., Ratti, D., Macchi, A., Casellato, S., et.al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients, J Urol, 2012. 188: p. 2046-54.
1367. Bochner, B. H., Montie, J. E., Lee, C. T., Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer, Urol Clin North Am, 2003. 30: p. 777-89.
1368. Mathers, M. J., Zumbe, J., Wyler, S., Roth, S., Gerken, M., Hofstadter, F., et.al. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers, World J Urol, 2008. 26: p. 251-6.
1369. Cagiannos, I., Morash, C., Surveillance strategies after definitive therapy of invasive bladder cancer, Can Urol Assoc J, 2009. 3: p. S237-42.
1370. Boorjian, S. A., Tollefson, M. K., Cheville, J. C., Costello, B. A., Thapa, P., Frank, I., Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival, J Urol, 2011. 186: p. 1796-802.
1371. Nieuwenhuijzen, J. A., de Vries, R. R., van Tinteren, H., Bex, A., Van der Poel, H. G., Meinhardt, W., et.al. Follow-up after cystectomy: regularly scheduled, risk adjusted, or symptom guided? Patterns of recurrence, relapse presentation, and survival after cystectomy, Eur J Surg Oncol, 2014. 40: p. 1677-85.
1372. Volkmer, B. G., Kuefer, R., Bartsch, G. C., Jr., Gust, K., Hautmann, R. E., Oncological followup after radical cystectomy for bladder cancer-is there any benefit?, J Urol, 2009. 181: p. 1587-93; discussion 1593.
1373. Slaton, J. W., Swanson, D. A., Grossman, H. B., Dinney, C. P., A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder, J Urol, 1999. 162: p. 710-4.
1374. Giannarini, G., Kessler, T. M., Thoeny, H. C., Nguyen, D. P., Meissner, C., Studer, U. E., Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?, Eur Urol, 2010. 58: p. 486-94.
1375. Meissner, C., Giannarini, G., Schumacher, M. C., Thoeny, H., Studer, U. E., Burkhard, F. C., The efficiency of excretory urography to detect upper urinary tract tumors after cystectomy for urothelial cancer, J Urol, 2007. 178: p. 2287-90.
1376. Battal, B., Kocaoglu, M., Akgun, V., Aydur, E., Dayanc, M., Ilica, T., Feasibility of MR urography in patients with urinary diversion, J Med Imaging Radiat Oncol, 2011. 55: p. 542-50.
1377. Kawamoto, S., Fishman, E. K., Role of CT in postoperative evaluation of patients undergoing urinary diversion, AJR Am J Roentgenol, 2010. 194: p. 690-6.
1378. Thomsen, H. S., European Society of Urogenital, Radiology, European Society of Urogenital Radiology guidelines on contrast media application, Curr Opin Urol, 2007. 17: p. 70-6.
1379. Fernandez, M. I., Parikh, S., Grossman, H. B., Katz, R., Matin, S. F., Dinney, C. P., et.al. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer, Urol Oncol, 2012. 30: p. 821-4.
1380. Kalble, T., Hofmann, I., Riedmiller, H., Vergho, D., Tumor growth in urinary diversion: a multicenter analysis, Eur Urol, 2011. 60: p. 1081-6.
1381. Vergho, D., Kocot, A., Bauer, C., Riedmiller, H., [Insufficiency of the efferent segment in continent cutaneous diversion], Urologe A, 2012. 51: p. 485-93.
1382. Mills, R. D., Studer, U. E., Metabolic consequences of continent urinary diversion, J Urol, 1999. 161: p. 1057-66.
1383. Duerksen, D. R., Fallows, G., Bernstein, C. N., Vitamin B12 malabsorption in patients with limited ileal resection, Nutrition, 2006. 22: p. 1210-3.
1384. Pattni, S., Walters, J. R., Recent advances in the understanding of bile acid malabsorption, Br Med Bull, 2009. 92: p. 79-93.
1385. Peyromaure, M., Slama, J., Beuzeboc, P., Ponvert, D., Debre, B., Zerbib, M., Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution, Urology, 2004. 63: p. 73-7.
1386. Weiss, C., Engehausen, D. G., Krause, F. S., Papadopoulos, T., Dunst, J., Sauer, R., et.al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer, Int J Radiat Oncol Biol Phys, 2007. 68: p. 1072-80.
1387. Zietman, A. L., Sacco, D., Skowronski, U., Gomery, P., Kaufman, D. S., Clark, J. A., et.al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors, J Urol, 2003. 170: p. 1772-6.
1388. Mohammed, A., Hameed, A., Shergill, I., Barua, J., The practice of the first check cystoscopy following radiotherapy for the treatment of muscle-invasive (T3N0M0) bladder cancer: a UK national survey, Int Urol Nephrol, 2011. 43: p. 377-81.
1389. Hautmann, RE, de Petriconi, RC, Volkmer, BG, 25 years of experience with 1,000 neobladders: long-term complications., J Urol, 2011. 185 (6)(6): p. 2207-12., https://pubmed.ncbi.nlm.nih.gov/21497841/
1390. Masson-Lecomte, A., Rava, M., Real, F. X., Hartmann, A., Allory, Y., Malats, N., Inflammatory biomarkers and bladder cancer prognosis: a systematic review, Eur Urol, 2014. 66: p. 1078-91.
1391. Miremami, J., Kyprianou, N., The promise of novel molecular markers in bladder cancer, Int J Mol Sci, 2014. 15: p. 23897-908.
1392. Talukdar, S., Emdad, L., Das, S. K., Sarkar, D., Fisher, P. B., Noninvasive approaches for detecting and monitoring bladder cancer, Expert Rev Anticancer Ther, 2015. 15: p. 283-94.
1393. Herr, HW, Donat, SM, Bajorin, DF, Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer., J Urol, 2001. 165 (3)(3): p. 811-4., https://pubmed.ncbi.nlm.nih.gov/11176475/
1394. (ÄZQ), Ärztliches Zentrum für Qualität in der Medizin, Manual Qualitätsindikatoren. Manual für Autoren., 2009. äzq Schriftenreihe: 36: